
# **PCT**





# INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: A61K 31/00

(11) International Publication Number:

**WO 00/54759** 

(43) International Publication Date: 21 September 2000 (21.09.00)

(21) International Application Number:

PCT/US00/06611

(22) International Filing Date:

15 March 2000 (15.03.00)

(30) Priority Data:

60/124,525

15 March 1999 (15.03.99)

US

(71) Applicant: TULARIK INC. [US/US]; Two Corporate Drive, South San Francisco, CA 94080 (US).

(72) Inventors: Lt. Leping; 2100 Davis Drive, Burlingame, CA 94010 (US). MEDINA, Julio, C.; 1407 Cedar St., San Carlos, CA 94070 (US). HASEGAWA, Hirohiko; 1-98, 1 Kasugadenaka 3-chome, Konohana-ku, Osaka 554 (JP). CUTLER, Serena, T.; 449 Hawthorne Ave. #3, Palo Alto, CA 94301 (US). LIU, Jiwen; Apt. 211, 1075 Rollins Rd., Burlingame, CA 94010 (US). ZHU, Liusheng; Apt. 211, 2001 Trousdale Drive, Burlingame, CA 94010 (US). SHAN, Bei; 349 Quay Lane, Redwood City, CA 94065 (US). LUSTIG, Kevin; Two Corporate Drive, South San Francisco, CA 94080 (US).

(74) Agents: KEZER, William, B. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR. BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published

Without international search report and to be republished upon receipt of that report.

(54) Title: LXR MODULATORS

(57) Abstract

The invention provides compounds, compositions and methods for modulating the effects of LXR in a cell. The compounds and compositions are useful both as diagnostic indicators of LXR function and as pharmacologically active agents. The compounds and compositions find particular use in the treatment of disease states associated with cholesterol metabolism, particularly atherosclerosis and hypercholesterolemia.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

12							
AL:	Albania	ES	Spain .	LS -	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT.	Lithuania	SK	Slovakia
ΑT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	. Gabon	ŁV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	MC :	Мопасо	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Gumea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR ·	Turkey
BG	Bulgaria .	HU	Hungary	ML	Malı	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	II.	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of Americ
CA	Canada	IT	Italy	MX	Мехісо	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Vict Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	· KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwc
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand	*	•
CM	Cameroon .		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korca	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	L.C	Saint Lucia	RU	Russian Federation		
DE	Germany	1.3	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sr: Lanka	SE	Sweden		
EE	Estonia	LR .	Liberia	SG	Singapore		

#### LXR MODULATORS

## FIELD OF THE INVENTION

5

The present invention relates to compounds and methods useful for the modulation of LXR. In view of the activity of LXR in the control of cholesterol homeostasis, the compounds described herein are useful for lowering plasma cholesterol levels.

10

15

20

25

30

## **BACKGROUND**

Cholesterol is used for the synthesis of bile acids in the liver, the manufacture and repair of cell membranes, and the synthesis of steroid hormones. There are both exogenous and endogenous sources of cholesterol. The average American consumes about 450 mg of cholesterol each day and produces an additional 500 to 1,000 mg in the liver and other tissues. Another source is the 500 to 1,000 mg of biliary cholesterol that is secreted into the intestine daily; about 50 percent is reabsorbed (enterohepatic circulation). Excess accumulation of cholesterol in the arterial walls can result in atherosclerosis, which is characterized by plaque formation. The plaques inhibit blood flow, promote clot formation and can ultimately cause heart attacks, stroke and claudication. Development of therapeutic agents for the treatment of atherosclerosis and other diseases associated with cholesterol metabolism has been focused on achieving a more complete understanding of the biochemical pathways involved. Most recently, liver X receptors (LXRs) were identified as key components in cholesterol homeostasis.

The LXRs were first identified as orphan members of the nuclear receptor superfamily whose ligands and functions were unknown. Two LXR proteins (α and β) are known to exist in mammals. The expression of LXRα is restricted, with the highest levels being found in the liver, and lower levels found in kidney, intestine, spleen, and adrenals (see Willy, et al., Genes Dev. 9(9):1033-45 (1995)). LXRβ is rather ubiquitous, being found in nearly all tissues examined. Recent studies on the LXRs indicate that they are activated by certain naturally occurring, oxidized derivatives of cholesterol, including 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol and 24,25(S)-epoxycholesterol (see Lehmann, et al., J. Biol. Chem. 272(6):3137-3140 (1997)). The expression pattern of LXRs and their

WO 00/54759 PCT/US00/06611

oxysterol ligands provided the first hint that these receptors may play a role in cholesterol metabolism (see Janowski, et al., Nature 383:728-731 (1996)).

As noted above, cholesterol metabolism in mammals occurs via conversion into steroid hormones or bile acids. The role of LXRs in cholesterol homeostasis was first postulated to involve the pathway of bile acid synthesis, in which cholesterol 7α-hydroxylase (CYP7A) operates in a rate-limiting manner. Support for this proposal was provided when additional experiments found that the CYP7A promoter contained a functional LXR response element that could be activated by RXR/LXR heterodimers in an oxysterol- and retinoid-dependent manner. Confirmation of LXR function as a transcriptional control point in cholesterol metabolism was made using knockout mice, particularly those lacking the oxysterol receptor LXRα (see Peet, et al., Cell 93:693-704 (1998)).

Mice lacking the receptor LXR $\alpha$  (e.g., knockout or (-/-) mice) lost their ability to respond normally to increases in dietary cholesterol and were unable to tolerate any cholesterol in excess of that synthesized de novo. LXR $\alpha$  (-/-) mice did not induce transcription of the gene encoding CYP7A when fed diets containing additional cholesterol. This resulted in an accumulation of large amounts of cholesterol and impaired hepatic function in the livers of LXR $\alpha$  (-/-) mice. These results further established the role of LXR $\alpha$  as the essential regulatory component of cholesterol homeostasis. LXR $\alpha$  is also believed to be involved in fatty acid synthesis. Accordingly, regulation of LXR $\alpha$  (e.g., use of LXR $\alpha$  agonist or antagonists) could provide treatment for a variety of lipid disorders including obesity and diabetes.

In view of the importance of LXRs, and particularly LXRas to the delicate balance of cholesterol metabolism and fatty acid biosynthesis, we describe modulators of LXRs which are useful as therapeutic agents or diagnostic agents for the treatment of disorders associated with bile acid and cholesterol metabolism, including cholesterol gallstones, atherosclerosis, lipid storage diseases, obesity, and diabetes. The agents described herein are also useful for disease states associated with serum hypercholesterolemia, such as coronary heart disease.

30

35

10

15

20

25

## SUMMARY OF THE INVENTION

In one aspect, the present invention provides compositions for modulation of LXR $\alpha$  function in a cell. The compositions typically comprise a pharmaceutically acceptable excipient and a compound having the formula:

10

15

20

25

30

$$\begin{array}{c}
X^{1} \xrightarrow{X^{2}} X^{3} \\
X^{1} \xrightarrow{C} \xrightarrow{Ar} \xrightarrow{Ar} \xrightarrow{Y} \\
X^{4} \xrightarrow{C} \xrightarrow{X^{6}} \xrightarrow{R^{2}}
\end{array}$$

**(I)** 

wherein Ar represents an aryl group;  $R^1$  is -OII, -O-( $C_1$ - $C_7$ )alkyl, -OC(O)-( $C_1$ - $C_7$ )alkyl, -O-( $C_1$ - $C_7$ )heteroalkyl, -OC(O)-( $C_1$ - $C_7$ )heteroalkyl, -CO $_2$ H, -NH $_2$ , -NH( $C_1$ - $C_7$ )alkyl, -N(( $C_1$ - $C_7$ )alkyl) $_2$  or -NH-S(O) $_2$ -( $C_1$ - $C_5$ )alkyl;  $R^2$  is ( $C_1$ - $C_7$ )alkyl, ( $C_1$ - $C_7$ )heteroalkyl, aryl and aryl( $C_1$ - $C_7$ )alkyl;  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$  and  $X^6$  are each independently H, ( $C_1$ - $C_5$ )alkyl, ( $C_1$ - $C_5$ )heteroalkyl, F or Cl, with the proviso that no more than three of  $X^1$  through  $X^6$  are H, ( $C_1$ - $C_5$ )alkyl or ( $C_1$ - $C_5$ )heteroalkyl; and Y is -N( $R^{12}$ )S(O) $_m$ -, -N( $R^{12}$ )S(O) $_m$ N( $R^{13}$ )-, -N( $R^{12}$ )C(O)-, -N( $R^{12}$ )C(O)N( $R^{13}$ )-, -N( $R^{12}$ )C(S)- or -N( $R^{12}$ )C(O)O-, wherein  $R^{12}$  and  $R^{13}$  are each independently hydrogen, ( $C_1$ - $C_7$ )alkyl, ( $C_1$ - $C_7$ )heteroalkyl, aryl and aryl( $C_1$ - $C_7$ )alkyl, and optionally when Y is -N( $R^{12}$ )S(O) $_m$ - or -N( $R^{12}$ )S(O) $_m$ N( $R^{13}$ )-,  $R^{12}$  forms a five-, six- or seven-membered ring fused to Ar or to  $R^2$  through covalent attachment to Ar or  $R^2$ , respectively . In the above Y groups, the subscript m is an integer of from 1 to 2.

Preferred compositions are those in which the compound above binds to the ligand binding domain of LXR $\alpha$  with an affinity of at least 1 micromolar.

A number of compounds that are useful in the above-described compositions are novel. Accordingly, the present invention further provides compounds of the above formula, with the proviso that when  $R^1$  is OH, and  $-Y-R^2$  is  $-N(R^{12})S(O)_m-R^2$  or  $-N(R^{12})C(O)N(R^{13})-R^2$  and is attached to a position para to the quaternary carbon attached to Ar, and when  $R^2$  is phenyl, benzyl or benzoyl, then i) at least one of  $R^{12}$  or  $R^{13}$  is other than hydrogen and contains an electron-withdrawing substituent, or ii)  $R^2$  is substituted with a moiety other than amino, acetamido, di( $C_1$ - $C_7$ )alkylamino, ( $C_1$ - $C_7$ )alkylamino, halogen, hydroxy, nitro, or ( $C_1$ - $C_7$ )alkyl, or iii) the benzene ring portion of  $R^2$  is trisubstituted in addition to the Y group.

In yet another aspect, the present invention provides methods for modulating LXR in a cell by administering to or contacting the cell with a composition containing a compound of Formula I above.

In still another aspect, the present invention provides methods for treating LXR-responsive diseases by administering to a subject in need of such treatment a composition containing a compound of Formula I. These methods are particularly useful for the treatment of pathology such as hypercholesterolemia, atherosclerosis, and hyperlipoproteinemia. In certain embodiments, the compound can be administered to the subject in combination with an additional anti-

WO 00/54759 PCT/US00/06611

hypercholesterolemic agent, for example, bile acid sequestrants, niconnic acid, fibric acid derivatives or HMG CoA reductase inhibitors.

The present compounds can exert their effects either systemically (the compounds permeate the relevant tissues, such as liver, upon entrance into the bloodstream) or locally (for example, by modulating LXR function of intestinal epithelial cells following oral administration, without necessitating the compounds' entrance into the bloodstream). In some disease states, some preferred compounds will be those with good systemic distribution, while, in other instances, preferred compounds will be those that can work locally on the intestinal track or on the skin without penetrating the bloodstream.

Certain compounds of the present invention are antiproliferative and can be used in compositions for treating diseases associated with abnormal cell proliferation (e.g., cancer). Other diseases associated with an abnormally high level of cellular proliferation include restenosis, where vascular smooth muscle cells are involved, inflammatory disease states, where endothelial cells, inflammatory cells and glomerular cells are involved, myocardial infarction, where heart muscle cells are involved, glomerular nephritis, where kidney cells are involved, transplant rejection, where endothelial cells are involved, infectious diseases such as HIV infection and malaria, where certain immune cells and/or other infected cells are involved, and the like. Infectious and parasitic agents per se (e.g. bacteria, trypanosomes, fungi, etc) are also subject to selective proliferative control using the subject compositions and compounds.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1 and 2 provide the structures of compounds prepared using the solid phase synthesis methodology outlined in Scheme 3.

30

10

15

20


25

#### DETAILED DESCRIPTION OF THE INVENTION

#### **Definitions**

35

The term "alkyl," by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can



include di- and multi-radicals, having the number of carbon atoms designated (i.e. C<sub>1</sub>-C<sub>10</sub> means one to ten carbons). Examples of saturated hydrocarbon radicals include groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3butynyl, and the higher homologs and isomers. The term "alkyl," unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below as "cycloalkyl" and "alkylene." The term "alkylene" by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified by -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>-. Typically, an alkyl group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms, preferably four or fewer carbon atoms.

The term "alkoxy," employed alone or in combination with other terms means, unless otherwise stated, an alkyl group, as defined above, connected to the remainder of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1-propoxy, 2-propoxy and the higher homologs and isomers.

The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S may be placed at any position of the heteroalkyl group except for the position at which the heteroalkyl group is attached to the rest of the molecule. The heteroatom Si may be placed at any position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule. Examples include -CH<sub>2</sub>-CH<sub>2</sub>-O-CH<sub>3</sub>, -CH<sub>2</sub>-CH<sub>2</sub>-NH-CH<sub>3</sub>, -CH<sub>2</sub>-CH<sub>2</sub>-N(CH<sub>3</sub>)-CH<sub>3</sub>, -CH<sub>2</sub>-S-CH<sub>2</sub>-CH<sub>3</sub>, -CH<sub>2</sub>-CH<sub>2</sub>-S(O)-CH<sub>3</sub>, -CH<sub>2</sub>-CH<sub>2</sub>-S(O)<sub>2</sub>-CH<sub>3</sub>, -CH=CH-O-CH<sub>3</sub>, -Si(CH<sub>3</sub>)<sub>3</sub>, -CH<sub>2</sub>-CH=N-OCH<sub>3</sub>, and -CH=CH-N(CH<sub>3</sub>)-CH<sub>3</sub>. Up to two heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. Also included in the term "heteroalkyl" are those radicals described in more detail below as "heteroalkylene" and "heterocycloalkyl." The term "heteroalkylene" by itself or as part of another

20

25

30

WO 00/54759 PCT/US00/06611

substituent means a Grealent radical derived from heteroalkyl, as exemplified by -CH<sub>2</sub>-CH<sub>2</sub>-S-CH<sub>2</sub>CH<sub>2</sub>- and -CH<sub>2</sub>-S-CH<sub>2</sub>-CH<sub>2</sub>-NH-CH<sub>2</sub>. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini. Still further, for alkylene and heteroalkylene linking groups, as well as all other linking groups described herein, no specific orientation of the linking group is implied.

The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl", respectively. The terms "cycloalkyl" and "heterocycloalkyl" are also meant to include bicyclic, tricyclic and polycyclic versions thereof. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, adamantyl, and the like. Examples of heterocycloalkyl include 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, 1,4-diazabicyclo[2.2.2]oct-2-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.

The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "fluoroalkyl," are meant to include monofluoroalkyl and polyfluoroalkyl.

The term "aryl," employed alone or in combination with other terms (e.g., aryloxy, arylthioxy, arylalkyl) means, unless otherwise stated, an aromatic substituent which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently. The rings may each contain from zero to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. The aryl groups that contain heteroatoms may be referred to as "heteroaryl" and can be attached to the remainder of the molecule through a carbon atom or a heteroatom. Non-limiting examples of aryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-pyridyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted

5

15

20

25

30

35

10

15

20

25

30

35



aryl ring systems are selected from the group of acceptable substituents described below.

The terms "arylalkyl" and "arylheteroalkyl" are meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) or a heteroalkyl group (e.g., phenoxymethyl, 2-pyridyloxymethyl, 1-naphthyloxy-3-propyl, and the like). The arylalkyl and arylheteroalkyl groups will typically contain from 1 to 3 aryl moieties attached to the alkyl or heteroalkyl portion by a covalent bond or by fusing the ring to, for example, a cycloalkyl or heterocycloalkyl group. For arylheteroalkyl groups, a heteroatom can occupy the position at which the group is attached to the remainder of the molecule. For example, the term "arylheteroalkyl" is meant to include benzyloxy, 2-phenylethoxy, phenethylamine, and the like.

Each of the above terms (e.g., "alkyl," "heteroalkyl," "aryl," etc.) are meant to include both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.

Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be a variety of groups selected from: -OR', =O, =NR', =N-OR', -NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R',  $-CO_{2}R'$ , -CONR'R'', -OC(O)NR'R'', -NR''C(O)R', - $C(NH_2)=NR'$ , -S(O)R',  $-S(O)_2R'$ ,  $-S(O)_2NR'R''$ , -CN and  $-NO_3$  in a number ranging from zero to (2N+1), where N is the total number of carbon ms in such radical. Preferably, substituted alkyl groups will have from one to six independently selected substituents, more preferably from one to four independently selected substituents. most preferably from one to three independently selected substituents. In the substituents listed above, R', R' and R'' each independently refer to hydrogen. unsubstituted(C<sub>1</sub>-C<sub>2</sub>)alkyl and heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted alkyl, alkoxy or thioalkoxy groups, or aryl-(C<sub>1</sub>-C<sub>4</sub>)alkyl groups. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -NR'R" is meant to include 1-pyrrolidinyl and 4-morpholinyl.

Similarly, substituents for the aryl groups are varied and are selected from: -halogen, -OR', -OC(O)R', -NR'R", -SR', -R', -CN, -NO<sub>2</sub>, -CO<sub>2</sub>R', -CONR'R", -OC(O)NR'R", -NR"C(O)<sub>2</sub>R', -NR"C(O)NR'R"'', -NH-C(NH<sub>2</sub>)=NH, -NR'C(NH<sub>2</sub>)=NH, -NH-C(NH<sub>2</sub>)=NR', -S(O)<sub>2</sub>R', -S(O)<sub>2</sub>R', -S(O)<sub>2</sub>NR'R", -N<sub>3</sub>, -CH(Ph)<sub>2</sub>, perfluoro( $C_1$ - $C_4$ )alkoxy, and perfluoro( $C_1$ - $C_4$ )alkyl, in a number ranging

WO 00/54759 PCT/US00/06611

from zero to the total-number of open valences on the aromatic ring system; and where R' and R" are independently selected from hydrogen, (C<sub>1</sub>-C<sub>8</sub>)alkyl and heteroalkyl, unsubstituted aryl, (unsubstituted aryl)-(C<sub>1</sub>-C<sub>4</sub>)alkyl, and (unsubstituted aryl)oxy-(C<sub>1</sub>-C<sub>4</sub>)alkyl. Preferably, substituted aryl groups will have from one to four independently selected substituents, more preferably from one to three independently selected substituents, most preferably from one to two independently selected substituents.

Two of the substituents on adjacent atoms of the aryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CH<sub>2</sub>)<sub>q</sub>-U-, wherein T and U are independently -NH-, -O-, -CH<sub>2</sub>- or a single bond, and q is an integer of from 0 to 2. Alternatively, two of the substituents on adjacent atoms of the aryl ring may optionally be replaced with a substituent of the formula -A-(CH<sub>2</sub>)<sub>r</sub>-B-, wherein A and B are independently -CH<sub>2</sub>-, -O-, -NH-, -S-, -S(O)-, -S(O)<sub>2</sub>-, -S(O)<sub>2</sub>NR'- or a single bond, and r is an integer of from 1 to 3. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl ring may optionally be replaced with a substituent of the formula -(CH<sub>2</sub>)<sub>s</sub>-X-(CH<sub>2</sub>)<sub>t</sub>-, where s and t are independently integers of from 0 to 3, and X is -O-, -NR'-, -S-, -S(O)-, -S(O)<sub>2</sub>-, or -S(O)<sub>2</sub>NR'-. The substituent R' in -NR'- and -S(O)<sub>2</sub>NR'- is selected from hydrogen or unsubstituted (C<sub>1</sub>-C<sub>6</sub>)alkyl.

As used herein, the term "heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).

The term "pharmaceutically acceptable salts" is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric,

10

15

20

25

30

35

10

15

20

25

30

35

dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, oxalic, maleic, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S.M., et al, "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.

In addition to salt forms, the present invention provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide a compound of formula I. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an *ex vivo* environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme.

Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention.

The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such

compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (<sup>3</sup>H), iodine-125 (<sup>125</sup>I) or carbon-14 (<sup>14</sup>C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

General

5

15

20

The present invention provides compositions, compounds and methods for modulating LXR function in a cell. The compositions which are useful for this modulation will typically be those which contain an effective amount of an LXR-modulating compound. In general, an effective amount of an LXR-modulating compound is a concentration of the compound that will produce at 50 percent increase/decrease in LXR activity in a cell-based reporter gene assay, or a biochemical peptide-sensor assay such as the assays described in co-pending applications Ser. Nos. 08/975,614 (filed November 21, 1997) and 09/163,713 (filed September 30, 1998).

## Embodiments of the Invention

In one aspect, the present invention provides compositions for modulation of LXR function in a cell. The compositions typically comprise a pharmaceutically acceptable excipient and an LXR-modulating amount of a compound having the formula:

$$X^{1} \xrightarrow{X^{2}} X^{3}$$

$$X^{1} \xrightarrow{X^{1}} Ar \xrightarrow{Y} Y$$


$$X^{4} \xrightarrow{X^{2}} X^{6}$$

$$X^{5}$$

(I)

The symbol Ar represents an aryl group. A variety of aryl groups, both unsubstituted and substituted, are useful in the present invention. Preferred Ar groups are either monocyclic or fused-bicyclic aromatic rings. Particularly preferred Ar ring systems are benzene, naphthalene, pyridine, quinoline, isoquinoline, pyrrole, furan and thiophene. More preferably, Ar represents either a benzene or pyridine ring, with benzene being the most preferred.

When Ar represents a substituted aromatic ring (substituents being in addition to -Y-R<sup>2</sup> and the carbon bearing R<sup>1</sup>), the substituents will typically be selected from -OH, -NH<sub>2</sub>, lower alkyl (e.g., methyl, butyl, trifluoromethyl,



trifluoroethyl, and the like), lower alkoxy (e.g., methoxy, ethoxy, trifluoromethoxy, butoxy, and the like), -NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R', -CO<sub>2</sub>R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR"C(O)<sub>2</sub>R', -NR"C(O)NR'R''', -NH-C(NH<sub>2</sub>)=NH, -NR'C(NH<sub>2</sub>)=NH, -NH-C(NH<sub>2</sub>)=NR', -S(O)R', -S(O)<sub>2</sub>R', -S(O)<sub>2</sub>NR'R", -CN and -NO<sub>2</sub>; wherein R', R" and R"'' are each independently selected from the group consisting of hydrogen and  $(C_1-C_5)$ alkyl. Preferred compounds are those in which the number of substituents on the Ar group (in addition to -Y-R<sup>2</sup> and the carbon bearing R<sup>1</sup>) ranges from 0 to 2.

The groups attached to Ar can be in any spatial arrangement. When Ar is a benzene ring, the two groups shown in Formula I will preferably be attached to Ar in a 1,3-orientation (meta) or a 1,4-orientation (para). More preferably the two groups shown in Formula I will be attached to a benzene or pyridine ring in a 1,4-orientation (para).

Returning now to Formula I,  $R^1$  represents -OH, -O-( $C_1$ - $C_7$ )alkyl, -OC(O)-( $C_1$ - $C_7$ )alkyl, -O-( $C_1$ - $C_7$ )heteroalkyl, -OC(O)-( $C_1$ - $C_7$ )heteroalkyl, -OC<sub>2</sub>H, -NH<sub>2</sub>, -NH( $C_1$ - $C_7$ )alkyl, -N(( $C_1$ - $C_7$ )alkyl)<sub>2</sub> or -NH-S(O)<sub>2</sub>-( $C_1$ - $C_5$ )alkyl. More preferably,  $R^1$  represents -OH, -CO<sub>2</sub>H, -NH<sub>2</sub>, -NH( $C_1$ - $C_7$ )alkyl, -N(( $C_1$ - $C_7$ )alkyl)<sub>2</sub> or -NH-S(O)<sub>2</sub>-( $C_1$ - $C_5$ )alkyl. Most preferably,  $R^1$  is -OH. For those embodiments in which  $R^1$  is a dialkylamino group (-N(( $C_1$ - $C_7$ )alkyl)<sub>2</sub>), the alkyl groups can either be the same or different.

The symbols  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$  and  $X^6$  each independently represent H,  $(C_1-C_5)$ alkyl,  $(C_1-C_5)$ heteroalkyl, F or Cl, with the proviso that no more than three of  $X^1$  through  $X^6$  are H,  $(C_1-C_5)$ alkyl or  $(C_1-C_5)$ heteroalkyl. More preferably, no more than three of  $X^1$  through  $X^6$  are H with the remaining being F. Most preferably,  $X^1$  through  $X^6$  are each F.

The symbol Y represents a linking group selected from  $-N(R^{12})S(O)_m$ -,  $-N(R^{12})S(O)_mN(R^{13})$ -,  $-N(R^{12})C(O)$ -,  $-N(R^{12})C(O)N(R^{13})$ -,  $-N(R^{12})C(S)$ - or  $-N(R^{12})C(O)O$ -, wherein  $R^{12}$  and  $R^{13}$  are each independently H,  $(C_1-C_7)$ alkyl,  $(C_1-C_7)$ heteroalkyl, aryl and aryl $(C_1-C_7)$ alkyl, and optionally when Y is  $-N(R^{12})S(O)_m$ - or  $-N(R^{12})S(O)_mN(R^{13})$ -,  $R^{12}$  forms a five-, six- or seven-membered ring fused to Ar or to  $R^2$  through covalent attachment to Ar or to  $R^2$ , respectively. In the above Y groups, the subscript m is an integer of from 1 to 2. Preferably, Y is  $-N(R^{12})S(O)_m$ -,  $-N(R^{12})S(O)_mN(R^{13})$ - or  $-N(R^{12})C(O)O$ -. Most preferably, Y is  $-N(R^{12})S(O)_m$ -.

As noted above,  $R^{12}$  and  $R^{13}$  represent hydrogen,  $(C_1-C_7)$ alkyl,  $(C_1-C_7)$ heteroalkyl, aryl or aryl $(C_1-C_7)$ alkyl, which in the case of the latter two groups, can also be either substituted or unsubstituted. In one group of embodiments,  $R^{12}$  is hydrogen or  $(C_1-C_4)$ alkyl, preferably fluoro $(C_1-C_4)$ alkyl. A particularly preferred  $R^{12}$ 

15

20

25

30

35

WO 00/54759 PCT/US00/06611

group is 2,2,2-trifluoroethyl. In another group of preferred embodiments, R<sup>12</sup> is attached to Ar to form a fused ring system, for example, indoline, tetrahydroquinoline or tetrahydroisoquinoline.

Attached to Y is  $R^2$ , which represents  $(C_1-C_7)$ alkyl,  $(C_1-C_7)$ heteroalkyl, aryl or aryl $(C_1-C_7)$ alkyl. Each of the recited  $R^2$  groups can be either substituted or unsubstituted. In preferred embodiments,  $R^2$  is an aryl group. More preferably,  $R^2$  is phenyl, thienyl, imidazolyl, oxazolyl or pyridyl. Most preferably,  $R^2$  is phenyl or thienyl (including 2-thienyl and 3-thienyl). Preferred substituted  $R^2$  groups include 3-chlorophenyl, 3-bromophenyl, 3-cyanophenyl, 3-(trifluoromethyl)phenyl, 2-chloro-3-thienyl and 2,5-dichloro-3-thienyl.

The above recitation describes a number of preferred groups for the compounds and compositions of the present invention. Additionally, certain combinations of the above groups will also be preferred. For example, in one group of embodiments, the compositions of the present invention will include a compound having a formula selected from the group consisting of

aving a formula selected from the group consisting of 
$$CF_2X^1$$
  $(R^{11})_n$   $R^1$   $CF_2X^1$   $(R^{11})_n$   $R^2$   $(R^{11})_n$   $(R^{11})_n$   $(R^{11})_n$  and  $(R^{11})_n$   $(R^{11})_n$   $(R^{11})_n$ 

In each of the above formulae, the subscript n represents an integer of from 0 to 4; and each  $R^{11}$  is independently -OH, -NH<sub>2</sub>, lower alkyl, lower alkoxy, -NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R', -CO<sub>2</sub>R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR"C(O)<sub>2</sub>R', -NR"C(O)NR'R"', -NH-C(NH<sub>2</sub>)=NH, -NR'C(NH<sub>2</sub>)=NH, -NH-C(NH<sub>2</sub>)=NR', -S(O)R', -S(O)<sub>2</sub>R', -S(O)<sub>2</sub>NR'R", -CN and -NO<sub>2</sub>; wherein each R', R" and R''' is independently hydrogen or  $(C_1-C_5)$ alkyl. The remaining groups in the above formulae have the meanings provided for Formula I.

In a further preferred group of embodiments, the compositions will include a compound having a formula selected from the group consisting of

5

10

15

25

In this group of preferred embodiments, the various groups (e.g.,  $R^1$ ,  $X^1$ ,  $X^6$ ,  $R^2$ ,  $R^{11}$ ,  $R^{12}$  and  $R^{13}$ ) have the meanings indicated above with reference to Formula I. Preferably,  $R^1$  is -OH or -NH<sub>2</sub>, and  $X^1$  and  $X^6$  are each independently hydrogen or fluorine. Still further preferred within this group of embodiments are those in which  $R^2$  is a substituted aryl group, more preferably a substituted phenyl or substituted thienyl group.

More preferably, the compositions will include a compound having a formula selected from the group consisting of

Most preferred, are those embodiments in which the compound has the

IIa IIb

5

10

formula:

With the group of preferred compounds provided as formulae IIa or IIb, at least three groupings of substituents are particularly preferred.

In a first group of preferred substituents,  $R^1$  is -OH or -NH<sub>2</sub>;  $X^1$  and  $X^6$  are each independently hydrogen or fluorine,  $R^{12}$  is fluoro( $C_1$ - $C_4$ )alkyl; and  $R^2$  is aryl.

In a second group of preferred substituents,  $R^1$  is -OH or -NH<sub>2</sub>;  $X^1$  and  $X^6$  are each independently hydrogen or fluorine,  $R^{12}$  is hydrogen or  $(C_1-C_4)$  alkyl; and  $R^2$  is substituted or unsubstituted thienyl.

In a third group of preferred substituents, the compositions will include at least one compound of formula II in which  $R^1$  is -OH or -NH<sub>2</sub>;  $X^1$  and  $X^6$  are each independently hydrogen or fluorine,  $R^{12}$  is  $(C_1-C_4)$ alkyl or  $(C_1-C_4)$ heteroalkyl; and  $R^2$  is phenyl substituted with at least one member selected from the group consisting of halogen, -CN, -CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)alkyl, -C(O)-(C<sub>1</sub>-C<sub>4</sub>)alkyl, -C(O)-O(C<sub>1</sub>-C<sub>4</sub>)alkyl, -C(O)-NH(C<sub>1</sub>-C<sub>4</sub>)alkyl and -C(O)N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>. Still further preferred are those embodiments in which  $R^1$  is -OH; and  $R^2$  is phenyl substituted with at least one member selected from -CN, -CF<sub>3</sub> and -O-(C<sub>1</sub>-C<sub>4</sub>)alkyl.

Still other preferred embodiments have a formula selected from:

$$R^{1}$$
  $\xrightarrow{CF_{2}X^{1}}$   $Ar-S(O)_{m}$   $N$   $R^{12}$   $F_{3}C$   $R^{12}$   $Ar-S(O)_{2}$   $N$   $R^{12}$   $Ar-N$   $R^{12}$   $R^{12$ 

In each of the formula above, the groups Ar, R<sup>2</sup>, R<sup>12</sup>, and the subscript m have the meanings provided above with reference to formula I.

Further preferred compositions are those in which the compound above binds to the ligand binding domain of an LXR receptor, more preferably LXR $\alpha$ , with an affinity of at least 1 micromolar.

A number of the compounds used in the present compositions are novel. Accordingly,the present invention provides, in another aspect, compounds of Formula I, above, (wherein each of the recited substituents has the meaning provided above) with the proviso that when  $-Y-R^2$  is  $-N(R^{12})S(O)_m-R^2$  or  $-N(R^{12})C(O)N(R^{13})-R^2$  and is attached to a position para to the quaternary carbon attached to Ar, and when  $R^2$  is substituted or unsubstituted phenyl, benzyl or benzoyl, then i) at least one of  $R^{12}$  or  $R^{13}$  is other than hydrogen or unsubstituted alkyl, or ii)  $R^2$  is substituted with a moiety other than amino, acetamido,  $di(C_1-C_7)$ alkylamino,  $(C_1-C_7)$ alkylamino, halogen, hydroxy, nitro, or  $(C_1-C_7)$ alkyl, or iii) the  $R^2$  phenyl group is trisubstituted in addition to the Y group.

Some of the compounds of Formula I may exist as stereoisomers, and the invention includes all active stereoisomeric forms of these compounds. In the case of optically active isomers, such compounds may be obtained from corresponding

35

5

20

25

optically active precursors using the procedures described above or by resolving racemic mixtures. The resolution may be carried out using various techniques such as chromatography, repeated recrystallization of derived asymmetric salts, or derivatization, which techniques are well known to those of ordinary skill in the art.

The compounds of the invention may be labeled in a variety of ways. For example, the compounds may contain radioactive isotopes such as, for example, <sup>3</sup>H (tritium) and <sup>14</sup>C (carbon-14). Similarly, the compounds may be advantageously joined, covalently or noncovalently, directly or through a linker molecule, to a wide variety of other compounds, which may provide pro-drugs or function as carriers, labels, adjuvents, coactivators, stabilizers, *etc*. Such labeled and joined compounds are contemplated within the present invention.

In yet another aspect, the present invention provides a method for modulating the action of an LXR receptor, preferably LXR $\alpha$ , in a cell. According to this method, the cell is contacted with a sufficient concentration of a composition containing a compound of formula I for either an agonistic or antagonistic effect to be detected. In preferred embodiments, the composition contains an amount of the compound which has been determined to provide a desired therapeutic or prophylactic effect for a given LXR-mediated condition.

In still another aspect, the present invention provides methods for the treatment of pathology such as hypercholesterolemia, atherosclerosis, and hyperlipoproteinemia using pharmaceutical compositions containing compounds of the foregoing description of the general Formula I. Briefly, this aspect of the invention involves administering to a patient an effective formulation of one or more of the subject compositions. In other embodiments, the compound of Formula I can be administered in combination with other anti-hypercholesterolemic agents (e.g., a bile acid sequestrant, nicotinic acid, fibric acid derivatives or HMG CoA reductase inhibitors), or in combination with other agents that affect cholesterol or lipid metabolism.

## **Synthesis**

20

25

30

35

Compounds of the present invention can be prepared using readily available starting materials or known intermediates. Scheme 1 provides a variety of synthesis avenues for the production of the subject compounds. One of skill in the art will understand that additional methods are also useful.

SCHEME 1

SCHEME 1

SCHEME 1

NH2

$$F_3C$$
 $F_3C$ 
 $CF_3$ 
 $C$ 

As shown in Scheme 1, aniline i (as representative of substituted anilines and other arylamines) can either be alkylated, acylated or arylated (general addition of R group) to form ii, or the aromatic ring can derivatized with, for example, hexafluoroacetone to form iii. Treatment of iii with an appropriate alkylating group, acylating group or arylating group provides iv, which can be sulfonylated with, for example, an appropriate sulfonyl halide to form vi. Alternatively, the aniline derivative iii can be sulfonylated to form v, which can then be alkylated or acylated to form compounds of formula vi.

10

15

BNSDOCID <WO\_\_0054759A2\_I\_>

Other compounds of the present invention can be formed by treating the substituted aniline iv (or, alternatively, iii), with reagents suitable for the formation of amides vii, carbamates viii, and ureas ix. A variety of reagents are useful in the above scheme and can be found in, for example, March, Advanced Organic Chemistry 4th Ed., John Wiley & Sons, New York, NY (1992). Preferred reagents and conditions are also found in the Examples below.


10

15

20

25

INSDOCID <WO 0054759A2 I



Methods for the preparation of compounds in which a sulfonamide linkage has the reverse orientation are provided in Scheme 2. According to Scheme 2, a substituted benzenesulfonamide x (prepared from a substituted benzenesulfonyl chloride and an amine or an aniline) can be converted to the desired alcohol xi upon treatment with  $CF_3$ -TMS in the presence of tetrabutylammonium fluoride in tetrahydrofuran. Alternatively, a halo-substituted benzenesulfonamide xii (similarly prepared from a halo-substituted benzenesulfonyl chloride and an amine or an aniline) can be coverted to the trifluoromethylketone xiii upon treatment with n-butyllithium followed by methyl trifluoroacetate at  $-78^{\circ}C$ . Subsequent treatment of xiii with  $CF_3$ -TMS in the presence of tetrabutylammonium fluoride in tetrahydrofuran provides compounds of formula xi.

SCHEME 2

SCHEME 2

OHCF3

R12-NS

R = Me or Et

X

$$CF_3$$
-TMS

TBAF/THF

CF3-TMS

TBAF/THF

 $CF_3$ -TMS

TBAF/THF

W = I or Br

xiii

## Solid Phase Synthesis

Scheme 3 provides one method for preparing compounds of the present invention using solid phase synthesis. In this method, an initial compound is further elaborated using a Suzuki coupling to include additional aryl substituents on a phenyl ring adjacent to the sulfonyl moiety. According to the method outlined in Scheme 2, an activated resin (e.g., 4-(bromomethyl)phenoxyethyl polystyrene from Nova Biochem) is treated with a parent compound to be derivatized (e.g., compound xiv) to provide a tethered reactive species xv. Suzuki coupling conditions are then employed to attach an aromatic moiety (Ar) in place of the bromine substituent (see Step 2) and provide a modified target compound tethered to the support (xvi). The modified target compound (xvii) is then cleaved from the support and filtered through silica gel.

Figures 1 and 2 provide structures of compounds prepared using this methodology. The aryl boronic acids used in the Suzuki coupling were from commercial sources (e.g., Aldrich Chemical Co., Milwaukee, Wisconsin, USA; Lancaster, Digital Specialty Chemicals Inc., and Combi-Blocks).

5

10

20

BNSDOCID <WO 0054759A2 L >

## Analysis of compounds

Representative compounds and compositions were demonstrated to have pharmacological activity in *in vitro* and *in vivo* assays, *e.g.*, they are capable of specifically modulating a cellular physiology to reduce an associated pathology or provide or enhance a prophylaxis.

Certain preferred compounds and compositions are capable of specifically regulating LXR. Compounds may be evaluated *in vitro* for their ability to activate LXR receptor function using biochemical assays (see co-pending applications Ser. Nos. 08/975,614 (filed November 21, 1997) and 09/163,713 (filed September 30,

15

20

25

30

1998)), or in cell-based assays such as that described in Lehnman, et al. (*J. Biol. Chem.* 1997, 272(6), 3137-3140). Alternatively, the compounds and compositions can be evaluated for their ability to increase or decrease gene expression modulated by LXR, using western-blot analysis. Established animal models to evaluate
hypocholesterolemic effects of the compounds are also known in the art. For example, compounds disclosed herein can lower cholesterol levels in hamsters fed a high-cholesterol diet, using a protocol similar to that described in Spady et al. (*J. Clin. Invest.* 1988, 81, 300), Evans et al. (*J. Lipid Res.* 1994, 35, 1634), and Lin et al (*J. Med. Chem.* 1995, 38, 277). Still further, LXRα animal models (e.g., LXRα (+/-) and (-/-) mice) can be used for evaluation of the present compounds and compositions (see, for example, Peet, et al. Cell 1998, 93, 693-704).

Accordingly, as used herein, the term "LXR-modulating amount" refers to that amount of a compound that is needed to produce a desired effect in any one of the cell-based assays, biochemical assays or animal models described above. Typically, an LXR-modulating amount of a compound will be at least that amount which exhibits an EC<sub>50</sub> in a reporter-gene cell-based assay (relative to an untreated control).

# Formulation and administration of compounds and pharmaceutical compositions

The invention provides methods of using the subject compounds and compositions to treat disease or provide medicinal prophylaxis, to activate LXR receptor function in a cell, to reduce blood cholesterol concentration in a host, to slow down and/or reduce the abnormal cellular proliferation including the growth of tumors, etc. These methods generally involve contacting the cell or cells with or administering to a host an effective amount of the subject compounds or

pharmaceutically acceptable compositions.

The compositions and compounds of the invention and the pharmaceutically acceptable salts thereof can be administered in any effective way such as via oral, parenteral or topical routes. Generally, the compounds are administered in dosages ranging from about 2 mg up to about 2,000 mg per day, although variations will necessarily occur depending on the disease target, the patient, and the route of administration. Preferred dosages are administered orally in the range of about 0.05 mg/kg to about 20 mg/kg, more preferably in the range of about 0.05 mg/kg to about 2 mg/kg, most preferably in the range of about 0.05 mg/kg to about 0.2 mg per kg of body weight per day.

WO 00/54759 PCT/US00/06611

In oh Embodiment, the invention provides the subject compounds combined with a pharmaceutically acceptable excipient such as sterile saline or other medium, water, gelatin, an oil, etc. to form pharmaceutically acceptable compositions. The compositions and/or compounds may be administered alone or in combination with any convenient carrier, diluent, etc. and such administration may be provided in single or multiple dosages. Useful carriers include solid, semi-solid or liquid media including water and non-toxic organic solvents.

In another embodiment, the invention provides the subject compounds in the form of a pro-drug, which can be metabolically converted to the subject compound by the recipient host. A wide variety of pro-drug formulations are known in the art.

The compositions may be provided in any convenient form including tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, suppositories, etc. As such the compositions, in pharmaceutically acceptable dosage units or in bulk, may be incorporated into a wide variety of containers. For example, dosage units may be included in a variety of containers including capsules, pills, etc.

The compositions may be advantageously combined and/or used in combination with other hypocholesterolemic therapeutic or prophylactic agents, different from the subject compounds. In many instances, administration in conjunction with the subject compositions enhances the efficacy of such agents. Exemplary hypocholesterolemic and/or hypolipemic agents include: bile acid sequestrants such as quaternary amines (e.g. cholestyramine and colestipol); nicotinic acid and its derivatives; HMG-CoA reductase inhibitors such as mevastatin, pravastatin, and simvastatin; gemfibrozil and other fibric acids, such as clofibrate, fenofibrate, benzafibrate and cipofibrate; probucol; raloxifene and its derivatives; and mixtures thereof.

The compounds and compositions also find use in a variety of *in vitro* and *in vivo* assays, including diagnostic assays. For example, various allotypic LDL receptor gene expression processes may be distinguished in sensitivity assays with the subject compounds and compositions, or panels thereof. In certain assays and in *in vivo* distribution studies, it is desirable to use labeled versions of the subject compounds and compositions, *e.g.* radioligand displacement assays. Accordingly, the invention provides the subject compounds and compositions comprising a detectable label, which may be spectroscopic (*e.g.* fluorescent), radioactive, *etc.* 

35

5

10

15

20

25

30

The following examples are offered by way of illustration and not by way of limitation.

## **EXAMPLES**

<sup>1</sup>H-NMR spectra were recorded on a Varian Gemini 400 MHz NMR spectrometer. Significant peaks are tabulated and typically include: number of protons, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet) and coupling constant(s) in Hertz. Electron Ionization (EI) mass spectra were recorded on a Hewlett Packard 5989A mass spectrometer. Mass spectrometry results are reported as the ratio of mass over charge, followed by the relative abundance of each ion (in parentheses). Starting materials in the synthesis examples below are either available from commercial sources such as Aldrich Chemical Co., Milwaukee, Wisconsin, USA, or via literature procedures. Abbreviations used in the examples below have their accepted meanings in the chemical literature. For example, THF (tetrahydrofuran), Et<sub>2</sub>O (diethyl ether), MeOH (methanol), CH<sub>2</sub>Cl<sub>2</sub> (methylene chloride), LDA (lithium diisopropylamide), MeCN (acetonitrile), and DMAP (4-dimethyaminopyridine).

## **EXAMPLE 1**

20

5

10

15

This example illustrates preparation of compound 1.

Commercially available 4-(1,1,1,3,3,3-hexafluoro-2-

hydroxyisopropyl)aniline (1.93 mmol, 500 mg, Lancaster Synthesis, LTD, Teaneck, New Jersey, USA) was dissolved in THF (8 mL) and triethylamine (3.86 mmol, 391 mg) was added, followed by ethyl isocyanate (1.93 mmol, 137 mg). The mixture was heated at 60°C for 24 hours. The resulting mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and quenched with water. The organic layer was separated and dried with MgSO<sub>4</sub>, the solvent was evaporated and the crude product was recrystallized from MeOH/CH<sub>2</sub>Cl<sub>2</sub> to afford 353 mg of 1.

30

25

mp 170-172°C.

<sup>1</sup>H-N.  $(CD_3OD)$ : (7.58 (d, J=8.8 Hz, 2H), 7.42 (d, 8.8 Hz, 2H), 3.23 (m, 2H), 1.15 (t, J=7.28 Hz, 3H). MS (ES+): 331 (M+H, 100). Anal. Calcd. for  $C_{12}H_{12}N_2F_6$   $O_2$ : C, 43.78; H, 3.66; N, 8.48. Found: C, 48.02; H, 3.72; N, 8.36.

5

## **EXAMPLE 2**

This example illustrates preparation of sulfonamide 2.

10

15

20

To a solution of 4-(hexafluoro-2-hydroxyisopropyl)aniline (77.2 mmol, 20 g) in MeOH (200 mL) was added benzenesulfonyl chloride (61.74 mmol, 11.01 g). The mixture was stirred at ambient temperature for 2.5 hours. The solvent was evaporated under reduced pressure and the crude product was dissolved in  $Et_2O$  and washed with 3N HCl. The organic layer was separated, the solvent was evaporated and the crude product was purified by silica column chromatography using 25% MeOH/CH<sub>2</sub>Cl<sub>2</sub> to afford 14.7g of product.

mp 111-113°C.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 7.16 (d, J=7.16 Hz, 2H), 7.56 (m, 2H), 7.45 (m, 2H), 7.14 (dd, J=2.12, 6.84 Hz, 2H), 6.89 (s, 1H), 3.41 (s, 1H). MS (ES-): 398 (M-H, 100). Anal. Calcd. for C<sub>15</sub>H<sub>11</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 45.12; H, 2.78; N, 3.51. Found: C, 45.02; H, 2.90; N, 3.54.

The following compounds were prepared in a manner similar to that described above.

25

2.1.

mp 205-209°C.

<sup>1</sup>H-NMR(d<sub>6</sub>-DMSO): δ 11.1 (bs, 1H), 8.61 (s, 1H), 8.08 (d, *J*=8.68 Hz, 1H), 7.89 (d, *J*=8.68 Hz, 1H), 7.55 (d, *J*=8.68 Hz, 2H), 7.20 (dd, *J*=1.96, 6.88 Hz, 2H). MS (ES-): 501 (M-H, 100). Anal. Calcd. for C<sub>15</sub>H<sub>8</sub>Cl<sub>3</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 35.84; H, 1.60; N, 2.79. Found: C, 36.42; H, 1.85; N, 2.66.

2.2

mp 113-115°C.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD): δ 7.71 (m, 1H), 7.61-7.54 (m, 3H), 7.24 (m, 2H), 7.06 (m, 1H). MS (ES+): 404 (M+H<sup>+</sup>, 100). Anal. Calcd. for C<sub>13</sub>H<sub>9</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 38.52; H, 2.24; N, 3.46. Found: C, 38.79; H, 2.28; N, 3.28.

15

20

25

## **EXAMPLE 3**

This example illustrates the preparation of (3) via N-methylation of (2).

To N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl-benzenesulfonamide (2) (2.5 g), in DMF (60 mL) was added K<sub>2</sub>CO<sub>3</sub> (1.6 g) and methyl iodide (0.64 mL). The reaction was stirred at room temperature for 1.5 hours, then worked up using standard methods, and the crude product was purified by column chromatography to afford the 3.5 g of the title compound.

. mp 79-81°C.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 7.63-7.45 (m, 7H), 7.26 (m, 2H), 3.50 (s, 3H), 3.22 (s, 3H). MS (ES+): 428 (M+H, 100). Anal. Calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 47.78; H, 3.54; N, 3.20; S, 7.50. Found: C, 47.87; H, 3.61; N, 3.27; S, 7.55.

5

10

15

20

## **EXAMPLE 4**

This example illustrates preparation of sulfonamide, 4.

To N-methyl-4-(hexafluoro-2-hydroxyisopropyl)aniline (0.915 mmol, 250 mg) prepared as reported by Gilbert et al. (J. Org. Chem., 1965, 30, 1001) in MeOH (2.5 mL) was added p-toluenesulfonyl chloride (0.763 mmol, 145 mg). The reaction was stirred overnight at ambient temperature and the solvent was evaporated under reduced pressure. The crude product was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and washed with 3N HCl. The organic layer was separated, the solvent evaporated and the crude product was purified by silica column chromatography to afford 130 mg of 4.

mp 98-101°C.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 7.64 (d, J=8.4 Hz, 2H), 7.39 (d, J=8.16 Hz, 2H), 7.21 (m, 4H), 3.16 (s, 3H), 2.40 (s, 3H). MS (ES-): 426 (M-H, 100). Anal. Calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>6</sub>NO3S: C, 47.78; H, 3.54; N, 3.20; S, 7.50. Found: C, 48.02; H, 3.52; N, 3.20; S, 7.57.

The following compounds were prepared using methods similar to those described in this and the preceding examples, with the appropriately substituted arylsulfonyl chlorides or alkylsulfonyl chlorides.

4.1

25

mp 132-134°C.

 $^{1}$ H-NMR(CDCl<sub>3</sub>): δ 7.64 (d, J=8.8Hz, 2H), 7.44 (s, 4H), 7.23 (d, J=8.8 Hz, 2H), 3.18 (s, 3H), 1.32 (s, 9H). MS (ES-): 468 (M-H, 100). Anal. Calcd. for  $C_{20}H_{21}F_6NO_3S$ : C, 51.17; H, 4.51; N, 2.98; S, 6.83. Found: C, 51.32; H, 4.47; N, 2.88; S, 6.76.

5

4.2

mp 104-106°C.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 8.30 (d, *J*=8.9 Hz, 2H), 7.70 (m, 4H), 7.20 (d, *J*=9 Hz, 2H), 3.24 (s, 3H). MS (ES-): 457 (M-H, 100). Anal. Calcd. for C<sub>16</sub>H<sub>12</sub>F<sub>6</sub>N<sub>2</sub>O<sub>5</sub>S: C, 41.93; H, 2.64; N, 6.11; S, 7.00. Found: C, 42.11; H, 2.71; N, 5.95; S, 6.85.

4.3

15

mp 65-69°C.

 $^{1}$ H-NMR(CDCl<sub>3</sub>):  $\delta$  7.63 (d, J=8.7 Hz, 2H), 7.34 (m, 3H), 7.03 (dd, 8.9, 3.0 Hz, 1H), 6.85 (d, J=9.04 Hz, 1H), 3.74 (s, 3H), 3.54 (s, 3H), 3.32 (s, 3H). MS (ES+): 474 (M+H, 100). Anal. Calcd. for  $C_{18}H_{17}F_{6}NO_{5}S$ : C, 45.67; H, 3.62; N, 2.96; S, 6.77. Found: C, 45.21; H, 3.71; N, 2.93; S, 6.58.

20

1 1

mp 109-111°C.

mp 175-180°C.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 8.4 (d, J=8.4 Hz, 2H), 7.44 (d, J=8.8 Hz, 2H), 7.21 (d, J=8.9 Hz, 2H), 6.90 (d, J=8.9 Hz, 2H), 3.84 (s, 3H), 3.16 (s, 3H). MS (ES+): 444 (M+H, 100). Anal. Calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>6</sub>NO<sub>4</sub>S: C, 46.05; H, 3.41; N, 3.16; S, 7.23. Found: C, 45.84; H, 3.41; N, 3.12; S, 7.14.

4.5

10

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 8.21 (d, J=8.8 Hz, 1H), 8.12 (d, J=7.6 Hz, 1H), 7.64 (dd, J=7.08, 8.8 Hz, 1H), 7.56 (d, J=8.76 Hz, 2H), 7.21 (d, J=8.5 Hz, 2H), 3.53 (s, 3H). MS (ES-): 470 (M-H, 100). Anal. Calcd. for C<sub>16</sub>H<sub>11</sub>F<sub>6</sub>N<sub>3</sub>O<sub>3</sub>S<sub>2</sub>: C, 40.77; H, 2.35; N, 8.91; S, 13.60. Found: C, 40.64; H, 2.22; N, 8.84; S, 13.78.

15

4.6

mp 113-115°C.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 8.06 (dd, *J*=9.12, 0.7 Hz, 1H), 7.85 (dd, *J*=6.88, 0.8 Hz, 1H), 7.60 (d, *J*=9.0 Hz, 2H), 7.46 (dd, *J*=9.08, 6.84 Hz, 1H), 7.25 (d, *J*=9.0 Hz, 2H), 3.55 (s, 3H).

mp195-197°C.

4.8

10

15

mp 90-91°C.

'H-NMR(CDCl<sub>3</sub>): δ 7.66 (d, *J*=8.5 Hz, 2H), 7.58 (d, *J*=8.6 Hz, 2H), 7.37 (d, *J*=8.64 Hz, 2H), 7.23 (d, *J*=8.8 Hz, 2H), 3.19 (s, 3H). MS (ES-): 491 (M-H, 100), 489 (M-H, 100). Anal. Calcd. for C<sub>16</sub>H<sub>12</sub>BrF<sub>6</sub>NO<sub>3</sub>S: C, 39.04; H, 2.46; N, 2.85; S, 6.51; Br, 16.23. Found: C, 39.24; H, 2.44; N, 2.71; S, 6.52; Br, 16.38.

4.9

mp 98-99°C.

 $^{1}$ H-N...R(CDCl<sub>3</sub>): δ 7.67 (d, J=9 Hz, 2H), 7.54 (m, 2..., 7.21 (d, J=9.0 Hz, 2H), 7.13 (m, 2H), 3.20 (s, 3H). MS (ES-): 430 (M-H, 100). Anal. Calcd. for  $C_{16}H_{12}F_{7}NO_{3}S$ : C, 44.55; H, 2.80; N, 3.25; S, 7.43. Found: C, 44.54; H, 2.83; N, 3.18; S, 7.39.

5

4.10

mp 98-100°C.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 8.8 (d, *J*=8.8 Hz, 2H), 7.55 (m, 1H), 7.49 (s, 1H), 7.38 (m, 2H), 7.21 (d, *J*=9 Hz, 2H), 3.21 (s, 3H). MS (ES-): 446 (M-H, 100). Anal. Calcd. for C<sub>16</sub>H<sub>12</sub>ClF<sub>7</sub>NO<sub>3</sub>S: C, 42.92; H, 2.70; N, 3.13; S, 7.16; Cl, 7.92. Found: C, 42.90; H, 2.62; N, 3.02; S, 7.15; Cl, 8.04.

4.11

15

20

mp 114-116°C.

 $^{1}$ H-NMR(CDCl<sub>3</sub>): δ 7.94 (d, J=6.5 Hz, 1H), 7.62 (d, J=8.8 Hz, 2H), 7.48 (m, 2H), 7.33 (m, 3H), 3.42 (s, 3H). MS (ES-): 446 (M-H, 100). Anal. Calcd. for  $C_{16}H_{12}ClF_{7}NO_{3}S$ : C, 42.92; H, 2.70; N, 3.13; S, 7.16; Cl, 7.92. Found: C, 42.84; H, 2.62; N, 3.02; S, 7.24; Cl, 8.03.

mp 124-126°C.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 7.68 (m, 4H), 7.42 (m, 1H), 7.33 (m, 1H), 7.21 (d, ./=8.08 Hz, 2H), 3.21 (s, 3H). Anal. Calcd. for C<sub>16</sub>H<sub>12</sub>BrF<sub>6</sub>NO<sub>3</sub>S: C, 39.04; H, 2.46; N, 2.85; S, 6.51; Br, 16.23. Found: C, 39.04; H, 2.38; N, 2.75; S, 6.45; Br, 16.36.

4.13

10

mp 79-81°C.

 $^{1}$ H-NMR(CDCl<sub>3</sub>): δ 7.83 (d, J=7.0 Hz, 1H), 7.74 (d, J=7.0 Hz, 1H), 7.66 (m, 3H), 7.63 (m, 1H), 7.18 (d, J=7.0 Hz, 2H), 3.20 (s, 3H). MS (ES-): 480 (M-H, 100). Anal. Calcd. for  $C_{17}H_{12}F_{9}NO_{3}S$ : C, 42.42; H, 2.51; N, 3.91; S, 6.66. Found: C, 42.66; H, 2.48; N, 2.96; S, 6.49.

15

4.14

mp 135-137°C.

MS (ES-): 430 (M-H, 100). Anal. Calcd. for C<sub>16</sub>H<sub>12</sub>F<sub>7</sub>NO<sub>3</sub>S: C, 44.55; 20 H, 2.80; N, 3.25; S, 7.43. Found: C, 44.45; H, 2.76; N, 3.17; S, 7.48.

mp 135-137°C.

MS (ES-): 430 (M-H, 100). Anal. Calcd. for  $C_{16}H_{12}F_7NO_3S$ : C, 44.55;

5 H, 2.80; N, 3.25; S, 7.43. Found: C, 44.65; H, 2.84; N, 3.17; S, 7.39.

4.16

mp 115-118°C.

4.17

15

mp 88-89°C.

 $^{1}$ H-NMR(d<sub>6</sub>-DMSO):  $\delta$  8.80 (s, 1H), 7.75-7.50 (m, 7H), 7.25 (m, 2H), 3.60 (m, 2H), 3.31 (s, 3H), 0.977 (m, 3H). MS (ES+): 428 (M+H, 100).

<sup>1</sup>H-NMR(CD<sub>3</sub>OD): δ 8.57 (dd, *J*=1.12, 8.56 Hz, 1H), 8.13 (m, 1H), 8.36 (m, 1H), 7.61-7.52 (m, 3H), 7.23-7.15 (m, 4H), 3.22 (s, 3H), 2.84 (s, 6H). MS (ES+): 507 (M+H, 100).

4.19

mp180-183°C.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD): δ 8.92 (dd, *J*=4.2, 1.76 Hz, 1H), 8.39 (dd, *J*=8.36, 1.72 Hz, 1H), 8.35 (dd, *J*=1.36, 7.36 Hz, 1H), 8.17 (dd, *J*=1.32, 8.2 Hz, 1H), 7.63 (m, 2H), 7.52 (m, 2H), 7.25 (dd, *J*=6.88, 2.0 Hz, 2H), 3.61 (s, 3H). MS (ES+): 465 (M+H, 100).

4.20

15

mp 208-210°C.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD): δ 8.12 (d, *J*=8.56 Hz, 2H), 7.70 (d, *J*=8.72 Hz, 2H), 7.64 (d, *J*=8.6 Hz, 2H), 7.26 (d, *J*=8.96 Hz, 2H), 3.24 (s, 3H). MS (ES-): 456 (M-H, 20 100).

mp 102-106°C.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD): δ 7.72 (d, *J*=8.4 Hz, 2H), 7.36 (dd, *J*=2.12, 6.88 Hz, 2H), 3.31 (s, 3H), 2.22 (s, 3H), 1.86 (s, 3H). MS (ES+): 492 (M+H, 100).

4.22

mp 204-206°C.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD): δ 9.30 (s, 1H), 8.41 (m, 2H), 8.13 (d, *J*=1.5 Hz, 1H), 7.83 (t, *J*=8.03 Hz, 1H), 7.74 (d, *J*=6.32 Hz, 1H), 7.60 (d, *J*=8.8 Hz, 2H), 7.20 (dd, *J*=2.08, 6.84 Hz, 2H), 3.24 (s, 3H). MS (ES+): 465 (M+H, 50).

4.23

15

mp 199-202°C.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD): δ 8.26 (m,1H), 7.71 (m, 3H), 7.63 (t, *J*=8.12 Hz, 1H), 7.25 (dd, *J*=2.12, 6.8 Hz, 2H), 3.23 (s, 3H). MS (ES+): 458 (M+H, 100).

4.24

mp 133-136°C.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD): δ 7.82 (dd, *J*=5.08, 1.28 Hz, 1H), 7.70 (d, *J*=8.52 Hz, 2H), 7.38 (dd, *J*=1.2, 3.74 Hz, 1H), 7.28 (m, 2H), 7.16 (m, 1H), 3.26 (s, 3H). MS (ES+): 420 (M+H, 100).

4.25

10

mp 120-122°C.

 $^{1}$ H-NMR(CD<sub>3</sub>OD):  $\delta$  7.68 (d, J=8.72 Hz, 2H), 7.61 (s, 1H), 7.43 (s, 1H), 7.38 (m, 2H), 3.40 (s, 3H). MS (ES-): 487 (M-H, 100).

4.26

15

Oil.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD): δ 7.90 (m, 1H), 7.70-7.63 (m, 3H), 7.40 (m, 2H), 3.42 (s, 3H). MS (ES-): 515 (M-H, 100).

mp 148-149°C.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD): δ 8.80 (d, *J*=4.76 Hz, 1H), 8.64 (s, 1H), 7.96 (m, 1H), 7.72 (d, *J*=8.72 Hz, 2H), 7.59 (m, 1H), 7.28 (d, *J*=9 Hz, 2H), 3.26 (s, 3H). MS (ES-): 413 (M-H, 100).

4.28

10

mp 130-134°C.

'H-NMR(CD<sub>3</sub>OD): δ 7.64 (m, 1H), 7.54 (m, 6H), 7.12 (dd, J=6.64, 2.12 Hz, 2H), 3.18 (s, 3H). MS (ES+): 459 (M+H<sup>+</sup>, 100). Anal. Calcd. for  $C_{16}H_{12}F_6N_2O_5S$ : C, 41.93; H, 2.64; N, 6.11. Found: C, 41.64; H, 2.69; N, 6.10.

15

4.29

4.29

mp 83-86°C.

 $^{1}$ H-NMR(CD<sub>3</sub>OD): δ 7.82 (m, 1H), 7.73 (m, 2H), 7.40 (m, 1H), 7.24 (m, 2H), 7.15 (m, 1H), 3.71 (q, J=7.16, 14.24 Hz, 2H), 1.09 (t, J= 7.24 Hz, 3H). MS (ES+): 434 (M+H $^{+}$ , 100).

PCT/US00/06611

4.30

mp 87-89°C.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD): δ 8.86 (s, 1H), 8.07 (dd, *J*=1.28, 4.92 Hz, 1H), 7.71 (m, 2H), 7.36 (m, 2H), 7.28 (m, *J*=3.84, 4.98 Hz, 1H), 4.61 (q, *J*=8.8, 17.6 Hz, 2H).

4.31

10 mp 142-145°C.

'H-NMR(CD<sub>3</sub>OD): δ 7.68 (m, 5H), 7.44 (s, 1H), 7.28 (m, 2H), 3.24 (s, 3H), 3.06 (s, 3H), 2.84 (s, 3H). Anal. Calcd. for  $C_{19}H_{18}F_6N_2O_4S$ : C, 47.11; H, 3.75; N, 5.78. Found: C, 47.19; H, 3.75; N, 5.77.

15 4.32

4.32

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.70 (d, J = 8.4 HZ, 2H), 7.50 (m, 4H), 7.25 (d, J = 8.4 Hz, 2H), 6.78 (dd, J = 16.0, 11.0 Hz, 1H), 5.90 (d, J = 16.0 Hz, 1H), 5.48 (d, J = 20 11.0 Hz, 1H), 3.55 (s, 1H), 3.28 (s, 3H). MS (ES-): 438 (M-H, 100).

4.33

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.70 (d, J = 8.5 Hz, 2H), 7.42 (d, J = 5.0 Hz, 1H), 7.35 (d, J = 8.5 Hz, 2H), 7.25 (d, J = 5 Hz, 1H), 3.75 (s, 3H), 3.65 (s, 1H), 3.35 (s, 3H). MS (ES+): 478 (M+H, 100).

4.34

10

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.91 (d, J = 7.5 Hz, 1H), 7.68 (d, J = 8.4 Hz, 2H), 7.63 (t, J = 8.4 Hz, 1H), 7.36 (t, J = 7.5 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H), 3.60 (s, 1H), 3.30 (s, 3H). MS (ES+): 498 (M+H, 100).

4.34

15

4.35

4.35

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.65 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 6.95 (d, J = 5.0 Hz, 1H), 6.70 (d, J = 5.0 Hz, 1H), 3.82 (s, 1H), 3.35 (s, 3H). MS (ES-20 ): 492 (M-H, 100).

4.36

4.36



 $^{3}$ H NMR (CDCl<sub>3</sub>): δ 8.05 (d, J = 7.5 Hz, 2H), 7.76 (d, J = 7.5 Hz, 2H), 7.70 (d, J = 8.2 Hz, 2H), 7.21 (d, J = 8.2 Hz, 2H), 3.57 (s, 1H), 3.21 (s, 3H), 3.06 (s, 3H). MS (ES-): 490 (M-H, 100).

5

4.37

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.68 (d, J = 8.5 Hz, 2H), 7.50 (s, 1H), 7.40 (d, J = 8.5 Hz, 2H), 7.20 (s, 1H), 3.70 (s, 3H), 3.30 (s, 3H). MS (ES+): 418 (M+H, 100).

10

4.38

4.37

4.38

<sup>1</sup>H NMR (CD<sub>3</sub>OD):  $\delta$  7.70 (d, J = 8.5 Hz, 2H), 7.43 (d, J = 8.5 Hz, 2H), 7.33 (d, J = 5.0 Hz, 1H), 6.92 (d, J = 5.0 Hz, 1H), 3.46 (s, 2H). MS (ES-): 925 (2M-H, 100). Anal. Calcd. for C<sub>15</sub>H<sub>11</sub>F<sub>6</sub>NO<sub>5</sub>S<sub>2</sub>: C, 38.88; , 2.39; N, 3.02; S, 13.84. Found: C, 39.65; H, 2.97; N, 2.70; S, 12.09.

4.39

20

4.39

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.90 (d, J = 7.5 Hz, 1H), 7.78 (d, J = 7.5 Hz, 1H), 7.70 (t, J = 7.5 Hz, 1H), 7.68 (d, J = 8.4 Hz, 2H), 7.57 (t, J = 7.5 Hz, 1H), 7.27 (d, J = 8.4 Hz, 2H), 3.83 (s, 1H), 3.36 (s, 3H). MS (ES-): 480 (M-H, 100). Anal. Calcd. for C<sub>17</sub>H<sub>12</sub>F<sub>9</sub>NO<sub>3</sub>S: C, 42.42; H, 2.51; N, 2.91; S, 6.66. Found: C, 43.71; H, 2.75; N, 2.67; S, 6.92.

4.40

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.72 (d, J = 7.2 Hz, 2H), 7.69 (d, J = 8.2 Hz, 2H), 7.66 (d, J = 7.2 Hz, 2H), 7.21 (d, J = 8.2 Hz, 2H), 3.52 (s, 1H), 3.20 (s, 3H). MS (ES-): 480 (M-H, 100).

4.41

4.41

•

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.72 (d, J = 7.2 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 3.58 (s, 1H), 3.25 (s, 3H), 2.25 (s, 3H), 1.96 (s, 3H). MS (ES-): 431 (M-H, 100).

4.42

4.42

15

10

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.56 (s, 1H), 7.78 (t, J = 7.2 Hz, 1H), 7.65 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 4.5 Hz, 1H), 7.30 (d, J = 8.4 Hz, 2H), 7.28 (m, 2H), 7.21 (d, J = 4.5 Hz, 1H), 3.30 (s, 3H). MS (ES-): 495 (M-H, 100).

20

4.43

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.72 (d, J = 7.5 Hz, 1H), 7.65 (d, J = 8.4 Hz, 2H), 7.50 (s, 1H), 7.48 (d, J = 7.5 Hz, 1H), 7.29 (d, J = 8.4 Hz, 2H), 3.85 (s, 1H), 3.35 (s, 3H). MS (ES-): 576 (M-H, 100).

5

4.44

4.44

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.86 (d, *J* = 7.8 Hz, 1H), 7.85 (s, 1H), 7.70 (d, *J* = 8.5 Hz, 2H), 7.60 (d, *J* = 7.8 Hz, 2H), 7.20 (d, *J* = 8.5 Hz, 2H), 3.48 (s, 1H), 3.25 (s, 3H). MS (ES-): 437 (M-H, 100). Anal. Calcd. for C<sub>17</sub>H<sub>12</sub>F<sub>6</sub>N<sub>2</sub>O<sub>3</sub>S: C, 46.58; H, 2.76; N, 6.39; S, 7.32. Found: C, 46.97; H, 2.92; N, 6.18; S, 7.17.

4.45

4.45

15

20

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.88 (d, J = 8.0 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 7.26 (t, J = 8.0 Hz, 1H), 3.45 (s, 3H), 3.44 (s, 1H). MS (ES-): 481 (M-H, 100). Anal. Calcd. for C<sub>16</sub>H<sub>11</sub>Cl<sub>2</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 39.85; H, 2.30; Cl, 14.70; N, 2.90; S, 6.65. Found: C, 40.49; H, 2.37; N, 2.89; S, 6.60; Cl, 14.95.

4.46

4.46

25

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.71 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.5 Hz, 2H), 6.86 (s, 1H), 3.41 (s, 1H), 3.35 (s, 3H). MS (ES-): 486 (M-H, 100). Anal. Calcd. for

 $C_{14}H_9C_{12}F_6NO_3S_2$ : C, 34.44; H, 1.86; Cl, 14.52; N, 2.87; S, 13.13. Found: C, 35.20; H. 1.87; N, 2.95; S, 13.31; Cl, 15.04.

4.47

4.47

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.75 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 3.49 (s, 1H), 3.37 (s, 3H), 2.88 (s, 3H). MS (ES-): 350 (M-H, 100). Anal. Calcd. for C<sub>11</sub>H<sub>11</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 37.61; H, 3.16; N, 3.99; S, 9.13. Found: C, 37.83; H, 3.27; N, 4.03; S, 9.28.

4.48

4.48

4.49

20

10

4.49

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.72 (d, J = 8.2 Hz, 2H), 7.48 (d, J = 8.2 Hz, 2H), 3.65 (s, 1H), 3.30 (s, 3H), 3.01 (t, J = 6.3 Hz, 2H), 1.80 (m, 2H), 1.31 (m, 2H), 0.92 (t, J = 6.0 Hz, 3H). MS (ES-): 392 (M-H, 100).

4.50

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.71 (d, *J* = 8.2 Hz, 2H), 7.50 (d, J= 8.2 Hz, 2H), 3.90 (s, 1H), 3.41 (s, 3H), 3.32 (m, 1H), 1.38 (d, *J* = 6.0 Hz, 6H). MS (ES-): 378 (M-H, 100).

4.51

10

4.51

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.60 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 7.25 (d, J = 2.5 Hz, 1H), 7.15 (dd, J = 7., 2.5 Hz, 1H), 7.06 (d, J = 7.2 Hz, 1H), 4.30 (q, J = 7.0 Hz, 2H), 4.20 (q, J = 7.0 Hz, 2H), 3.50 (s, 1H), 3.38 (s, 3H). MS (ES-): 610 (M+H, 100).

15

4.52

4.52

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.78 (d, J = 7.0 Hz, 2H), 7.70 (d, J = 8.2 Hz, 2H), 7.62 (d, J = 7.0 Hz, 2H), 7.20 (d, J = 8.2 Hz, 2H), 3.51 (s, 1H), 3.21 (s, 3H). MS (ES): 437 (M-H, 100).

4.53

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.82 (m, 2H), 7.68 (d, J = 8.4 Hz, 2H), 7.65 (m, 2H), 7.28 (d, J = 8.4 Hz, 2H), 3.72 (s, 1H), 3.40 (s, 3H). MS (ES-): 437 (M-H, 100).

4.54

10

15

20

25

4.54

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.90 (s, 1H), 7.66 (d, J = 8.4 Hz, 2H), 7.42 (m, 2H), 7.33 (d, J = 8.4 Hz, 2H), 3.47 (s, 1H), 3.40 (s, 3H). MS (ES-): 481 (M-H, 100). Anal. Calcd. for C<sub>16</sub>H<sub>11</sub>Cl<sub>2</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 39.85; H, 2.30; N, 2.90; S, 6.65. Found: C, 40.01; H, 2.19; N, 2.99; S, 6.82.

4.55

4.55

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.80 (s, 1H), 7.77 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 3.50 (s, 1H), 3.31 (s, 3H). MS (ES-): 496 (M-H, 100).

4.56

4.56

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.72 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 7.12 (s,1H), 3.48 (s, 1H), 3.28 (s, 3H). MS (ES-): 531 (M+H, 100). Anal. Calcd. for C<sub>14</sub>H<sub>9</sub>BrClF<sub>6</sub>NO<sub>3</sub>S<sub>2</sub>: C, 31.57; H, 1.70; N, 2.63; S, 12.21. Found: C, 40.01; H, 2.19; N, 2.99; S, 6.82.

4.57

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.66 (d, J = 8.4 Hz, 2H), 7.35 (, 3H), 7.20 (m, 3H), 3.50 (s, 1H), 3.19 (s, 3H), 2.30 (s, 3H). MS (ES-): 426 (M-H, 100).

4.58

4.58

<sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 8.59 (s, 1H), 7.97 (2H, J = 7.8 Hz, 2H), 7.70 (t, J = 7.8 Hz, 1H), 7.68 (d, J = 8.2 Hz, 2H), 7.62 (t, J = 7.8 Hz, 2H), 7.50 (s, 1H), 7.20 (d, J = 8.2 Hz, 2H), 3.30 (s, 1H), 3.21 (s, 3H). MS (ES-): 558 (M-H, 100). Anal. Calcd. for C<sub>20</sub>H<sub>15</sub>F<sub>6</sub>NO<sub>5</sub>S<sub>3</sub>: C, 42.93; H, 2.73; N, 2.50; S, 17.19. Found: C, 43.07, H, 2.70; N, 2.50; S, 17.30.

15

4.59

4.59

This compound was prepared from 4.46 using conditions similar to the palladium-catalyzed reduction of Example 5, below (monitoring the reaction to obtain an incomplete reduction of the chloro substituents).

'H NMR (CDCl<sub>3</sub>): δ 7.70 (d, J = 8.8 Hz, 2H), 7.50 (s, 1H), 7.28 (d, J = 8.8 Hz, 2H), 6.83 (s, 1H), 3.37 (s, 1H), 3.25 (s, 1H). MS (ES-): 907 (2M-H, 100). Anal. Calcd. for  $C_{14}H_{10}ClF_6NO_3S_2$ : C, 37.05; H, 2.22; N, 3.09. Found: C, 37.92; H, 2.35; N, 3.11.

4.60

This compound was prepared from **4.46** using conditions similar to the palladium-catalyzed reduction of Example 5, below.

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.76 (d, J = 3.0 Hz, 1H), 7.67 (d, J = 8.8 Hz, 2H), 7.37 (dd, J = 4.0, 1.5 Hz, 1H), 7.27 (d, J = 8.8 Hz, 2H), 6.99 (d, J = 4.0 Hz, 1H), 3.49 (s, 1H), 3.22 (s, 3H). MS (ES-): 461 (M-H, 100). MS (ES-): 837 (2M-H, 100). Anal. Calcd. for  $C_{14}H_{11}F_6NO_3S_2$ : C, 40.10; H, 2.64; N, 3.34. Found: C, 40.22; H, 2.67; N, 3.36.

4.61

The starting aniline was prepared via treatment of 4-

15 (trifluoroacetyl)aniline with methyl magnesium bromide. Subsequent alkylation and sulfonylation was carried out as described in the examples above.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD): δ 7.64 (m, 1H), 7.54 (m, 6H), 7.12 (dd, *J*=6.64, 2.12, 2H), 3.18 (s, 3H). MS (ES+): 382 (M+Na<sup>+</sup>, 50). Oil

20

4.28.

10

### **EXAMPLE 5**

This example illustrates preparation of compound 5 by reduction of

To a mixture of N-Methyl-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-3-nitrobenzenesulfonamide (4.28) (70 mg), dissolved in 10 mL of MeOH was added 10% Pd/carbon (10mg) and the reaction was stirred under a  $H_2$  atmosphere for 2 days. The resulting mixture was filtered through Celite and the solvent was evaporated under reduced pressure. The crude product was purified by preparative-TLC to obtain 30 mg of the title compound as an oil.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD): δ 7.66 (d, J=8.76 Hz, 2H), 7.23 (m, 3H), 6.91 (d, J=7.9 Hz, 1H), 6.86 (d, J=1.62, 7.96 Hz, 1H), 6.74 (s, 1H), 3.19 (s, 3H). Anal. Calcd. For C<sub>19</sub>H<sub>18</sub>F<sub>6</sub>N<sub>2</sub>O<sub>4</sub>S: C, 47.11; H, 3.75; N, 5.78. Found: C, 47.19; H, 3.75; N, 5.77.

# **EXAMPLE 6**

This example illustrates preparation of compound 6 via esterification

15 of 4.23.

10

20

25

30

To N-Methyl-N-[4-[2,2,2-trifluoro-1-hydroxy-1vl)ethyl]phenyl]-3-carboxybenzenesulfonamide (4

(trifluoromethyl)ethyl]phenyl]-3-carboxybenzenesulfonamide (4.23, 0.536 mmol, 245 mg) under  $N_2$  at 0°C, in 10 mL of THF was added triethylamine (2.15 mmol, 300  $\mu$ L), MeOH (0.864 mmol, 35  $\mu$ L), and bis(2-oxo-3-oxazolidinyl)phosphinic chloride (0.833 mmol, 212 mg). The mixture was stirred for 20 h at 0°C. The reaction was quenched with water, the THF was removed under vacuum, and the reaction product was extracted with EtOAc. The organic extract was dried with MgSO<sub>4</sub>, the solvent was evaporated and the crude product was purified by preparative TLC to afford 106 mg of the title compound as a solid.

mp 88-90°C.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD): δ 8.26 (d, J=7.68 Hz, 1H), 8.03 (d, J=1.7 Hz, 1), 7.73 (m, 3H), 7.68 (m, 3H), 7.25 (m, 2H) 3.89 (s, 3H), 3.22 (s, 3H). MS (ES+): 472 (M+H<sup>+</sup>, 100). Anal. Calcd. for C<sub>18</sub>H<sub>15</sub>F<sub>6</sub>NO<sub>5</sub>S: C, 45.86; H, 3.21; N, 2.97. Found: C, 46.02; H, 3.32; N, 2.91.

## **EXAMPLE 7**

This example provides the synthesis of compound 7.

7

To a stirred solution of N-methyl-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]aniline (80 mg, 0.293 mmol) and diisopropylethylamine (112 mL, 0.630 mmol) in dichloromethane (2 mL) was added isobutyl chloroformate (42 mL, 0.323 mmol) at 0°C. The resulting mixture was stirred for 6 h as the cooling bath temperature increased to room temperature. The reaction mixture was diluted with ethyl acetate, and the organic phase was washed sequentially with 1N HCl and brine. The separated organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by flash chromatography on silica gel (hexanes and ethyl acetate (4:1) as eluant) to give the title compound (80 mg, 73.2%) as a clear oil.

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.70 (d, J=8.5 Hz, 2H), 7.39 (d, J=8.5 Hz, 2H), 3.93 (d, J=7.2 Hz, 2H), 3.69 (s, 1H), 3.37 (s, 3H), 1.92 (m, 1H), 0.90 (d, J=6.3 Hz, 6H). Anal. Calcd. for C<sub>15</sub>H<sub>17</sub>F<sub>6</sub>NO<sub>3</sub>: C, 48.26; H, 4.59; N, 3.75. Found: C, 48.34; H, 4.61; N, 3.72.

20

10

15

The following carbamates were prepared according to the procedure described.

7.1

25 ·

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.71 (d, *J*=8.6 Hz, 2H), 7.43 (d, *J*=8.6 Hz, 2H), 7.05 (m, 4H), 4.46 (s, 1H), 3.42 (s, 3H). MS (ES-): 412 (M+H, 100).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.69 (d, *J*=8.4 Hz, 2H), 7.37 (d, *J*=8.4 Hz, 2H), 5.75 (m, 1H), 5.05 (d, *J*=16.5 Hz, 1H), 5.04 (d, *J*=10.0 Hz, 1H), 4.20 (t, *J*=6.5 Hz, 2H), 3.40 (s, 1H), 3.35 (s, 3H), 2.40 (m, 2H). MS (ES-): 370 (M-H, 100).

7.3

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.69 (d, *J*=8.4 Hz, 2H), 7.35 (d, *J*=8.4 Hz, 2H), 10 5.15 (s, 1H), 4.30 (m, 2H), 3.60 (m, 2H). MS (ES-): 374 (M-H, 100).

7.4

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.05 (d, *J*=7.8 Hz, 2H), 7.75 (d, *J*=8.5 Hz, 2H), 7.43 (d, *J*=8.5 Hz, 2H), 7.20 (d, *J*=7.8 Hz, 2H), 4.81 (s, 1H), 3.90 (s, 3H), 3.45 (s, 3H). MS (ES-): 452 (M+H, 100).

7.5

INSDOCID <WO\_\_\_0054759A2\_1\_>

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.70 (d, *J*=8.6 Hz, 2H), 7.37 (d, *J*=8.6 Hz, 2H), 3.81 (s, 2H), 1.10 (s, 9H). MS (ES-): 386 (M-H, 100). Anal. Calcd. for C<sub>17</sub>H<sub>13</sub>F<sub>6</sub>NO<sub>3</sub>: C, 49.62; H, 4.94; N, 3.62. Found: C, 49.78; H, 5.02; N, 3.64.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.70 (d, *J*=8.6 Hz, 2H), 7.35 (d, *J*=8.6 Hz, 2H), 7.30 (m, 5H), 5.18 (s, 2H), 5.05 (s, 1H), 3.32 (s, 3H). MS (ES-): 408 (M-H, 100).

5

### **EXAMPLE 8**

This example provides the synthesis of urea (8).

$$\begin{array}{c} \text{HO} \\ \text{F}_3 \text{C} \\ \end{array} \begin{array}{c} \text{O} \\ \text{CH}_3 \\ \end{array} \begin{array}{c} \text{CF}_3 \\ \end{array}$$

10

. 15

20

8

A mixture of N-methyl-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]aniline (50 mg, 0.83 mmol), N,N-dimethylaminopyridine (DMAP, 22 mg, 0.183 mmol) and 4-trifluoromethylphenylisocyanate (26 mL, 0.183 mmol) in toluene (1 mL) was stirred at room temperature until reaction was completed by tlc. The resulting mixture was diluted with ethyl acetate, washed with 1N HCl and brine. The organic layer was dried over MgSO<sub>4</sub>, and filtered. Solvents were evaporated and the residue was purified by flash chromatography on silica gel (hexanes:ethyl acetate (4:1) as eluant) to provide the title compound (8, 70.0 mg, 85%).

 $^{1}$ H NMR (DMSO): δ 9.00 (s, 1H), 7.69 (d, J=8.2 Hz, 4H), 7.48 (d, J=8.2 Hz, 2H), 7.48 (d, J=8.2 Hz, 2H), 3.35 (s, 3H). MS (ES+): 459 (M-H, 100).

The following ureas were prepared as described above, using the appropriate isocyanates:

10

8.1

 $^{1}$ H NMR (CD<sub>3</sub>OD): δ 7.80 (d, J=8.2 Hz, 2H), 7.45 (d, J=8.2 Hz, 2H), 7.30 (d, J=8.0 Hz, 2H), 6.98 (t, 8.0 Hz, 2H), 3.35 (s, 3H).

8.2

<sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.80 (d, *J*=8.2 Hz, 2H), 7.45 (d, *J*=8.5 Hz, 2H), 7.20 (d, *J*=8.0 Hz, 2H), 6.82 (d, *J*=8.0 Hz, 2H), 4.85 (s, 1H), 3.72 (s, 3H), 3.35 (s, 3H), 3.38 (s, 3H). MS (ES-): 421 (M+H, 100).

8.3

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.81 (d, J=8.4 Hz, 2H), 7.42 (d, J=8.4 Hz, 2H), 7.20-7.32 (m, 4H), 7.00 (t, J=7.0 Hz, 1H), 6.25 (bs, 1H), 3.91 (bs, 1H), 3.38 (s, 3H). MS (ES-): 193 (M-H, 100). Anal. Calcd. for  $C_{17}H_{14}F_6N_2O_2$ : C, 52.05; H, 3.60; N, 7.14. Found: C, 52.09; H, 3.70; N, 7.29.

20

### **EXAMPLE 9**

This example illustrates an alternative procedure for the preparation of ureas of the present invention, exemplified by N-methyl-N-(4-morpholinecarbonyl)-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]aniline (9).

10

15

20

To a stirred solution of N-methyl-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]aniline (50 mg, 0.183 mmol) and diisopropylethylamine (73.3 mL, 0.421 mmol) in dichloromethane (2 mL) was added 4-morpholinecarbonyl chloride (21 mL, 0.183 mmol). Stirring was continued for 100 hours at room temperature. At the completion of the reaction, the reaction mixture was diluted with ethyl acetate, and washed sequentially with 1N HCl and brine. The organic layer was dried over MgSO<sub>4</sub> and filtered. Solvents were removed from the filtrate under reduced pressure and the residue was purified by flash chromatography on silica gel (hexanes and ethyl acetate (4:1) as eluant) to provide the title compound (50 mg, 70.0%) as a clear oil.

<sup>1</sup>H (CDCl<sub>3</sub>): δ 7.69 (d, *J*=8.4 Hz, 2H), 7.12 (d, *J*=8.4 Hz, 2H), 3.95 (bs, 1H), 3.50 (m, 4H), 3.25 (s, 3H), 3.20 (m, 4H). MS (ES-): 387 (M+H, 100).

### **EXAMPLE 10**

This example provides procedures for the preparation of N-alkyl derivatives of the sulfonamide compounds of the invention provided in Example 2, and related analogs.

$$CF_3$$
 $CF_3$ 
 $CF_3$ 
 $CF_3$ 
 $CF_3$ 
 $O=S=C$ 
 $Ph$ 

### Synthesis of compund 10.1

10.1

50

25

BNSDOCID <WO\_\_\_0054759A2\_I\_



To a stirred mixture of sulfonamide 2 (2.08 g, 5.21 mmol, from Example 2) and ethyl bromoacetate (0.950 g, 5.68 mmol) in DMF (15 mL) and THF (5 mL), was added sodium hydride (60% dispersion in mineral oil, 0.230 g, 5.70 mmol) at 0°C. The mixture was stirred overnight as the temperature was allowed to warm to room temperature. At the completion of the reaction (as determined by thin-layer chromatography), the mixture was diluted with ethyl acetate, washed with brine (3X), dried over MgSO<sub>4</sub>, and concentrated. The residue was purified by flash chromatography on silica gel (hexane/EtOAc gradient from 8:1 to 2:1, as eluant) to give the title compound (2.01 g, 84%) as a clear oil.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.69 (d, J=7.6 Hz, 2H), 7.66 (d, J=8.4 Hz, 2H), 7.60 (t, J=7.6 Hz, 1H), 7.48 (t, J=7.6 Hz, 2H), 7.32 (d, J=8.4 Hz, 2H), 4.44 (s, 2H), 4.15 (q, J=6.5 Hz, 2H), 3.75 (s, 1H), 1.21 (t, J=6.5 Hz, 3H). MS (ES-): 484 (M-H, 100). Anal. Calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>6</sub>NO<sub>5</sub>S: C, 47.01; H, 3.53; N, 2.89; S, 6.61. Found: C, 47.10; H, 3.59; N, 2.81; S, 6.64.

15

10

### Synthesis of compound 10.2

### 10.2

To a solution of compound 10.1 (100 mg, 0.176 mmol) in 1 mL

methanol, 1 mL THF, and 1 mL water was added 1 N NaOH (0.440 mL). The
resulting mixture was stirred at room temperature for 3 hours, then diluted into ethyl
acetate, washed with brine (3X), dried over MgSO<sub>4</sub>, and concentrated under reduced
pressure. The residue was purified by flash chromatography on SiO<sub>2</sub>
(CH<sub>2</sub>Cl<sub>2</sub>:MeOH:AcOH (10:1:0.05) as eluant) to give the title compound (60 mg, 65%
yield) as a clear oil.

<sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.80 (m, 5H), 7.66 (t, *J*=7.2 Hz, 2H), 7.46 (d, *J*=8.2 Hz, 2H), 4.60 (s, 2H). MS (ES-): 456 (M-H, 100). Anal. Calcd. for C<sub>17</sub>H<sub>13</sub>F<sub>6</sub>NO<sub>5</sub>S: C, 44.65; H, 2.87; N, 3.06; S, 7.01. Found: C, 44.84; H, 2.96; N, 3.21.

Synts as of compound 10.3

10.3

A portion of the compound from Example 10.1 (71 mg, 0.146 mmol)

was treated with LiAlH<sub>4</sub> (1 M in THF, 200 mL, 0.200 mmol) in THF at 0°C. The reaction was quenched by careful addition of water. Ethyl acetate was added and the resulting suspension was filtered through a Celite pad. The filtrate was washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. Crude product was purified by chromatography on SiO<sub>2</sub> (hexanes/EtOAc (2:1) as eluant) to provide the title compound (48 mg, 74% yield).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.68 (d, J=8.6 Hz, 2H), 7.62 (d, J=8.0 Hz, 2H), 7.60 (t, J=7.2 Hz, 1H), 7.50 (dd, J=8.0, 7.2 Hz, 2H), 7.20 (d, J=8.6 Hz, 2H), 3.73 (m, 4H), 3.60 (s, 1H). MS (ES-): 442 (M-H, 100). Anal. Calcd. for C<sub>17</sub>H<sub>15</sub>F<sub>6</sub>NO<sub>4</sub>S: C, 46.05; H, 3.41; N, 3.16; S, 7.23. Found: C, 46.15; H, 3.44; N, 3.21.

15

### Synthesis of compound 10.4

### 10.4

A solution of the acid (10.2) from above (137 mg, 0.300 mmol) in 4

20 mL of CH<sub>2</sub>Cl<sub>2</sub> with two drops of DMF added was treated with a solution of oxalyl chloride (2M in CH<sub>2</sub>Cl<sub>2</sub>, 4 mL) at room temperature for 2 hours. Solvent was evaporated under reduced pressure to provide an intermediate acyl chloride. To a solution of acyl chloride in CH<sub>2</sub>Cl<sub>2</sub> was added pyrrolidine (80 (L, 0.958 mmol). After stirring for 30 min, additional CH<sub>2</sub>Cl<sub>2</sub> was added. The organic layer was washed with 1 N HCl (2X) and brine (3X), dried over MgSO<sub>4</sub>, and concentrated. The crude

product was purified by flushing chromatography on SiO<sub>2</sub> (4:1 hexanes:EtOAc as eluant) to provide 150 mg of the title compound (100%).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.68 (d, J=8.6 Hz, 2H), 7.60 (d, J=7.6 Hz, 2H), 7.55 (t, J=7.6 Hz, 1H), 7.42 (t, J=7.6 Hz, 2H), 7.35 (t, J=7.6 Hz, 2H), 4.45 (s, 2H), 4.40 (s, 1H), 3.52 (t, J=5.5 Hz, 2H), 3.38 (t, J=5.5 Hz, 2H), 1.95 (m, 2H), 1.82 (m, 2H). MS (ES-): 509 (M-H, 100). Anal. Calcd. for  $C_{21}H_{20}F_6N_2O_4S$ : C, 49.41; H, 3.95; N, 5.49; S, 6.28. Found: C, 49.59; H, 4.00; N, 5.42; S, 6.25.

The following compounds were prepared in accordance with the above procedure, replacing pyrrolidine with the appropriate amine:

# 10.5 (using diethylamine)

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.65 (d, J=8.5 Hz, 2H), 7.60 (d, J=7.5 Hz, 2H), 7.55 (t, J=7.5 Hz, 1H), 7.45 (d, J=7.5 Hz, 2H), 7.31 (d, J=8.5 Hz, 2H), 4.38 (s, 2H), 3.97 (s, 1H), 3.42 (q, J=6.6 Hz, 2H), 3.25 (q, J=6.6 Hz, 2H), 1.21 (t, J=6.6 Hz, 3H), 0.90 (t, J=6.6 Hz, 3H). MS (ES+): 513 (M+H, 100). Anal. Calcd. for  $C_{21}H_{22}F_6N_2O_4S$ : C, 49.22; H, 4.33; N, 5.47; S, 6.26. Found: C, 49.48; H, 4.35; N, 5.37; S, 6.24.

### 10.6 (using 4-methylpiperazine)

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.62 (d, J=8.5 Hz, 2H), 7.60 (t, J=7.5 Hz, 1H), 7.55 (t, J=7.5 Hz, 2H), 7.45 (t, J=7.5 Hz, 2H), 7.25 (d J=7.5 Hz, 2H), 4.45 (s, 2H), 3.70 (m, 2H), 3.45 (m, 2H), 2.50 (m, 2H), 2.35 (m, 2H), 2.30 (s, 3H). MS (ES-): 540 (M-H, 100), MS (ES-): 538 (M-H, 100). Anal. Calcd. for  $C_{22}H_{23}F_6N_3O_4S$ : C, 48.98; H, 4.30; F, 21.13; N, 7.79; O, 11.86; S, 5.94. Found: C, 49.26; H, 4.38; N, 7.64; S, 5.83.

### 10.7 (using 2-methylpiperidine)

'H NMR (CDCl<sub>3</sub>): δ 7.62 (d, J=8.5 Hz, 2H), 7.60 (t, J=7.5 Hz, 1H), 7.60 (d, J=7.5 Hz, 2H), 7.45 (t, J=7.5 Hz, 2H), 7.30 (d, J=8.5 Hz, 2H), 4.50 (s, 2H), 4.30 (m, 1H), 3.85 (m, 1H), 1.40-1.70 (m, 6H), 0.80 (d, J=5.5 Hz, 3H). MS (ES-): 537 (M-H, 100). Anal. Calcd. for C<sub>23</sub>H<sub>24</sub>F<sub>6</sub>N<sub>2</sub>O<sub>4</sub>S: C, 51.30; H, 4.49; N, 5.20; S, 5.95. Found: C, 51.81; H, 4.68; N, 5.13; S, 5.89.

### **EXAMPLE 11**

35

15

20

25

30

This example illustrates a procedure for the reduction of the amides prepared in Example 10 to their corresponding amine derivatives.


20

25

30

&NSDOCID <WO\_\_0054759A2\_I

# Synthesis of compound 11.1 from compound 10.4:



The amide produced in 10.4 (126 mg, 0.247 mmol) was treated with

LiAlH<sub>4</sub> (18.7 mmg, 37.4 mmol) in THF (3 mL) at reflux for 2 hours. The reaction was quenched by careful addition of water, ethyl acetate was added, and the resulting suspension was filtered through a Celite pad. The filtrate was washed with brine, dried over MgSO<sub>4</sub>, and stripped. Crude product was purified by flushing chromatography on SiO<sub>2</sub> eluted CH<sub>2</sub>Cl<sub>2</sub>:MeOH (20:1) to give 60 mg (50%) of amine

11.1.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.60 (t *J*=7.6 Hz, 1H), 7.57 (d, *J*=8.5 Hz, 2H), 7.52 (d, *J*=7.6 Hz, 2H), 7.45 (t, *J*=7.6 Hz, 2H), 7.11 (d *J*=8.5 Hz, 2H), 3.80 (t, *J*=6.5 Hz, 2H), 2.70 (m. 2H), 2.55 (m, 4H), 1.80 (m, 4H). MS (ES+): 497 (M+H, 100). Anal. Calcd. for : C, 50.80; H, 4.47; N, 5.64; S, 6.46; Found: C, 51.06; H, 4.58; N, 5.51; S, 6.42.

In a similar manner, the amides 10.5, 10.6 and 10.7 were reduced to their corresponding amides.

Compound 11.2 (prepared from compound 10.5)

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.55 (m, 5H), 7.45 (t, J=7.5 Hz, 2H), 7.15 (t, J=8.5 Hz, 2H), 3.70 (m, 2H), 2.40-2.65 (m, 6H), 0.95 (, 3H). MS (ES+): 499 (M+H, 100). Anal. Calcd. for  $C_{21}H_{24}F_6N_2O_3S$ : C, 50.60; H, 4.85; N, 5.62; S, 6.43. Found: C, 50.65; H, 4.90; N, 5.59; S, 6.35.

Compound 11.3 (prepared from compound 10.6)

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.65 (d, J=8.5 Hz, 2H), 7.60 (m, 3H), 7.45 (t, J=7.5 Hz, 2H), 7.12 (d, J=8.5 Hz, 2H), 3.70 (t, J=6.3 Hz, 2H), 2.30-2.50 (m, 8H), 2.20 (s, 3H). MS (ES-): 524 (M-H, 100). Anal. Calcd. for  $C_{22}H_{25}F_6N_3O_3S$ : C, 50.28; H, 4.80; N, 8.00; S, 6.10. Found: C, 49.28; H, 5.12; N, 7.59; S, 5.74.



Compound 11.4 (prepared from compound 10.7)

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.65 (d, J=8.6 Hz, 2H), 7.57 (d, J=7.4 Hz, 2H), 7.56 (t, J=7.4 Hz, 1H), 7.46 (t, J=7.4 Hz, 2H), 7.17 (d, J=8.6 Hz, 2H), 3.65 (m, 2H), 2.76 (m, 1H), 2.45 (m, 1H), 2.25 (m, 1H), 2.15 (m, 1H), 1.20-1.70 (m, 6H). 0.92 (d, J=5.0 Hz, 3H). MS (ES+): 525 (M+H, 100). Anal. Calcd. for C<sub>23</sub>H<sub>26</sub>F<sub>6</sub>N<sub>2</sub>O<sub>3</sub>S: C, 52.67; H, 5.00; N, 5.34; S, 6.11. Found: C, 52.96; H, 5.10; N, 5.18; S, 5.89.

### **EXAMPLE 12**

10

This example illustrates the synthesis of compound 12.

12

15

# **12.1** Preparation of N-trifluoroethylaniline derivative

12.1a

12.1b

To a suspension of 4-[2,2,2-trifluoro-1-hydroxy-1(trifluoromethyl)ethyl]aniline (9.07 g, 35.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) was added a

20 solution of trifluoroacetic anhydride (5.7 mL, 40.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL)
dropwise at room temperature. The solution was stirred for 3 hours (solution cleared and TLC indicated that the reaction was completed. The reaction mixture was washed with water, aqueous NaHCO<sub>3</sub>, and brine. The organic layer was drawn off, dried over MgSO<sub>4</sub>, filtered, and concentrated to give 12.1 g of the intermediate

25 trifluoroacetanilide (12.1a). The intermediate 12.1a was taken up in THF (50 mL) and treated with LiAlH<sub>4</sub> (4.00 g, 106 mmol) at reflux for 10 hours. The reaction was quenched by sequentially adding 4 mL water, 4 mL of 15% NaOH, and 12 mL of water. The resulting suspension was stirred for an additional 30 minutes, filtered through a Celite pad, which was then rinsed with THF. The combined filtrate and

15

20

rinse was concentrated under reduced pressure. The residue was taxtup in EtOAc, washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The resulting crude product was purified by chromatography on SiO<sub>2</sub> (4:1 hexanes:EtOAc as eluant) to provide 11.0 g (92%) of the title compound (12.1b).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.52 (d, *J*=8.6 Hz, 2H), 6.72 (d, *J*=8.6 Hz, 2H), 4.10 (bs, 1H), 3.80 (q, *J*=8.5 Hz, 2H), 3.31 (bs, 1H). MS (ES+): 342 (M+H, 100).

### 12.2 Sulfonylation of 12.1b

A sample of 12.1b from above (1.87 g, 5.48 mmol) was treated with benzenesulfonyl chloride (1.18 g, 6.68 mmol) in pyridine (10 mL) at room temperature for 10 days. The reaction mixture was diluted with EtOAc, washed with aqueous NaHCO<sub>3</sub>, and brine. The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated. The crude product was purified by chromatography on SiO<sub>2</sub> (4:1 hexanes:EtOAc as eluant) to provide 1.65 g (62%) of compound 12.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.78 (d, J=8.8 HZ, 2H), 7.61 (t, J=7.6 Hz, 1H), 7.58 (d, J=7.6 Hz, 2H), 7.46 (t, J=7.6 Hz, 2H), 4.24 (q, J=8.2 Hz, 2H), 3.41 (s, 1H). MS (ES-): 480 (M-H, 100). Anal. Calcd. for C<sub>17</sub>H<sub>12</sub>F<sub>9</sub>NO<sub>3</sub>S: C. 42.42; H, 2.51; N, 2.91; S, 6.66. Found: C, 42.70; H, 2.55; N, 2.84; S, 6.61.

In a similar manner, compound 12.3 was prepared by substituting 3-cyanobenzenesulfonyl chloride for benzenesulfonyl chloride.

12.3

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.91 (s, 1H), 7.90 (d, J=7.5 Hz, 2H), 7.80 (d, J=7.5 Hz, 1H), 7.75 (d, J=8.8 Hz, 2H), 7.80 (d J=7.5 Hz, 1H), 7.75 (d, J=8.8 Hz, 2H), 7.62 (t, J=7.5 Hz, 1H), 7.19 (d, J=8.8 Hz, 2H), 4.30 (q, J=8.2 Hz, 2H), 3.62 (s, 1H). MS (ES-): 505 (M-H, 100). Anal. Calcd. for  $C_{18}H_{11}F_{9}N_{2}O_{3}S$ : C, 42.70; H, 2.19; N, 5.53; S, 6.33. Found: C, 43.41; H, 2.46; N, 5.67.



#### **EXAMPLE 13**

This example illustrates the preparation of 13, and related derivatives 13.3 and 13.4.

13.1

13

### Synthesis of compound 13.1

To a stirred mixture of indoline (5.32 g, 44.6 mmol) and toluenesulfonic acid (75 mg, 0.395 mmol) was added hexafluoroacetone hydrate (7 mL, 49.1 mmol) at 90°C over 15 min. The resulting mixture was heated at 135 °C overnight. After cooling to room temperature, the mixture was diluted with EtOAc, washed with aqueous NaHCO<sub>3</sub> (2X) and brine (2X). The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated. The crude product was purified by chromatography on SiO<sub>2</sub> (6:1 to 4:1 hexanes:EtOAc as eluant) to give the intermediate substituted indoline (13.1, 6.35 g, 50% yield).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.41 (s, 1H), 7.32 (d, *J*=8.5 Hz, 1H), 6.65 (d, *J*=8.5 Hz, 1H), 3.60 (d, *J*=5.5 Hz, 2H), 3.08 (d, *J*=5.5 Hz, 2H). MS (ES+): 286 (M+H, 100).

20

25

5

10

15

Synthesis of compound 13.

Sulfonylation of compound 13.1 was carried out as described in the Examples above to provide the title compound (13).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.84 (d, J=8.0Hz, 2H), 7.68 (d, J=8.4 Hz, 2H), 7.59 (t, J=8.0 Hz, 1H), 7.52 (d, J=8.4 Hz, 1H), 7.48 (t, J=8.0 Hz, 2H), 7.41 (s, 1H), 3.97 (t, J=5.6 Hz, 2H), 3.38 (s, 1H), 3.00 (t, J=5.6 Hz, 2H). MS (ES-): 424 (M-H, 100). Anal. Calcd. for C<sub>17</sub>H<sub>13</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 48.00; H, 3.08; N, 3.29. Found: C, 48.17; H, 3.06; N, 3.37.

In a similar manner, the following compounds were prepared, beginning with the tetrahydroquinoline and the appropriate (substituted)benzenesulfonyl chlorides.

5

10

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.86 (d, J=8.5 Hz, 1H), 7.62 (d, J=7.2 Hz, 2H), 7.55 (t, J=7.5 Hz, 1H), 7.48 (d, J=8.5 Hz, 1H), 7.41 (t, J=7.2 Hz, 2H), 7.36 (s, 1H), 3.81 (dd, J=6.5, 4.5 Hz, 2H), 3.40 (s, 1H), 2.52 (dd, J=7.0, 4.5 Hz, 2H), 1.70 (m. 2H). MS (ES-): 438 (M-H, 100). Anal. Calcd. for C<sub>18</sub>H<sub>15</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 49.20; H, 3.44; N, 3.19; S, 7.30. Found: C, 49.55; H, 3.36; N, 3.31; S, 7.53.

13.4

13.4

15

20

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.90 (s, 1H), 7.81 (d, J=8.5 Hz, 2H), 7.80 (d, J=7.5 Hz, 1H), 7.55 (d, J=7.5 Hz,1H), 7.50 (t, J=7.5 Hz, 1H), 7.36 (s, 1H), 3.82 (dd, J=6.5, 5.5 Hz, 2H), 3.35 (s, 1H), 2.55 (t, J=5.5 Hz, 2H), 1.72 (m, 2H). MS (ES-): 577 (M-H, 100). Anal. Calcd. for C<sub>19</sub>H<sub>14</sub>F<sub>6</sub>N<sub>2</sub>O<sub>3</sub>S: C, 49.14; H, 3.04; N, 6.03; S, 6.91. Found: C, 49.25; H, 3.08; N, 5.86; 6.84.

10

15

20

25

INSDOCID <WO\_\_\_0054759A2\_I\_:

### **EXAMPLE 14**

This example illustrates the synthesis of compound 14.1.

Hexafluoroacetone trihydrate (9.68 g, 44 mmol) was added to 2,6-dimethylaniline (4.84 g, 40 mmol) and p-toluenesulfonic acid (304 mg, 1.6 mmol) at room temperature. The mixture was stirred at 130°C for 14 hours under a nitrogen atmosphere. After cooling down, the solidified mixture was washed with sodium bicarbonate solution, water, and hexane and dried to afford 10g of 4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-2,6-dimethylaniline. <sup>1</sup>H NMR (DMSO): δ 8.11 (s, 1H), 7.08 (s, 2H), 4.89 (s, 2H), 2.10 (s, 6H). MS (ES) m/z 288.1 ([M+H]<sup>†</sup>).

To a solution of 4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-2,6-dimethylaniline (4.3 g, 15 mmol) and 2,6-lutidine (3.5 mL, 30 mmol) in acetone (25 mL), was added benzenesulfonyl chloride (3.18 g, 18 mmol). The mixture was stirred at room temperature for 20 hours, at 50°C for 20 hours, and at 70°C for 24 hours. After cooling down, the solid was filtered off. The filtrate was concentrated, and the residue was treated by 3N HCl (200 mL), and it was extracted with ethyl acetate. The organic layer was separated, washed with saturated sodium bicarbonate solution and brine, dried, and concentrated. The residue was purified by silica column chromatography (eluted by 9:1 DCM/EtOAc) to afford 5.1 g of product (example 14.1).  $^{1}$ H NMR (DMSO):  $\delta$  9.52 (s, 1H), 8.64 (s, 1H), 7.69 (m, 3H), 7.59 (m, 2H), 7.31 (s, 2H), 1.99 (s, 6H). MS (ES) m/z 426.0 ([M-H]). Anal. Calcd. for  $C_{17}H_{15}F_6NO_3S$ : C, 47.78; H, 3.54; N, 3.28. Found: C, 47.69; H, 3.45; N, 3.33.

Compounds 14.2-14.11 were prepared from their corresponding anilines in a manner similar to that described for 14.1.

5

<sup>1</sup>H NMR (DMSO): δ 9.75 (s, 1H), 8.42 (s, 1H), 7.72 (m, 2H), 7.66 (m, 1H), 7.57 (m, 2H), 7.18 (s, 1H), 6.91 (s, 1H), 2.40 (s, 3H), 1.97 (s, 3H). MS (EI) m/z 427 (M<sup>+</sup>). Anal. Calcd. for  $C_{17}H_{15}F_6NO_3S$ : C, 47.78; H, 3.54; N, 3.28. Found: C, 47.60; H, 3.57; N, 3.33.

10

14.3

14.3

<sup>1</sup>H NMR (DMSO): δ 9.59 (s, 1H), 8.65 (s, 1H), 7.72 (m, 2H), 7.66 (m, 1H), 7.58 (m, 2H), 7.39 (s, 1H), 7.29 (s, 1H), 3.17 (h, J=6.9 Hz, 1H), 1.98 (s, 3H), 0.93 (d, J=6.9 Hz, 6H). MS (EI) *m/z* 455 (M<sup>+</sup>). Anal. Calcd. for C<sub>19</sub>H<sub>19</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 50.11; H, 4.21; N, 3.08. Found: C, 50.18; H, 4.23; N, 3.06.

14.4

14.4

 $^{1}$ H NMR (CDCl<sub>3</sub>): δ 7.78 (m, 3H), 7.65-7.50 (m, 4H), 7.34 (d, J=8.5 Hz, 1H), 3.54 (s, 1H), 3.23 (s, 3H). MS (El) m/z 447 (M $^{4}$ ). Anal. Calcd. for  $C_{16}H_{12}ClF_{6}NO_{3}S$ : C, 42.92; H, 2.70; N, 3.13; S, 7.16. Found: C, 43.19; H, 2.80; N, 3.16; S, 7.27.

20

14.5

<sup>1</sup>H-NMR (DMSO): δ 9.80 (s, 1H), 8.68 (s, 1H), 7.78 (d, J= 7.12, 1.56 Hz, 2H), 7.56 (m, 3H), 7.33 (d, J=8.36, 1H), 7.15 (d, J=12.00 Hz, 2H), 3.59 (s, 3H). MS (ES+): 430 (M+H, 75). Anal. Calc. for  $C_{16}H_{13}F_6NO_4S$ : C, 44.76; H, 3.05; N, 3.26;

S, 7.47. Found: C, 44.90; H, 3.10; N, 3.32; S, 7.57.

14.6

10

15

20

14.6

<sup>1</sup>H-NMR (DMSO): δ 9.34 (s, 1H), 8.71 (s, 1H), 7.60(m, 5H), 7.12 (s, 1H), 6.91 (s, 1H), 3.17 (s, 3H), 2.33 (s, 3H). MS (ES+): 444 (M+H, 17). MS (ES-): 442 (M-H, 100). Anal. Calc. for C<sub>17</sub>H<sub>15</sub>F<sub>6</sub>NO<sub>4</sub>S: C, 46.05; H, 3.41; N, 3.16; S, 7.23. Found: C, 46.18; H, 3.50; N, 3.16; S,7.33.

14.7

$$\begin{array}{c|c} & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

14.7

<sup>1</sup>H-NMR (DMSO): δ 10.22 (s, 1H), 8.69 (s, 1H), 7.50 (m, 2H), 7.20 (m, 2H), 2.21 (s, 3H). MS (ES+): 488 (M+H, 15). Anal. Calc. for C<sub>14</sub>H<sub>2</sub>Cl<sub>2</sub>F<sub>6</sub>NO<sub>3</sub>S<sub>2</sub>:

C, 34.44; H, 1.86; 1.87; Cl, 4.52; S, 13.13. Found: C, 34.65; H, 1.80; N, 2.69; Cl, 14.44; S, 13.02.

14.8

14.8

 $^{1}$ H-NMR (DMSO): δ 9.90 (s, 1H), 8.65 (s, 1H), 7.6 (m, 6H), 7.36 (d, J=8.40 Hz, 1H), 7.08 (d, J=8.48 Hz, 1H), 3.17 (m, 1H), 0.90 (d, J=6.80 Hz, 6H). MS (ES-): 440 (M-H, 100). Anal. Calc. for  $C_{18}H_{17}F_6NO_3S$ : C, 48.98; H, 3.88; N, 3.17; S, 7.26. Found: C, 49.03; H, 3.83; N, 3.18; S, 7.37.

14.9

14.9

<sup>1</sup>H-NMR (DMSO): δ 10.14 (s, 1H), 8.69 (s, 1H), 8.15 (d, J=7.76 Hz, 1H), 8.01 (m, 2H), 7.81 (t, J=7.72 Hz, 1H), 7.54 (s, 1H), 7.40 (d, J=8.44 Hz, 1H), 7.04 (d, J=8.64 Hz, 1H), 3.15 (m, 1H), 0.94 (d, J=6.88 Hz, 6H). MS (ES-): 465 (M-H, 100). Anal. Calc. for  $C_{19}H_{16}F_6N_2O_3S$ : C, 48.93; H, 3.46; N, 6.01; S, 6.88. Found: C, 48.99; H, 3.39; N, 5.84; S, 6.82.

20

10

15

14.10

10

15

20

25

### 14.10

<sup>1</sup>H-NMR (DMSO): δ 9.44 (s, 1H), 8.71 (s, 1H), 7.90 (m, 2H), 7.70 (m, 4H), 7.30 (m, 1H), 6.65 (d, J=8.44 Hz, 1H),1.43 (s, 9H). MS (ES-): 454 (M-H, 100). Anal. Calc. for C<sub>19</sub>H<sub>19</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 50.11; H, 4.21; N, 3.08; S, 7.04. Found: C, 50.18; H, 4.22; N, 3.07; S, 7.04.

## 14.11

### 14.11

<sup>1</sup>H-NMR (DMSO): δ 11.06 (s, 1H), 8.64 (s, 1H), 7.60 (d, J=9Hz, 2H), 7.39 (s, 1H), 7.25 (d, J=9Hz, 2H). Anal. Calc. for C<sub>14</sub>H<sub>9</sub>Cl<sub>2</sub>F<sub>6</sub>NO<sub>3</sub>S<sub>2</sub>: C, 32.92; H, 1.49; N, 2.95; S, 13.52. Found: C, 33.06; H, 1.44; N, 2.89; S, 13.53.

### **EXAMPLE 15**

This example illustrates the preparation of compound 15.1

### 15.1

Fuming nitric acid (90%, 5 mL) was added drop wise to 1,1,1,3,3,3-hexafluoro-2-phenyl-2-propanol (4.2 mL, 25 mmol) in concentrated sulfuric acid (15 mL) at 0°C. The mixture was stirred at 0°C for 30 minutes, and at room temperature for 2 hours. Then it was poured into ice water. The solid was filtered, washed with sodium bicarbonate solution, water, and hexane, and dried to give 6.2 g of 1-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-3-nitrobenzene. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ

WO 00/54759 PCT/US00/06611

8.66 (s, 1H), 8.38 (d, J=2, 1H), 8.06 (d, J=8 Hz, 1H), 7.69 (t, J=8 Hz, H), 3.66 (bs, 1H). MS (EI) m/z 289 (M<sup>+</sup>).

Palladium on carbon (10%, 150 mg) was added to the product above (2.0 g, 6.9 mmol) in ethanol (20 mL). The mixture was stirred under 1 atmosphere of hydrogen at room temperature for 6 hours. The catalyst was filtered off through celite. The filtrate was concentrated to give 1.78 g of solid product (3-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]aniline). <sup>1</sup>H NMR (DMSO): 8 8.36 (s, 1H), 7.11 (t, J=8 Hz, 1H), 6.93 (s, 1H), 6.78 (d, J=8 Hz, 1H), 6.66 (d, J=8 Hz, 1H), 5.40 (bs, 1H). MS (EI) m/z 259 (M<sup>+</sup>).

To a solution of the above product (770 mg, 3 mmol) and 2,6-lutidine (0.7 mL, 6 mmol) in acetone (10 mL), was added benzenesulfonyl chloride (0.46 mL, 3.6 mmol). The mixture was stirred at room temperature for 20 hours. The solid was filtered off. The filtrate was concentrated, and the residue was treated by 3N HCl (100 mL), and it was extracted with ethyl acetate. The organic layer was separated, washed with saturated sodium bicarbonate solution and brine, dried, and concentrated. The residue was purified by silica column chromatography (eluted by 1:2 EtOAc/Hexane) to afford 1.08 g of 15.1. <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.73 (d, J=7.2 Hz, 2H), 7.54 (m, 1H), 7.45 (m, 3H), 7.35 (m, 2H), 7.24 (s, 1H), 6.52 (s, 1H), 3.39 (s, 1H). MS (ES) *m/z* 398.0 ([M-H]<sup>-</sup>). Anal. Calcd. for C<sub>15</sub>H<sub>11</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 45.12; H, 2.78; N, 3.51; S, 8.03. Found: C, 45.27; H, 2.88; N, 3.49; S, 8.05.

Compound 15.2 was prepared in a manner the same as that described above except that 3-(2,5-dimethylthienyl)sulfonyl chloride was used instead of benzenesulfonyl chloride.

15.2

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.51 (m, 1H), 7.39 (m, 2H), 7.23 (m, 1H), 6.81 (s, 1H), 6.60 (s, 1H), 3.66 (s, 1H), 2.35 (s, 3H), 2.33 (s, 3H). MS (EI) *m/z* 433 (M<sup>+</sup>).

5

10

15

20

Anal. Calcd. for C<sub>15</sub>H<sub>13</sub>F<sub>6</sub>NO<sub>3</sub>S<sub>2</sub>: C, 41.57; H, 3.02; N, 3.23. Found: C, 41.70; H, 3.02; N, 3.20.

5

### **EXAMPLE 16**

This example illustrates the preparation of compound 16.1

16.1

10

15

20

Sodium hydride (60 %, 116.4 mg, 2.91 mmol) was added to compound 14.1 (1.13 g, 2.65 mmol) in DMF (10 mL) at room temperature. The mixture was stirred at room temperature for 20 minutes. Then iodomethane (0.18 ml, 2.91 mmol) was added. The mixture was stirred at room temperature for 2 hours. DMF was evaporated under vacuum, and the residue was treated with water, which was extracted with EtOAc. The organic layer was separated, washed with brine, dried, and concentrated. The residue was purified by silica column chromatography (eluted by 1;5 EtOAc/Hexane) to afford 1.06 g of product.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.82 (m, 2H), 7.60 (m, 1H), 7.52 (m, 2H), 7.38 (s, 2H), 3.85 (bs, 1H), 3.18 (s, 3H), 2.12 (s, 6H). MS (ES) *m/z* 440.0 ([M-H]<sup>-</sup>). Anal. Calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 48.98; H, 3.88; N, 3.17. Found: C, 49.12; H, 3.86; N, 3.26.

Compounds 16.2-16.38 were prepared in a manner similar to that described for 16.1.

16,2

16.2

<sup>1</sup>H NMR (DMSO): δ 8.55 (s, 1H), 7.77 (m, 1H), 7.68 (m, 4H), 7.38 (s, 1H), 6.53 (s, 1H), 3.07 (s, 3H), 2.36 (s, 3H), 2.26 (s, 3H). MS (EI) *m/z* 441 (M<sup>+</sup>). Anal. Calcd. for C<sub>18</sub>H<sub>17</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 48.98; H, 3.88; N, 3.17. Found: C, 49.20; H, 3.93; N, 3.16.

16.3

16.3

<sup>1</sup>H NMR (DMSO): δ 8.73 (s, 1H), 7.85 (m, 2H), 7.74 (m, 1H), 7.66 (m, 2H), 7.45 (s, 1H), 7.37 (s, 1H), 3.14 (s, 3H), 2.90 (h, J=6.9 Hz, 1H), 2.05 (s, 3H), 1.06 (dd, J=6.9 Hz, 6H). MS (ES) m/z 468.1 ([M-H]). Anal. Calcd. for  $C_{20}H_{21}F_6NO_3S$ : C, 51.17; H, 4.51; N, 2.98. Found: C, 51.18; H, 4.54; N, 3.10.

16.4

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.65-7.30 (m, 9H), 3.40 (s, 1H), 3.19 (s, 3H). MS 20 (ES) *m/z* 412.0 ([M-H]<sup>-</sup>). Anal. Calcd. for C<sub>16</sub>H<sub>13</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 46.49; H, 3.17; N, 3.39; S, 7.76. Found: C, 46.74; H, 3.30; N, 3.35; S, 7.79.

10

$$H_3C$$
 $CH_3$ 
 $CH_3$ 
 $CH_3$ 
 $CH_3$ 
 $CH_3$ 

16.5

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.63 (m, 1H), 7.43 (m, 3H), 6.67 (s, 1H), 3.37 (s, 1H), 3.24 (s, 3H), 2.36 (s, 3H), 2.05 (s, 3H). MS (EI) *m/z* 447 (M<sup>+</sup>). Anal. Calcd. for C<sub>16</sub>H<sub>15</sub>F<sub>6</sub>NO<sub>3</sub>S<sub>2</sub>: C, 42.95; H, 3.38; N, 3.13; S, 14.33. Found: C, 43.00; H, 3.29; N, 3.08; S, 14.44.

10

<sup>1</sup>H-NMR (DMSO): δ 8.84 (s, 1H), 7.60 (m, 5H), 7.32 (d, J=8.92 Hz, 1H), 7.22(m, 2H), 3.44 (s, 1H), 3.12 (s, 1H). MS (ES-): 442 M-H, 100). Anal. Calc. for C<sub>17</sub>H<sub>15</sub>F<sub>6</sub>NO<sub>4</sub>S: C, 46.05; H, 3.41; N, 3.16; S, 7.23. Found: C, 46.14; H, 3.43; N, 3.15; S, 7.34.

16.7

16.6

20

15

 $^{1}$ H-NMR (DMSO): δ 8.78 (s, 1H), 7.70 (m, 3H), 7.60 (m, 2H), 7.17 (s, 1H), 7.01(s, 1H), 3.26 (s, 3H), 3.07 (s, 3H), 2.38 (s, 3H). MS (ES-): 456 (M-H, 100). Anal. Calc. for  $C_{18}H_{17}F_6NO_4S$ : C, 47.27; H, 3.75; N, 3.06; S, 7.01. Found: C, 47.32; H, 3.75; N, 3.07; S, 7.08.

16.8

<sup>1</sup>H-NMR (DMSO): δ 8.80 (s, 1H), 7.63 (s, 1H), 7.50 (d, J=8.52 Hz, 1H), 7.32 (s, 1H), 7.14 (d, J=8.52 Hz, 1H), 3.23 (s, 3H), 2.37 (s, 3H). MS (ES+): 502 (M+H, 100). Anal. Calc. for C<sub>15</sub>H<sub>11</sub>Cl<sub>2</sub>F<sub>6</sub>NO<sub>3</sub>S<sub>2</sub>: C, 35.87; H, 2.21; N, 2.79; Cl, 14.12; S, 12.77. Found: C, 35.95; H, 2.10; N, 2.63; Cl, 14.12; S, 12.88.

16.9

10

16.9

<sup>1</sup>H-NMR (DMSO): δ 8.77 (s, 1H), 7.62 (d, J=8.44 Hz, 2H), 7.50 (m, 1H), 7.40 (d, J=8.96 Hz, 2H), 7.36 (s,1H), 7.31 (s, 1H), 7.0 (m, 1H), 4.96 (m, 2H), MS (ES-): 568 (M-H, 56). Anal. Calc. for C<sub>18</sub>H<sub>11</sub>Cl<sub>2</sub>F<sub>6</sub>NO<sub>3</sub>S<sub>3</sub>: C, 37.90; H, 1.94; N, 2.46; Cl, 12.43; S, 16.87. Found: C, 37.84; H, 1.81; N, 2.38; Cl, 12.52; S, 16.96.

16.10

16.10

15

<sup>1</sup>H-NMR (DMSO): δ 8.74 (s, 1H), 8.36 (d, J=8.4 Hz, 1H), 7.94 (d, J=8.04 Hz, 1H), 7.88 (d, J=8.4 Hz, 1H), 7.70 (m, 1H), 7.6 (m, 6H), 7.42 (s, 1H), 5.29(s, 2H). MS (ES-): 613 (M-H, 83). Anal. Calc. for  $C_{23}H_{14}Cl_2F_6N_2O_3S_2$ : C, 44.89; H, 2.29; N, 4.55; CI, 11.52; S, 10.42. Found: C, 45.32; H, 2.33; N, 4.51; Cl, 11.31; S, 10.22.

16.11

$$HO \xrightarrow{CF_3} N \xrightarrow{O} N$$

16.11

<sup>1</sup>H-NMR (DMSO): δ 8.78 (s, 1H), 7.64 (d, J=8.8 Hz, 2H), 7.40(m, 4H), 6.9(m, 2H), 5.17 (s, 2H). MS (ES-): 568 (M-H, 20). Anal. Calc. for C<sub>18</sub>H<sub>11</sub>Cl<sub>2</sub>F<sub>6</sub>NO<sub>3</sub>S<sub>3</sub>: C, 37.90; H, 1.94; N, 2.46; Cl, 12.43; S, 16.87. Found: C, 37.63; H, 1.88; N, 2.45; Cl, 12.68; S, 16.77.

16.12

 $HO \xrightarrow{CF_3} O \xrightarrow{Q} CI$ 

16.12

<sup>1</sup>H-NMR (DMSO): δ 8.82 (s, 1H), 7.68 (d, J=8.44 Hz, 2H), 7.47(d, J=8.8 Hz, 2H), 7.34 (s, 1H), 6.8(m, 3H), 6.58(m, 1H), 4.25(m, 2H), 4.06(m, 3H), MS

20 (ES-): 620 (M-H, 100). Anal. Calc. for C<sub>22</sub>H<sub>15</sub>Cl<sub>2</sub>F<sub>6</sub>NO<sub>5</sub>S<sub>2</sub>: C, 42.46; H, 2.43; N, 2.25; Cl, 11.39; S, 10.30. Found: C, 42.55; H, 2.34; N, 2.27; Cl, 11.46; S, 10.22.

16.13

<sup>1</sup>H-NMR (DMSO): δ 8.77 (s, 1H), 7.62 (d, J=8.44 Hz, 2H), 7.40 (m, 3H), 6.70(m, 3H), 4.85(s, 2H), 4.17(s, 4H). MS (ES-): 620 (M-H, 100). Anal. Calc. for C<sub>22</sub>H<sub>15</sub>Cl<sub>2</sub>F<sub>6</sub>NO<sub>5</sub>S<sub>2</sub>: C, 42.46; H, 2.43; N, 2.25; Cl, 11.39; S, 10.30. Found: C, 42.54; H, 2.47; N, 2.18; Cl, 11.35; S, 10.39.

16.14

16.14

 $^{1}$ H-NMR (DMSO): δ 8.73 (s, 1H), 7.58 (d, J=8.8 Hz, 2H), 7.28(m, 7H), 6.97 (d, J=1.12 Hz, 1H), 4.86 (s, 2H), 2.41 (s, 3H), 1.93 (s, 3H). MS (ES+): 524 (M+H, 100). Anal. Calc. for  $C_{22}H_{19}F_6NO_3S_2$ : C, 50.47; H, 3.66; N, 2.68; S, 12.25. Found: C, 50.57; H, 3.58; N, 2.60; S, 12.35.

16.15

$$H_3C$$
 $CH_3$ 
 $CH_3$ 
 $CH_3$ 
 $CH_3$ 

16.15

10

5

<sup>1</sup>H-NMR (DMSO): δ 8.84 (s, 1H), 7.44 (d, J=8.44 Hz, 2H), 7.24(d, J=8.68 Hz, 2H), 6.90 (s, 1H), 4.41 (m, 1H), 2.39 (s, 3H), 2.20 (s, 3H), 1.02 (d, J=6.72 Hz, 6H), MS (ES+): 476 (M+H, 100). ). Anal. Calc. for  $C_{18}H_{19}F_6NO_3S_2$ : C, 45.47; H, 4.03; N, 2.95; S, 13.49. Found: C, 45.66; H, 4.10; N, 2.90; S, 13.58.

16.16

16.16

<sup>1</sup>H-NMR (DMSO): δ 8.76 (s, 1H), 7.60 (d, J=8.52 Hz, 2H), 7.46(s, 1H), 7.40(m, 1H), 7.32(m, 3H), 7.24(t, 1H), 6.96 (s, 1H), 4.87 (s, 2H), 2.41 (s, 3H), 1.93 (s, 3H). MS (ES-): 600 (M-H, 60). Anal. Calc. for C<sub>22</sub>H<sub>18</sub>BrF<sub>6</sub>NO<sub>3</sub>S<sub>2</sub>: C, 43.86; H, 3.01; N, 2.33; S, 10.65. Found: C, 43.83; H, 2.87; N, 2.36; S, 10.81.

16.17

16.17

<sup>1</sup>H-NMR (DMSO): δ 8.75 (s, 1H), 7.60 (d, J=8.45 Hz, 2H), 7.30 (d, J=8.88 Hz, 2H), 6.94(s, 1H), 6.73(m, 3H), 4.73(s, 2H), 4.16(s, 4H), 2.40 (s, 3H), 1.91 (s, 3H). MS (ES-): 580 (M-H, 80). Anal. Calc. for  $C_{24}H_{21}F_6NO_5S_2$ : C, 49.57; H, 3.64; N, 2.41; S, 11.03. Found: C, 49.39; H, 3.77; N, 2.48; S, 11.01.

15

16,18

16.18

<sup>1</sup>H-NMR (DMSO): δ 8.79 (s, 1H), 7.70 (m, 6H), 7.40 (m, 1H), 6.76 (d, J=8.50 Hz, 1H), 3.49 (m, 1H), 3.11 (s, 3H), 1.20 (m, 6H). MS (ES-): 454 (M-H, 100). Anal. Calc. for C<sub>19</sub>H<sub>19</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 50.11; H, 4.21; N, 3.08; S, 7.04. Found: C, 50.12; H, 4.18; N, 3.09; S, 7.12.

16.19

$$CF_3$$
 $CI$ 
 $CF_3$ 
 $CI$ 

16.19

<sup>1</sup>H-NMR (DMSO): δ 8.76 (s, 1H), 8.21 (m, 1H), 8.11 (s, 1H), 7.90 (d, J=8.08 Hz, 1H), 7.79 (m, 1H), 7.58 (m, 2H), 7.32 (m, 6H), 4.99 (s, 2H), MS (ES-): 547 (M-H, 100). Anal. Calc. for C<sub>23</sub>H<sub>15</sub>ClF<sub>6</sub>N<sub>2</sub>O<sub>3</sub>S: C, 50.33; H, 2.75; N, 5.10; Cl, 6.46; S, 5.84. Found: C, 50.49; H, 2.80; N, 5.09; Cl, 6.54; S, 5.73.

16.20

HO 
$$CF_3$$
  $N$   $CN$ 

16.20

'H-NMR (DMSO): δ 8.73 (s, 1H), 8.21 (d, J=8.60 Hz, 1H), 8.07 (s, 1H), 7.81 (m, 2H), 7.54 (d, J=8.44 Hz, 2H), 7.26 (d, J=8.80 Hz, 2H), 7.10 (m, 3H), 7.00 (m, 1H), 4.88 (s, 2H), 2.28 (s, 3H). MS (ES-): 527 (M-H, 90). Anal. Calc. for

20

 $C_{24}H_{18}F_6N_2O_3S$ : C, 54.55; H, 3.43; N, 5.30; S, 6.07. Found: C, 54.05; H, 3.46; N, 5.26; S, 5.97.

16.21

$$\begin{array}{c|c} CF_3 & O & O \\ CF_3 & O & S \\ \hline Me & CN \\ \end{array}$$

16.21

<sup>1</sup>H-NMR (DMSO): δ 8.74 (s, 1H), 8.21 (m, 1H), 8.10 (s, 1H), 7.87 (m, 2H), 7.58 (d, J=8.48 Hz, 2H), 7.28 (d, J=8.84 Hz, 2H), 7.13 (m, 1H), 7.02 (m, 3H), 4.85 (s, 2H), 2.21 (s, 3H). MS (ES-): 527 (M-H, 100). Anal. Calc. for  $C_{24}H_{18}F_6N_2O_3S$ : C, 54.55; H, 3.43; N, 5.30; S, 6.07. Found: C, 54.59; H, 3.47; N, 5.24; S, 6.00.

16.22

HO 
$$CF_3$$
  $CH$   $CN$ 

16.22

<sup>1</sup>H-NMR (DMSO): δ 8.77 (s, 1H), 8.30 (m, 1H), 8.15 (s, 1H), 7.84 (m, 2H), 7.60 (d, J=8.44 Hz, 2H), 7.27 (m, 6H), 4.92 (s, 2H). MS (ES-): 547 (M-H, 100). Anal. Calc. for C<sub>23</sub>H<sub>15</sub>ClF<sub>6</sub>N<sub>2</sub>O<sub>3</sub>S: C, 50.33; H, 2.75; N, 5.10; Cl, 6.46; S, 5.84. Found: C, 50.26; H, 2.77; N, 5.07; Cl, 6.50; S, 5.82.

16.23

-10

15

<sup>1</sup>H-NMR (DMSO): δ 8.74 (s, 1H), 8.20 (d, J=7.32 Hz, 1H), 8.09 (s, 1H). 7.85 (m, 2H), 7.57 (d, J=8.12 Hz, 2H), 7.27 (d, J=8.40 Hz, 2H), .7.11 (m, 4H), 4.85 (s, 2H), 2.21 (s, 3H). MS (ES-): 527 (M-H, 60). Anal. Calc. for C<sub>24</sub>H<sub>18</sub>F<sub>6</sub>N<sub>2</sub>O<sub>3</sub>S: C, 54.55; H, 3.43; N, 5.30; S, 6.07. Found: C, 54.56; H, 3.39; N, 5.29; S, 5.98.

16.24

16.24

<sup>1</sup>H-NMR (DMSO): δ 8.76 (s, 1H), 8.21 (m, 1H), 8.13 (d, J=1.60 Hz, 1H), 7.83 (m, 2H), 4.92 (s, 2H), 7.58 (d, J=8.44 Hz, 2H), 7.30 (m, 6H), 4.90 (s, 2H). MS (ES-): 547 (M-H, 100). Anal. Calc. for C<sub>23</sub>H<sub>15</sub>ClF<sub>6</sub>N<sub>2</sub>O<sub>3</sub>S: C, 50.33; H, 2.75; N, 5.10; Cl, 6.46; S, 5.84. Found: C, 50.42; H, 2.75; N, 5.01; Cl, 6.53; S, 5.76.

15

5

16.25

16.25

<sup>1</sup>H-NMR (DMSO): δ 8.74 (s, 1H), 8.21 (m, 1H), 8.11 (d, J=1.48 Hz, 1H), 7.85 (m, 2H), 7.57 (d, J=8.44 Hz, 2H), 7.26 (m, 7H), 4.91 (s, 2H). MS (ES-): 513 (M-H, 100). Anal. Calc. for C<sub>23</sub>H<sub>16</sub>F<sub>6</sub>N<sub>2</sub>O<sub>3</sub>S: C, 53.70; H, 3.13; N, 5.45; S, 6.23. Found: C, 53.65; H, 3.04; N, 5.33; S, 6.09.

16.26

<sup>1</sup>H-NMR (DMSO): δ 8.75 (s, 1H), 8.21 (m, 1H), 8.08 (s, 1H), 7.83 (m, 2H), 7.57 (d, J=8.44 Hz, 2H), 7.27 (m, 2H), 7.15 (m, 2H), 6.81 (m, 2H), 4.82 (s, 2H), 3.67 (s, 3H). MS (ES-): 543 (M-H, 54). Anal. Calc. for C<sub>24</sub>H<sub>18</sub>F<sub>6</sub>N<sub>2</sub>O<sub>4</sub>S: C, 52.94; H, 3.33; N, 5.15; S, 5.89. Found: C, 52.89; H, 3.37; N, 5.12; S, 5.97.

16.27

16.27

<sup>1</sup>H-NMR (DMSO): δ 8.76 (s, 1H), 8.23 (m, 1H), 8.12 (d, J=1.76 Hz, 1H), 7.86 (m, 2H), 7.58 (d, J=8.40 Hz, 2H), 7.28 (m, 4H), 7.10 (m, 2H), 4.89 (s, 2H). MS (ES-): 531 (M-H, 100). Anal. Calc. for  $C_{23}H_{15}F_7N_2O_3S$ : C, 51.88; H, 2.84; N, 5.26; S, 6.02. Found: C, 51.91; H, 2.83; N, 5.25; S, 6.09.

16.28

$$CF_3$$
 $CN$ 
 $CF_3$ 
 $CN$ 

16.28

10

<sup>1</sup>H-NML MSO): δ 8.76 (s, 1H), 8.23 (m, 1H), 8.14 (α, 1.72 Hz, 1H), 7.80 (m, 2H), 7.60 (d, J=8.32 Hz, 2H), 7.41 (m, 2H), 7.30 (m, 4H), 4.91 (s, 2H). MS (ES-): 593 (M-H, 100). Anal. Calc. for C<sub>23</sub>H<sub>15</sub>BrF<sub>6</sub>N<sub>2</sub>O<sub>3</sub>S: C, 46.56; H, 2.55; N, 4.72; S, 5.40. Found: C, 46.71; H, 2.56; N, 4.67; S, 5.22.

5

16.29

HO 
$$CF_3$$
  $CN$ 

16.29

<sup>1</sup>H-NMR (DMSO): δ 8.76 (s, 1H), 8.23 (m, 1H), 8.14 (d, J=1.28 Hz, 1H), 7.87 (m, 2H), 7.59 (d, J=8.40 Hz, 2H), 7.31 (m, 3H), 7.10 (m, 3H), 4.93 (s, 2H). MS (ES-): 531 (M-H, 100). Anal. Calc. for C<sub>23</sub>H<sub>15</sub>F<sub>7</sub>N<sub>2</sub>O<sub>3</sub>S: C, 51.88; H, 2.84; N, 5.26; S, 6.02. Found: C, 51.89; H, 2.88; N, 5.23; S, 5.89.

16.30

$$\begin{array}{c|c} CF_3 & O & O \\ \hline CF_3 & CN \\ \hline MeO & \end{array}$$

15

20

16.30

<sup>1</sup>H-NMR (DMSO): δ 8.75 (s, 1H), 8.22 (m, 1H), 8.12 (s, 1H), 7.89 (d, J=8.08 Hz, 1H), 7.80 (m, 1H), 7.58 (d, J=8.40 Hz, 2H), 7.31 (m, 2H), 7.18 (m, 1H), 6.82 (d, J=7.68 Hz, 1H), 6.76 (m, 2H), 4.88 (s, 2H), 3.66 (s, 3H). MS (ES-): 543 (M-H, 54). Anal. Calc. for  $C_{24}H_{18}F_6N_2O_4S$ : C, 52.94; H, 3.33; N, 5.15; S, 5.89. Found: C, 53.15; H, 3.50; N, 5.15; S, 5.80.

$$CF_3$$
 $CF_3$ 
 $CN$ 
 $CF_3$ 
 $CN$ 

16.31

<sup>1</sup>H-NMR (DMSO): δ 8.76 (s, 1H), 8.23 (m, 1H), 8.09 (d, J=1.24 Hz, 1H), 7.90 (d, J=8.16 Hz, 1H), 7.80 (m, 1H), 7.57 (m, 3H), 7.46 (d, J=7.60 Hz, 1H), 7.30 (m, 3H), 7.17 (m, 1H), 4.97 (s, 2H). MS (ES-): 593 (M-H, 30). Anal. Calc. for C<sub>23</sub>H<sub>15</sub>BrF<sub>6</sub>N<sub>2</sub>O<sub>3</sub>S: C, 46.56; H, 2.55; N, 4.72; S, 5.40. Found: C, 46.63; H, 2.57; N, 4.73; S, 5.36.

10 16.32

- 5

16.32

<sup>1</sup>H-NMR (DMSO): δ 8.76 (s, 1H), 8.21 (m, 1H), 8.11 (s, 1H), 7.85 (m, 2H), 7.59 (m, 2H), 7.30 (m, 4H), 7.10 (m, 2H), 4.95 (s, 2H). MS (ES-): 531 (M-H, 100). Anal. Calc. for C<sub>23</sub>H<sub>15</sub>F<sub>7</sub>N<sub>2</sub>O<sub>3</sub>S: C, 51.88; H, 2.84; N, 5.26; S, 6.02. Found: C, 51.83; H, 2.78; N, 5.16; S, 6.01.

16.33

HO 
$$CF_3$$
  $CN$ 

16.33

20

'H-NMI MSO): δ 8.76 (s, 1H), 8.23 (m, 1H), 8.12 (d, 1.40 Hz, 1H), 7.80 (m, 2H), 7.58 (d, J=8.72 Hz, 2H), 7.47 (m, 2H), 7.30 (d, J=8.88 Hz, 2H), 7.22 (d, J=8.52 Hz, 2H), 4.89 (s, 2H). MS (ES-): 593 (M-H, 30). Anal. Calc. for C<sub>23</sub>H<sub>15</sub>BrF<sub>6</sub>N<sub>2</sub>O<sub>3</sub>S: C, 46.56; H, 2.55; N, 4.72; S, 5.40. Found: C, 46.73; H, 2.51; N, 4.53; S, 5.31.

16.34

$$HO \xrightarrow{CF_3} O \xrightarrow{S} CN$$

16.34

10

5

'H-NMR (DMSO): δ 8.82 (s, 1H), 8.15 (dd, J=1.64, 7.04 Hz, 1H), 7.95 (s, 1H), 7.76 (m, 2H), 7.66 (d, J=8.40 Hz, 2H), 7.27 (m, 5H), 7.11 (d, J=6.88 Hz, 2H), 3.92 (t, J=7.64 Hz, 2H), 2.67 (t, J=7.32 Hz, 2H). MS (ES-): 527 (M-H, 54). Anal. Calc. for  $C_{24}H_{18}F_6N_2O_3S$ : C, 54.55; H, 3.43; N, 5.30; S, 6.07. Found: C, 54.64; H, 3.37; N, 5.25; S, 6.10.

15

16.35

16.35

<sup>1</sup>H-NMR (DMSO): δ 8.76 (s, 1H), 8.20 (d, J=6.44 Hz, 1H), 8.08 (s, 2H), 7.82 (m, 2H), 7.59 (d, J=8.36 Hz, 2H), 7.29 (m, 2H), 6.71 (m, 3H), 4.78 (s, 2H), 4.17 (s, 4H). MS (ES-): 571 (M-H, 100). Anal. Calc. for C<sub>25</sub>H<sub>18</sub>F<sub>6</sub>N<sub>2</sub>O<sub>5</sub>S: C, 52.45; H, 3.17; N, 4.89; S, 5.60. Found: C, 52.34; H, 3.13; N, 4.80; S, 5.46.

16.36

<sup>1</sup>H-NMR (DMSO): δ 8.81 (s, 1H), 7.88 (s, 1H), 7.75 (m, 5H), 7.39 (m, 1H), 6.61 (m, 1H), 3.06 (s, 3H), 1.49 (s, 9H). MS (ES-): 468 (M-H, 100). Anal. Calc. for C<sub>20</sub>H<sub>21</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 51.57; H, 4.51; N, 2.98; S, 6.83. Found: C, 51.14; H, 4.55; N, 2.96; S, 6.77.

16.37

16.37

'H-NMR (DMSO): δ 9.75 (s, 1H), 8.19 (m, 1H), 8.098 (d, J=1.64 Hz, 1H), 7.91 (m, 1H), 7.80 (t, J=7.88 Hz, 1H), 7.58 (d, J=8.52 Hz, 2H), 7.25 (m, 4H), 6.86 (m, 2H), 4.84 (s, 2H), 3.55 (s, 3H). MS (ES-): 453 (M-H, 92). Anal. Calc. for  $C_{24}H_{18}F_6N_2O_4S$ : C, 52.94; H, 3.33; N, 5.15; S, 5.89. Found: C, 53.00; H, 3.21; N, 5.13; S, 5.91.

16.38

16.38

 $^{1}$ H NMR (CDCl<sub>3</sub>):  $\delta$  7.74 (d, J= 8.7 Hz, 2H), 7.22 (d, J= 8.7 Hz, 2H), 6.93 (s, 1H), 4.12 (h, J = 6.7 Hz, 1H), 3.55 (s, 1H), 1.15 (d, J = 6.7 Hz, 6H). MS (EI)

20

m/z 515 (M<sup>+</sup>). Anal. Ca. for  $C_{16}H_{13}Cl_2F_6NO_3S_2$ : C, 37.22; H, 2.54; N, 1; S 12.42. Found: C, 37.33; H, 2.47; N, 2.65; S, 12.48.

EXAMPLE 17

This example illustrates the preparation of compound 17.1

17.1

Nitric acid (90%, 0.2 mL) was added to compound 14.11 (273 mg, 0.5 mmol) in acetic acid (2 mL) at 0°C. The mixture was stirred at room temperature for 18 hour, at 60°C for 6 hours, and at 100°C for 3 hours. The mixture was poured into ice and extracted with EtOAc. The organic layer was washed with sodium bicarbonate solution and 0.1 N HCl, dried, and concentrated. The residue was purified by silica column chromatography (eluted with 1:5 EtOAc/Hexane) to give 210 mg of product.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 10.35 (s, 1H), 8.63 (s, 3H), 7.93 (d, J=9 Hz, 1H), 7.86 (d, J=9 Hz, 1H), 7.23 (s, 1H), 3.90 (s, 1H). MS (ES) m/z 516.9 ([M-H]). Anal. Calcd. for C<sub>13</sub>H<sub>6</sub>Cl<sub>2</sub>F<sub>6</sub>N<sub>2</sub>O<sub>5</sub>S<sub>2</sub>•1/3EtOAc: C, 31.38; H, 1.59; N, 5.11; S, 11.69. Found: C, 31.53; H, 1.58; N, 5.09; S, 11.85.

#### **EXAMPLE 18**

This example illustrates the preparation of compound 18.1.

18.1

25

5

10

15

20

25

A mixture of N-methylaniline (1.08 mL, 10 mmol), pipsyl chloride (3.02 g, 10 mmol), and 2,6-lutidine (2.33 mL, 20 mmol) in acetone (30 mL) was stirred at room temperature for 20 hours. The lutidine HCl salt was filtered. The filtrate was washed with hexane and water and dried to give 3.6 g of a white solid (N-methyl-N-phenyl-4-iodobenzenesulfonamide).

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.80 (d, J= 8.5 Hz, 2H), 7.23-7.35 (m, 5H), 7.09 (d, J= 8.5 Hz, 2H), 3.18 (s, 3H). MS (EI) m/z 373 (M<sup>+</sup>).

n-BuLi (1.6 M, 1.25 mL, 2 mmol) was added to the above product (373 mg, 1 mmol) in THF (10 mL) at -78°C. The mixture was stirred for 30 minutes, and this mixture was added dropwise to a solution of methyl trifluoroacetate (0.4 mL, 4 mmol) in THF (10 mL) at -78°C. The mixture was allowed to warm to room temperature slowly and stirred at room temperature for 1 hour. The mixture was treated with EtOAc, and it was washed with brine, dried, and concentrated. The residue was purified by silica column chromatography (eluted with 30% EtOAc/Hexane) to give 200 mg of product (N-methyl-N-phenyl-4-trifluoroacetylbenzenesulfonamide).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.14 (d, J= 8.0 Hz, 2H), 7.72 (d, J= 8.7 Hz, 2H), 7.32 (m, 3H), 7.09 (d, J= 8.0 Hz, 2H), 3.24 (s, 3H). MS (ES) m/z 362.0 ([M+H<sub>3</sub>O]<sup>+</sup>).

Tetrabutylammonium fluoride (1.0 M in THF, 0.01 mL) was added to a solution of the above product (186 mg, 0.54 mmol) and trifluoromethyl trimethylsilane (0.5 M in THF, 1.62 mL, 0.81 mmol) in THF (7 mL) at 0°C. Then the mixture was stirred at room temperature overnight. EtoAc (50 mL) was added to the reaction mixture, and it was washed with brine, dried, and concentrated. The residue was purified by silica column chromatography (eluted with 30% EtOAc/Hexane) to give 90 mg of product (18.1).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.83 (d, J= 8.4 Hz, 2H), 7.62 (d, J= 7.0 Hz, 2H), 7.30 (m, 3H), 7.07 (d, J= 8.4 Hz, 2H), 4.11 (bs, 1H), 3.20 (s, 3H). MS (ES) m/z 412.1 ([M-H]<sup>-</sup>). Anal. Calcd. for C<sub>16</sub>H<sub>13</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 46.49; H, 3.17; N, 3.39. Found: C, 46.71; H, 3.23; N, 3.36.

Similar procedures to the one described for the synthesis compound 18.1 were followed to produce compounds 18.2 to 18.15.

18.2

18.2

<sup>1</sup>H-NMR (DMSO): δ 9.08 (s, 1H), 7.80 (m, 4H), 7.58 (m, 1H), 7.20 (m, 1H), 7.09 (m, 2H), 3.78 (t, J=5.96 Hz, 2H), 2.40 (m, 2H), 1.61 (m, 2H). MS (ES-): 438 (M-H, 42). Anal. Calc. for  $C_{18}H_{15}F_6NO_3S$ : C, 49.20; H, 3.43; N, 3.19; S, 7.30. Found: C, 49.42; H, 3.58; N, 5.15; S, 7.23.

18.3

10

18.3

<sup>1</sup>H-NMR (DMSO): δ 9.10 (s, 1H), 7.90 (d, J=8.52 Hz, 2H), 7.71 (m, 2H), 7.43 (m, 2H), 7.14 (m, 2H), 3.17 (s, 3H). MS (ES-): 446 (M-H, 100). Anal. Calc. for C<sub>16</sub>H<sub>12</sub>ClF<sub>6</sub>NO<sub>3</sub>S: C, 42.92; H, 2.70; N, 3.13; Cl, 7.92; S, 7.16. Found: C, 43.04; H, 2.69; N, 3.17; Cl, 8.01; S, 7.20.

18.4

18.4

<sup>1</sup>H-NMR (DMSO): δ 9.09 (s, 1H), 7.90 (d, J=8.44 Hz, 2H), 7.70 (m, 2H), 6.96 (m, 2H), 6.88 (m, 2H), 3.74 (s, 3H), 3.13 (s, 3H). MS (ES-): 442 (M-H, 62).

Anal. Calc. for  $C_{17}H_{15}F_6NO_4S$ : C, 46.05; H, 3.41; N, 3.16; S, 7.23. Found: C, 46.15; H, 3.29; N, 3.17; S, 7.21.

18.5

18.5

<sup>1</sup>H-NMR (DMSO): δ 9.09 (s, 1H), 7.92 (s, 4H), 7.41 (m, 3H), 7.03 (m, 2H), 4.45 (m, 1H), 0.96 (d, J=6.76 Hz, 6H). MS (ES+): 442 (M+H, 100). Anal. Calc. for C<sub>18</sub>H<sub>17</sub>F<sub>6</sub>NO<sub>3</sub>S: C, 48.98; H, 3.88; N, 3.17; S, 7.26. Found: C, 49.07; H, 3.76; N, 3.16; S, 7.19.

18.6

18.6

<sup>1</sup>H-NMR (DMSO): δ 9.13 (s, 1H), 7.94 (d, J=8.44 Hz, 2H), 7.86 (d, J=8.72 Hz, 2H), 7.22 (m, 6H), 7.09 (m, 1H), 6.95 (m, 2H), 4.87 (s, 2H). MS (ES+): 508 (M+H, 75). Anal. Calc. for  $C_{22}H_{16}F_7NO_3S$ : C, 52.07; H, 3.18; N, 2.76; S, 6.32. Found: C, 52.14; H, 3.28; N, 2.77; S, 6.42.

18.7

$$\mathsf{HO} \overset{\mathsf{CF}_3}{\longleftarrow} \overset{\mathsf{O}}{\underset{\mathsf{CF}_3}{\longleftarrow}} \overset{\mathsf{O}}{\longrightarrow} \mathsf{CF}_3$$

18.7

10

15

5

15

<sup>1</sup>H-NMi MSO): δ 9.13 (s, 1H), 7.93 (d, J=8.40 Hz, 27.84 (m, 2H), 7.60 (d, J=8.00 Hz, 1H), 7.52 (t, J=8.08 Hz, 1H), 7.43 (d, J=8.36 Hz, 1H), 7.24 (m, 6H), 4.93 (s, 2H).

MS (ES+): 558 (M+H, 35). Anal. Calc. for C<sub>23</sub>H<sub>16</sub>F<sub>9</sub>NO<sub>3</sub>S: C, 49.56; H, 2.89; N, 2.51; S, 5.75. Found: C, 49.74; H, 3.01; N, 2.55; S, 5.70.

18.8

$$\mathsf{HO} \xrightarrow{\mathsf{CF}_3} \mathsf{CF}_3 \xrightarrow{\mathsf{N}} \mathsf{Me}$$

18.8

<sup>1</sup>H-NMR (DMSO): δ 9.11 (s, 1H), 7.90 (d, J=8.44 Hz, 2H), 7.71 (m, 3H), 7.62 (m, 1H), 7.50 (m, 1H), 7.25 (3, 1H), 3.24 (s, 3H). MS (ES+): 482 (M+H, 100). Anal. Calc. for C<sub>17</sub>H<sub>12</sub>F<sub>9</sub>NO<sub>3</sub>S: C, 42.42; H, 2.51; N, 2.91; S, 6.66. Found: C, 42.69; H, 2.59; N, 3.01; S, 6.38.

18.9

18.9

<sup>1</sup>H-NMR (DMSO): δ 9.13 (s, 1H), 7.96 (m, 2H), 7.86 (m, 2H), 7.2 (m, 7H), 6.83 (m, 1H), 6.74 (m, 1H), 4.86 (s, 2H), 2.26 (s, 3H). MS (ES+): 536 (M+H, 100). Anal. Calc. for C<sub>23</sub>H<sub>19</sub>F<sub>6</sub>NO<sub>3</sub>S<sub>2</sub>: C, 51.58; H, 3.58; N, 2.62; S, 11.98. Found: C, 52.30; H, 3.66; N, 2.71; S, 12.14.

18.10

$$\mathsf{HO} \overset{\mathsf{CF}_3}{\longleftarrow} \overset{\mathsf{Q}}{\longrightarrow} \overset{\mathsf{Me}}{\longrightarrow} \mathsf{SMe}$$

 $^{1}$ H-NMR (DMSO): δ 9.11 (s, 1H), 7.91 (d, J=8.32 Hz, 2H), 7.74 (m, 2H), 7.28 (m, 1H), 7.18 (d, J=7.12 Hz, 1H), 6.80 (d, J=7.76 Hz, 1H), 6.80 (d, J=1.48 Hz, 1H), 3.18 (s, 3H), 2.33 (s, 3H). MS (ES+): 460 (M+H, 87). Anal. Calc. for  $C_{17}H_{15}F_6NO_3S_2$ : C, 44.44; H, 3.29; N, 3.05; S, 13.96. Found: C, 45.24; H, 3.36; N, 3.10; S, 14.26.

#### 18.11

18.11

#### .

<sup>1</sup>H-NMR (DMSO): δ 9.12 (s, 1H), 7.90 (d, J=8.44 Hz, 2H), 7.77 (d, J=7.28 Hz, 1H), 7.72 (d, J=8.56 Hz, 2H), 7.56 (m, 3H), 3.20 (s, 3H). MS (ES+): 439 (M+H, 60). Anal. Calc. for  $C_{17}H_{12}F_6N_2O_3S$ : C, 46.58; H, 2.76; N, 6.39; S, 7.32. Found: C, 46.58; H, 2.78; N, 6.32; S, 17.22.

# 18.12

10

15

#### 18.12

<sup>1</sup>H-NMR (DMSO): δ 9.10 (s, 1H), 7.92 (s, 4H), 7.57 (m, 1H), 7.49 (m, 20 1H), 7.19 (m, 1H), 6.81 (s, 1H), 4.51 (m, 1H), 0.99 (d, J=6.80 Hz, 6H). MS (ES+): 526 (M+H, 80). Anal. Calc. for C<sub>19</sub>H<sub>16</sub>F<sub>9</sub>NO<sub>4</sub>S: C, 43.44; H, 3.07; N, 2.67; S, 6.10. Found: C, 44.52; H, 3.25; N, 2.75; S, 2.03.

18.13

<sup>1</sup>H-NMR (DMSO): δ 9.10 (s, 1H), 7.92 (s, 4H), 7.31 (m, 2H), 6.83 (d, J=7.60 Hz, 1H). 6.68 (s, 1H), 4.49 (m, 1H), 2.34 (s, 3H), 0.98 (d, J=6.68 Hz, 6H). MS (ES+): 488 (M+H, 100). Anal. Calc. for C<sub>19</sub>H<sub>19</sub>F<sub>6</sub>NO<sub>3</sub>S<sub>2</sub>: C, 46.81; H, 3.93; N, 2.87; S, 13.16. Found: C, 47.17; H, 3.98; N, 2.89; S, 12.93.

18.14

18.14

<sup>1</sup>H-NMR (DMSO): δ 9.07 (s, 1H), 7.88 (s, 4H), 7.41 (m, 4H), 7.17 (m, 2H), 7.00 (m, 2H), 6.83 (m, 1H), 6.51 (m, 1H), 4.43 (m, 1H), 0.93 (d, J=6.72 Hz, 6H). MS (ES+): 534 (M+H, 75). Anal. Calc. for  $C_{24}H_{21}F_6NO_4S$ : C, 54.03; H, 3.97; N, 2.63; S, 6.01. Found: C, 54.10; H, 3.93; N, 2.65; S, 6.05.

18.15

18.15

<sup>1</sup>H-NMR (DMSO): δ 9.10 (s, 1H), 7.95 (s, 4H), 7.20 (m, 1H), 7.50 (m, 6H), 7.08 (m, 2H), 4.55 (m, 1H),1.02(d, J=6.68 Hz, 6H). MS (ES+): 518 (M+H, 100). Anal. Calc. for  $C_{24}H_{21}F_6NO_3S$ : C, 55.70; H, 4.09; N, 2.71; S, 6.20. Found: C, 56.26; H, 4.27; N, 2.70; S, 6.02.

10

1,5

Additional examples prepared by procedures similar to those described

above:

18.16

`18.16

5

10

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): δ 7.78 (d, J = 8.3 Hz, 2H), 7.27 (d, J = 8.3 Hz, 2H), 3.90 (bs, 1H), 3.26 (s, 3H), 2.20 (m, 1H), 1.40-1.70 (m, 8H), 1.15-1.35 (m, 2H). MS (ES-): 382 (M-H). Anal. Calcd. For  $C_{17}H_{19}F_6NO_2$ : C, 53.27; H, 5.00; N, 3.65. Found: C, 53.72; H, 5.21; N, 3.47.

18.17

18.17

<sup>1</sup>H-NMR (CDCl<sub>3</sub>):  $\delta$  7.76 (d, J = 8.4 Hz, 2H), 7.32 (s, J = 8.4 Hz, 2H), 3.60 (s, 1H), 3.22 (s, 3H), 1.84 (s, 3H), 1.73 (s, 6H), 1.57 (d, J = 12.4 Hz, 3H), 1.47 (d, J = 12.4 Hz, 3H). MS (ES-): 434 (M-H). Anal. Calcd. For  $C_{21}H_{23}F_6NO_2$ : C, 57.93; H, 5.32; N, 3.22. Found: C, 58.07; H, 5.33; N, 3.18.

18.18

20

<sup>1</sup>H-NMR  $_{\bullet}$   $_{\bullet}$   $_{0}$  OD):  $\delta$   $\delta$  7.61 (d, J = 8.4 Hz, 2H), 7.25 (n,  $_{\bullet}$   $_{\bullet}$   $_{\bullet}$   $_{\bullet}$  ), 3.49 (s, 3H). MS (ES+): 378 (M+ H), MS (ES-): 376 (M-H). Anal. Calcd. for  $C_{17}H_{13}F_{6}NO_{2}$ : C, 54.12; H, 3.47; N, 3.71. Found: C, 54.33; H, 3.41; N, 3.70.

18.19

18.19

<sup>1</sup>H-NMR (CD<sub>3</sub>OD): δ 7.65 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 8.7 Hz, 4H), 7.19 (s, 2H), 3.48 (s, 3H). MS (ES+): 412 (M+ H), MS (ES-): 410 (M-H). Anal. Calcd. for C<sub>17</sub>H<sub>12</sub>ClF<sub>6</sub>NO<sub>2</sub>: C, 49.59; H, 2.94; N, 3.40. Found: C, 49.72; H, 2.96; N, 3.40.

18.20

15

20

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): δ 8.12 (d, J = 9.1 Hz, 1H), 7.90 (s, 1H), 7.74 (d, J = 7.0 Hz, 1H), 7.69 (d, J = 6.8 Hz, 2H), 7.62 (dd, J = 9.1, 7.0 Hz, 1H), 7.20 (d, J = 6.8 Hz, 2H), 4.82 )s, 2H), 3.80 (s, 1H), 3.22 (s, 3H). MS (ES-): 491 (M-H). Anal. Calcd. For  $C_{16}H_{14}F_6N2O_5S_2$ : C, 39.02; H, 2.87; N, 5.69; S, 13.02. Found: C, 39.52; H, 2.87; N, 5.44, S, 12.71.

18.21

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): δ 7.74 (d, J = 7.9 Hz, 2H), 7.69 (d, J = 8.4 Hz, 2H), 7.57 (t, J = 7.6 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 7.15 (d, J = 8.5 Hz, 2H), 4.61 (m, 1H), 3.46 (s, 1H), 1.05(d, J = 6.8 Hz, 6H). MS (ES+): 442 (M+ H), MS (ES-): 440 (M-H). Anal. Calcd. for  $C_{18}H_{17}F_6NO_3S$ : C, 48.98; H, 3.88; N, 3.17; S, 7.26. Found: C, 49.08; H, 3.82; N, 3.09; S, 7.27.

18.22

10

18.22

<sup>1</sup>H-NMR (CD<sub>3</sub>OD): δ 7.88 (d, J = 8.9 Hz, 1H), 7.68 (d, J = 8.2 Hz, 2H), 7.65 (t, J = 7.6 Hz, 1H), 7.52 (t, 7.8 Hz, 2H), 7.25 (d, J = 8.6 Hz, 1H), 7.14 (s, 1H), 3.92 (t, J = 4.6 Hz, 2H), 3.75 (t, J = 4.6 Hz, 2H). MS (ES-): 440 (M-H). Anal. Calcd. for  $C_{17}H_{13}F_6NO_4S$ : C, 46.26; H, 2.97; N, 3.17; S, 7.27. Found: C, 46.39; H, 2.97; N, 3.18; S, 7.29.

WO 00/54759 PCT/US00/06611

18.23

18.23

<sup>1</sup>H-NMR (CDCl<sub>3</sub>):  $\delta$  7.94 (d, J = 9.0 Hz, 1H), 7.59 (d, J = 5.0 Hz, 1H),

7.48 (d, J = 5.1 Hz, 1H), 7.27 (d, 9.5 Hz, 1H), 7.23 (s, 1H), 7.07 (t, J = 5.0 Hz, 1H), 3.93 (t, J = 5.0 Hz, 2H), 3.86 (t, J = 4.9 Hz, 2H), 3.37 (s, 1H). MS (ES+): 448 (M+H), MS (ES-): 446 (M-H). Anal. Calcd. for  $C_{15}H_{11}F_6NO_4S_2$ : C, 40.27; H, 2.48; N, 3.13; S, 14.34. Found: C, 40.10; H, 2.51; N, 3.12; S, 14.32.

18.24

10

BNSDOCID <WO\_\_0054759A2\_I\_:

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): δ 7.98 (s, 1H), 7.85 (m, 3H), 7.61 (t, J = 7.9 Hz,

15 1H), 7.29 (d, J = 8.8 Hz, 1H), 7.23 (s, 1H), 4.05 (s, 1H), 3.94 (t, J = 3.6 Hz, 2H), 3.90

(t, J = 3.6 Hz, 2H). MS (ES-): 465 (M-H). Anal. Calcd. for C<sub>18</sub>H<sub>12</sub>F<sub>6</sub>N<sub>2</sub>O<sub>4</sub>S : C, 46.36;

H, 2.59; N, 6.01; S, 6.88. Found: C, 46.76; H, 2.72; N, 5.76; S, 6.52.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): δ 7.71 (d, J = 8.8 Hz, 1H), 7.27 (s, 1H), 7.24 (d, J = 8.8 Hz, 1H), 6.99 (s, 1H), 4.12(t, J = 4.6 Hz, 2H), 3.99 (t, J = 4.2 Hz, 2H) 3.33 (s, 1H). MS (ES-): 514 (M-H). Anal. Calcd. for  $C_{15}H_9Cl_2F_6NO_4S_2$ : C, 34.90; H, 1.76; N, 2.71; S, 12.42. Found: C, 35.00; H, 1.66; N, 2.71; S, 12.55.

18.26

-10

18.26

<sup>1</sup>H-NMR (CDCl<sub>3</sub>):  $\delta$  7.73 (d, J = 7.9 Hz, 2H), 7.57 (t, J = 7.9 Hz, 1H), 7.48 (m, 4H), 7.39 (d, J = 8.8 Hz, 1H), 3.72 (bs, 2H), 3.44 (s, 1H), 2.42 (t, J = 4.5 Hz, 2H), 1.80 (m, 2H), 1.57 (m. 2H). MS (ES+): 454 (M+ H), MS (ES-): 452 (M-H). Anal. Calcd. for C<sub>19</sub>H<sub>17</sub>F<sub>6</sub>NO<sub>3</sub>S : C, 50.33; H, 3.78; N, 3.09; S, 7.07. Found: C, 50.06; H, 3.69; N, 3.06; S, 7.22.

18.27

5

<sup>1</sup>H-NMR (CDCl<sub>3</sub>):  $\delta$  8.02 (s, 1H), 7.91 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 7.7 Hz, 1H), 7.61 (t, J = 7.9 Hz, 1H), 7.539 (d, J = 8.5 Hz, 1H), 7.51 (s, 1H) 7.31 (d, J = 8.2 Hz, 1H), 4.06 (s, 1H), 3.74 (bs, 2H), 2.42 (t, J = 5.0 Hz, 2H), 1.81 (q, J = 5.7 Hz, 2H), 1.60 (bs. 2H). MS (ES-): 477 (M-H). Anal. Calcd. for  $C_{20}H_{16}F_6N_2O_3S$ : C, 50.21; H, 3.37; N, 5.86; S, 6.70. Found: C, 51.28; H, 3.75; N, 5.50; S, 6.39.

10


18.28

15

20

#### Reductive amination:

A mixture of 4-(hexafluoro-2-hydroxyisopropyl)aniline (1.0 g, 0.386 mol) and tetrahydro-4H-pyran-4-one (0.433 g, 0.433 mol, available from Aldrich Chemical Company) in methanol was stirred overnight. To this solution was added acetic acid (0.25 mL) followed by sodium cyanoborohydride (0.365 g, 0.006 mol). Stirring was continued for an additional 3 hr, at which time TLC analysis revealed completion of reaction. The reaction mixture was concentrated under vacuum. The residue was dissolved in ethyl acetate, washed with brine, dried, and concentrated. Purification of the crude product by flash chromatography on silica gel eluted with 4:1 to 2:1 hexane/EtOAc produced pure product (18.28) 1.06 g, 80.0%.



 $^{1}$ H-NMR (CDCl<sub>3</sub>):  $\delta$  7.48 (d, J = 8.0 Hz, 2H), 6.61 (d, J = 8.0 Hz, 2H), 4.00 (m, 1H), 3.83 (s, 1H), 3.50 (t, J = 6.5 Hz, 4H), 3.40 (s, 1H), 1.52 (m, 4H). MS (ES+): 344 (M+H).

18.29

5

10

15

20

Starting from compound 18.28 and following the standard procedure for sulfonylation, compound 18.29 was obtained.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>):  $\delta$  7.72 (d, J = 7.7 Hz, 2H), 7.66 (d, J = 8.1 Hz, 2H), 7.57 (t, J = 7.3 Hz, 1H), 7.47 (t, J = 7.7 Hz, 2H), 7.09 (d, J = 8.4 Hz, 1H), 3.72 (m, 1H), 4.19 (s, 1H), 3.91 (dd, J = 11.5, 4 Hz, 2H), 3.45 (t, J = 11.8 Hz, 2H), 1.72 (d, J = 12 Hz, 2H), 1.44 (q, J = 12 Hz, 2H). MS (ES+): 484 (M+ H), MS (ES-): 482 (M-H). Anal. Calcd. for  $C_{20}H_{19}F_6NO_4S$ : C, 49.69; H, 3.96; N, 2.90; S, 6.63. Found: C, 49.66; H, 3.84; N, 2.89; S, 6.52.

18.30

18.30

Substituting cyclopentanone for tetrahydro-4H-pyran-4-one, compound 18.30 was prepared by a procedure similar to the synthesis of compound 18.28.

 $^{1}$ H-NMR (CDCl<sub>3</sub>):  $\delta$  7.45 (d, J = 8.0 Hz, 2H), 6.60 (d, J = 8.0 Hz, 2H), 3.88 (s, 1H), 3.80 (s, 1H), 2.05 (m, 4H), 1.65 (m, 4H). MS (ES+): 260 (M+ H).

18.31

'H-NMR (CDCl<sub>3</sub>):  $\delta$  7.70 (d, J=8.5 Hz, 2H), 7.59 (d, J=4.9 Hz, 1H), 7.43 (d, J=5.0 Hz, 1H), 7.19(d, 8.4 Hz, 2H), 7.06 (t, J=4.0 Hz, 1H), 4.52 (m, 1H), 3.45 (s, 1H), 1.89(t, J=5.2 Hz, 2H), 1.48 (m, 4H), 1.32 (m, 2H). MS (ES-): 472 (M-H). Anal. Calcd. for  $C_{18}H_{17}F_6NO_3S_2$ : C, 45.66; H, 3.62; N, 2.96; S, 13.55. Found: C, 45.77; H, 3.69; N, 2.97; S, 13.69.

18.32

10

BNSDOCID <WU\_\_0054759A2\_I\_>

18.32

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): δ 8.01 (s, 1H), 7.89 (d, J=8.0 Hz, 21H), 7.85 (d, J=7.8 Hz, 1H), 7.71 (d, J=8.4 Hz, 2H), 7.61(t, J=7.9 Hz, 1H), 7.10 (d, J=8.7 Hz, 2H), 4.53 (m, 1H), 3.53 (s, 1H), 1.86(m, 2H), 1.51 (m, 4H), 1.30 (m, 2H). MS (ES-): 491 (M-H). Anal. Calcd. for  $C_{21}H_{18}F_6N_2O_3S$ : C, 51.22; H, 3.68; N, 5.69; S, 6.51. Found: C, 51.29; H, 3.56; N, 5.63; S, 6.49.

5

10

15

20

18.33

18.33

18.34

Compound 18.33 was prepared from the corresponding sulfonyl chloride following the standard sulfonylation procedure described above. Compound 18.33 (150 mg, 0.342 mmol) was treated under Lemieux-Johnson oxidative cleavage conditions (OsO<sub>4</sub>, 0.0342 mmol; NaIO<sub>4</sub>, 250 mg, 1.27 mmol; in 2:1 acetone/H<sub>2</sub>O) to give the corresponding aldehyde. The aldehyde was then reduced with NaBH<sub>4</sub> in methanol at 0°C to give compound 18.34, 50 mg, 30%.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>):  $\delta$  7.82 (d, J = 7.2 Hz, 1H), 7.80 (bs, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.51 (t, J = 7.2 Hz, 1H), 7.37 (d, J = 7.6 Hz, 1H), 7.25 (t, J = 7.6 Hz, 1H), 7.13 (d, J = 8.4 Hz, 2H), 4.04 (t, J = 6.1 Hz, 2H), 3.57 (s, 1H), 3.43 (t, J = 6.1 Hz, 2H), 2.15 (bs, 1H). MS (ES-): 442 (M-H).

18.35

18.35

A sample of compound **18.34** (22 mg, 0.049 mmol) was dissolved in anhydrous THF (2 mL). To it was added triphenylphosphine (32.5 mg, 0.124 mmol)

WO 00/54759 PCT/US00/06611

followed by diethyl azo Carboxylate (15.6 mL, 0.10 mmol) at 0°C. Sharing was continued for an additional 2 hrs. The reaction mixture was diluted with ethyl acetate, washed with aqueous NaHCO<sub>3</sub> solution, dried over MgSO<sub>4</sub>, filtered and concentrated. Crude product was purified by flash chromatography on silica gel, eluted with 1:1 hexane/EtOAc to give compound 18.35, 18.2 mg, 86.2%.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>):  $\delta$  7.89 (d, J = 7.6 Hz, 1H), 7.69 (d, J = 8.4 Hz, 2H), 7.532 (t, J = 7.6 Hz, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 7.6 Hz, 1H), 4.27 (t, J = 6.4 Hz, 2H), 3.58 (s, 1H), 3.19 (t, J = 6.4 Hz, 2H). MS (ES-): 424 (M- H).

18.36

5

10

15

20

25

18.36

4-(Hexafluoro-2-hydroxyisopropyl)benzoic acid (100 mg, 0.35 mmol, available from Lancaster) was treated with oxalyl chloride (2.0M solution in dichloromethane, 0.35 mL, 0.70 mmol) in dichloromethane (2 mL) at ambient temperature for two hours. The reaction mixture was evaporated to dryness, redissolved in dichloromethane (2 mL), and was added to a stirred mixture of N-methylaniline (56 mg, 0.53 mmol) and diisopropylethylamine (0.12 mL, 0.70 mmol) in dichloromethane (2 mL). Upon completion of reaction, the mixture was diluted with dichloromethane, washed with 0.5 N HCl, brine, and NaHCO<sub>3</sub> solution. The organic phase was dried over MgSO<sub>4</sub>, filtered and concentrated. The crude product was purified by flash chromatography on silica gel to give compound 18.36, 118 mg, 90.1%.

 $^{1}$ H-NMR (CDCl<sub>3</sub>):  $\delta$  7.50 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 7.0 Hz, 2H), 7.20 (t, J = 7.0 Hz, 2H), 7.14 (t, J = 7.0 Hz, 1H), 7.01 (d, J = 8.0 Hz, 2H), 3.80 (s, 1H), 3.50 (s, 3H). MS (ES-): 376 (M-H).

#### **EXAMPLE 19**

LXR $\alpha$  agonist activity can be characterized in a cell-based assay or a peptide-sensor assay. The same assays can be utilized to characterize LXR $\alpha$  antagonist activity, by evaluating the ability of a compound to block the effects of an LXR $\alpha$  agonist, such as 24,25-epoxycholesterol.

Briefly, for the cell-based assay, a DNA-binding domain of the nonreceptor transcription factor GAL4 was fused to the putative ligand-binding domain of LXRα. The resultant construct was introduced into 293 cells, together with UAS-containing luciferase reporter construct. The transfected cells were then treated with chemical libraries and luciferase activity was measured. Individual compounds were evaluated relative to a control (no addition of compound) and the EC<sub>50</sub> was determined as the concentration necessary to produce 50% of the maximal luciferase activity.

The peptide sensor LXR assay is an *in vitro* assay and was conducted as generally described in co-pending applications Ser. Nos. 08/975,614 (filed November 21, 1997) and 09/163,713 (filed September 30, 1998). Exemplary of the activity observed for the compounds provided herein was exhibited by compound 2 (EC<sub>50</sub> in each of the assays was less than 2 micromolar).

All publications and patent applications cited in this specification are

herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

25 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

30

10

15

# WHAT IS CLAIMED IS:

1. A composition for modulation of LXR function in a cell, said composition comprising a pharmaceutically acceptable excipient and a compound having the formula:

$$X^{1} \xrightarrow{X^{2}} X^{3}$$
 $R^{1} \xrightarrow{C} A^{1} \xrightarrow{R^{2}} X^{6}$ 
 $X^{4} \xrightarrow{C} X^{6}$ 

or a pharmaceutically acceptable salt thereof, wherein Ar is an aryl group;

 $R^1$  is a member selected from the group consisting of -OH, -CO<sub>2</sub>H, -O-(C<sub>1</sub>-C<sub>7</sub>)alkyl, -OC(O)-(C<sub>1</sub>-C<sub>7</sub>)alkyl, -O-(C<sub>1</sub>-C<sub>7</sub>)heteroalkyl, -OC(O)-(C<sub>1</sub>-C<sub>7</sub>)heteroalkyl, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>7</sub>)alkyl, -N((C<sub>1</sub>-C<sub>7</sub>)alkyl), and -NH-S(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>5</sub>)alkyl;

 $R^2$  is a member selected from the group consisting of  $(C_1-C_7)$ alkyl,  $(C_1-C_7)$ heteroalkyl, aryl and  $aryl(C_1-C_7)$ alkyl;

 $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$  and  $X^6$  are each independently a member selected from the group consisting of H,  $(C_1-C_5)$ alkyl,  $(C_1-C_5)$ heteroalkyl, F and Cl, with the proviso that no more than three of  $X^1$  through  $X^6$  are H,  $(C_1-C_5)$ alkyl or  $(C_1-C_5)$ heteroalkyl; and

Y is a divalent linking group selected from the group consisting of  $-N(R^{12})S(O)_m$ ,  $-N(R^{12})S(O)_mN(R^{13})$ -,  $-N(R^{12})C(O)$ -,  $-N(R^{12})C(O)N(R^{13})$ -,  $-N(R^{12})C(S)$ - and  $-N(R^{12})C(O)O$ -;

wherein  $R^{12}$  and  $R^{13}$  are each independently selected from the group consisting of H,  $(C_1-C_7)$ alkyl,  $(C_1-C_7)$ heteroalkyl, aryl and aryl $(C_1-C_7)$ alkyl, and optionally when Y is  $-N(R^{12})S(O)_m$ - or  $-N(R^{12})S(O)_mN(R^{13})$ -,  $R^{12}$  forms a five- or six-membered ring fused to Ar or to  $R^2$  through covalent attachment to Ar or to  $R^2$ , respectively; and the subscript m is an integer of from 1 to 2;

with the proviso that when  $R^1$  is OH, and  $-Y-R^2$  is  $-N(R^{12})S(O)_m-R^2$  or  $-N(R^{12})C(O)N(R^{13})-R^2$  and is attached to a position para to the quaternary carbon attached to Ar, and when  $R^2$  is phenyl, benzyl or benzoyl, then i) at least one of  $R^{12}$  or  $R^{13}$  is other than hydrogen and contains an electron-withdrawing substituent, or ii)  $R^2$  is substituted with a moiety other than amino, acetamido,  $di(C_1-C_2)alkylamino$ ,  $(C_1-C_2)alkylamino$ , halogen, hydroxy, nitro, or  $(C_1-C_2)alkyl$ , or iii) the benzene ring

10

15

20

25

10

15

20



portion of R<sup>2</sup> is substituted with at least three independently selected groups in addition to the Y group or point of attachment to Y.

- 2. A composition in accordance with claim 1, wherein Ar represents a substituted or unsubstituted ring selected from the group consisting of benzene, naphthalene, pyridine, quinoline, isoquinoline, pyrrole, furan and thiophene.
- 3. A composition in accordance with claim 1, wherein Ar represents a benzene ring.
- 4. A composition in accordance with claim 1, wherein R<sup>1</sup> is a member selected from the group consisting of -OH, -CO<sub>2</sub>H, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>7</sub>)alkyl, -N((C<sub>1</sub>-C<sub>7</sub>)alkyl)<sub>2</sub> and -NH-S(O)<sub>2</sub>CH<sub>3</sub>.
  - 5. A composition in accordance with claim 1, wherein R<sup>2</sup> is aryl.
- 6. A composition in accordance with claim 1, wherein R<sup>2</sup> is phenyl, said phenyl group being substituted with at least one substituent at the ortho or meta position relative to the point of attachment to Y.
- 7. A composition in accordance with claim 1, wherein no more than one of  $X^1$  through  $X^6$  is hydrogen or  $(C_1-C_5)$  alkyl.
- 8. A composition in accordance with claim 1, selected from the group consisting of

wherein the subscript n represents an integer of from 0 to 4; and each R<sup>11</sup> is independently selected from the group consisting of -OH, -NH<sub>2</sub>, lower alkyl, lower alkoxy, -NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R', -CO<sub>2</sub>R', -CONR'R'', -OC(O)NR'R'', -NR"C(O)R', -NR"C(O)<sub>2</sub>R', -NH-C(NH<sub>2</sub>)=NH, -NR'C(NH<sub>2</sub>)=NH, -NH-C(NH<sub>2</sub>)=NR', -S(O)R', -S(O)<sub>2</sub>R', -S(O)<sub>2</sub>NR'R'', -CN and -NO<sub>2</sub>

9. A composition in accordance with claim 1, said compound having a formula selected from the group consisting of

10. A composition in accordance with claim 9, said compound having a formula selected from the group consisting of

$$X^{6}F_{2}C \xrightarrow[R^{2}]{(R^{11})_{n}} X^{6}F_{2}C \xrightarrow[R^{11}]{(R^{11})_{n}} X^{$$

- 11. A composition in accordance with claim 1, wherein  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$  and  $X^6$  are each F.
  - 12. A composition in accordance with claim 1, wherein  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$  and  $X^6$  are each F,  $R^1$  is a member selected from the group consisting of -OH, -NH<sub>2</sub>, -CO<sub>2</sub>H, -O-(C<sub>1</sub>-C<sub>7</sub>)alkyl, and -OC(O)-(C<sub>1</sub>-C<sub>7</sub>)alkyl, Y is a member selected from the group consisting of -N( $R^{12}$ )S(O)<sub>m</sub>-, -N( $R^{12}$ )C(O)- and -N( $R^{12}$ )C(O)N( $R^{13}$ )-, and  $R^2$  is aryl.
  - 13. A composition in accordance with claim 10, said compound having a formula selected from the group consisting of:



$$X^{6}F_{2}C$$

$$Q = S = 0$$

$$R^{1}$$

$$X^{6}F_{2}C$$

$$Q = S = 0$$

$$R^{2}$$

wherein  $R^1$  is a member selected from the group consisting of -OH and -NH<sub>2</sub>;  $X^1$  and  $X^6$  are each independently hydrogen or fluorine,  $R^{12}$  is fluoro( $C_1$ - $C_4$ )alkyl; and  $R^2$  is aryl.

14. A composition in accordance with claim 10, said compoundhaving a formula selected from the group consisting of:

wherein  $R^1$  is a member selected from the group consisting of -OH and -NH<sub>2</sub>;  $X^1$  and  $X^6$  are each independently hydrogen or fluorine,  $R^{12}$  is H,  $(C_1-C_4)$ alkyl or  $(C_2-C_4)$ heteroalkyl; and  $R^2$  is substituted or unsubstituted thienyl.

15. A composition in accordance with claim 10, said compoundhaving a formula selected from the group consisting of:

wherein  $R^1$  is a member selected from the group consisting of -OH and -NH<sub>2</sub>;  $X^1$  and  $X^6$  are each independently H or F;  $R^{12}$  is  $(C_1-C_4)$ alkyl; and  $R^2$  is phenyl substituted with at least one member selected from the group consisting of halogen -CN, -CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)alkyl, -C(O)-(C<sub>1</sub>-C<sub>4</sub>)alkyl, -C(O)-O(C<sub>1</sub>-C<sub>4</sub>)alkyl, -C(O)-NH(C<sub>1</sub>-C<sub>4</sub>)alkyl and -C(O)N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>.

16. A composition in accordance with claim 15, wherein  $R^1$  is -OH;  $X^1$  and  $X^6$  are each fluorine; and  $R^2$  is phenyl substituted with at least one member selected from the group consisting of -CN, -CF<sub>3</sub> and -O-(C<sub>1</sub>-C<sub>4</sub>)alkyl.

17. A composition in accordance with claim 1, wherein said compound is selected from the group consisting of:

$$F_3$$
C  $F_3$ C

18. A composition in accordance with claim 1, wherein said compound is selected from the group consisting of:

19. A composition in accordance with claim 1, wherein said compound is selected from the group consisting of:

20. A compound having the formula:

$$X^{1}$$
 $X^{2}$ 
 $X^{3}$ 
 $R^{1}$ 
 $Ar$ 
 $X^{4}$ 
 $X^{5}$ 
 $R^{2}$ 

10

15

20

25

30

or a pharmaceutically acceptable salt thereof, wherein Ar is an aryl group;

 $R^1$  is a member selected from the group consisting of -OH, -CO<sub>2</sub>H, -O-(C<sub>1</sub>-C<sub>7</sub>)alkyl, -OC(O)-(C<sub>1</sub>-C<sub>7</sub>)alkyl, -O-(C<sub>1</sub>-C<sub>7</sub>)heteroalkyl, -OC(O)-(C<sub>1</sub>-C<sub>7</sub>)heteroalkyl, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>7</sub>)alkyl, -N((C<sub>1</sub>-C<sub>7</sub>)alkyl)<sub>2</sub> and -NH-S(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>5</sub>)alkyl;

 $R^2$  is a member selected from the group consisting of  $(C_1-C_7)$ alkyl,  $(C_1-C_7)$ heteroalkyl, aryl and aryl $(C_1-C_7)$ alkyl;

 $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$  and  $X^6$  are each independently a member selected from the group consisting of H,  $(C_1-C_5)$ alkyl,  $(C_1-C_5)$ heteroalkyl, F and Cl, with the proviso that no more than three of  $X^1$  through  $X^6$  are H,  $(C_1-C_5)$ alkyl or  $(C_1-C_5)$ heteroalkyl; and

Y is a divalent linking group selected from the group consisting of  $-N(R^{12})S(O)_m$ -,  $-N(R^{12})S(O)_mN(R^{13})$ -,  $-N(R^{12})C(O)$ -,  $-N(R^{12})C(O)N(R^{13})$ -,  $-N(R^{12})C(S)$ - and  $-N(R^{12})C(O)O$ -;

wherein  $R^{12}$  and  $R^{13}$  are each independently selected from the group consisting of H,  $(C_1-C_7)$ alkyl,  $(C_1-C_7)$ heteroalkyl, aryl and aryl $(C_1-C_7)$ alkyl, and optionally when Y is  $-N(R^{12})S(O)_m$  or  $-N(R^{12})S(O)_mN(R^{13})$ -,  $R^{12}$  forms a five- or six-membered ring fused to Ar or to  $R^2$  through covalent attachment to Ar or to  $R^2$ , respectively; and the subscript m is an integer of from 1 to 2;

with the proviso that when  $R^1$  is OH, and  $-Y-R^2$  is  $-N(R^{12})S(O)_m-R^2$  or  $-N(R^{12})C(O)N(R^{13})-R^2$  and is attached to a position para to the quaternary carbon attached to Ar, and when  $R^2$  is phenyl, benzyl or benzoyl, then i) at least one of  $R^{12}$  or  $R^{13}$  is other than hydrogen and contains an electron-withdrawing substituent, or ii)  $R^2$  is substituted with a moiety other than amino, acetamido,  $di(C_1-C_7)alkylamino$ ,  $(C_1-C_7)alkylamino$ , halogen, hydroxy, nitro, or  $(C_1-C_7)alkyl$ , or iii) the benzene ring portion of  $R^2$  is trisubstituted in addition to the attached Y group.

- 21. A compound in accordance with claim 20, wherein Ar represents a substituted or unsubstituted ring selected from the group consisting of benzene, naphthalene, pyridine, quinoline, isoquinoline, pyrrole, furan and thiophene.
- 22. A compound in accordance with claim 20, wherein Ar represents a benzene ring.
- 23. A compound in accordance with claim 20, wherein  $R^1$  is a member selected from the group consisting of -OH, -CO<sub>2</sub>H, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>7</sub>)alkyl, -N((C<sub>1</sub>-C<sub>7</sub>)alkyl)<sub>2</sub> and -NH-S(O)<sub>2</sub>CH<sub>3</sub>.

- 24. A compound in accordance with claim 20, wherein R<sup>2</sup> is aryl.
- 25. A compound in accordance with claim 20, wherein R<sup>2</sup> is phenyl, said phenyl group being substituted with at least one substituent at the ortho or meta position relative to the point of attachment to Y.
- 26. A compound in accordance with claim 20, wherein no more than one of X<sup>1</sup> through X<sup>6</sup> is hydrogen or (C<sub>1</sub>-C<sub>5</sub>)alkyl.
- 27. A compound in accordance with claim 20, selected from the group consisting of

wherein the subscript n represents an integer of from 0 to 4; and each R<sup>11</sup> is independently selected from the group consisting of -OH, -NH<sub>2</sub>, lower alkyl, lower alkoxy, -NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R', -CO<sub>2</sub>R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR"C(O)NR'R"', -NR"C(O)<sub>2</sub>R', -NH-C(NH<sub>2</sub>)=NH, -NR'C(NH<sub>2</sub>)=NH, -NH-C(NH<sub>2</sub>)=NR', -S(O)R', -S(O)<sub>2</sub>R', -S(O)<sub>2</sub>NR'R", -CN and -NO<sub>2</sub>.

wherein R', R" and R" are each independently selected from the group consisting of  $(C_1-C_5)$  alkyl and  $(C_1-C_5)$  haloalkyl.

28. A compound in accordance with claim 27, said compound having a formula selected from the group consisting of:

10



29. A compound in accordance with claim 28, said compound having a formula selected from the group consisting of

- 30. A compound in accordance with claim 20, wherein X¹, X², X³, X⁴,
  X⁵ and X⁶ are each F.
  - 31. A compound in accordance with claim 20, wherein  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$  and  $X^6$  are each F;  $R^1$  is a member selected from the group consisting of -OH, -CO<sub>2</sub>H, -NH<sub>2</sub>, -O-(C<sub>1</sub>-C<sub>7</sub>)alkyl, and -OC(O)-(C<sub>1</sub>-C<sub>7</sub>)alkyl; Y is a member selected from the group consisting of -N( $R^{12}$ )S(O)<sub>m</sub>-, -N( $R^{12}$ )C(O)- and -N( $R^{12}$ )C(O)N( $R^{13}$ )-; and  $R^2$  is aryl.
  - 32. A compound in accordance with claim 29, said compound having the formula:

wherein  $R^1$  is a member selected from the group consisting of -OH and -NH<sub>2</sub>;  $X^1$  and  $X^6$  are each independently hydrogen or fluorine,  $R^{12}$  is fluoro( $C_1$ - $C_4$ )alkyl; and  $R^2$  is aryl.

# 33. A compound in accordance with claim 29, said compound having

### 5 the formula:

wherein  $R^1$  is a member selected from the group consisting of -OH and -NH<sub>2</sub>;  $X^1$  and  $X^6$  are each independently H or F;  $R^{12}$  is H,  $(C_1-C_4)$ alkyl or  $(C_2-C_4)$ heteroalkyl; and  $R^2$  is substituted or unsubstituted thienyl.

# 34. A compound in accordance with claim 29, said compound having

#### 10 the formula:

15

BNSDCCID <WO\_\_0054759A2

$$X^{6}F_{2}C$$
 $(R^{11})_{n}$ 
 $X^{6}F_{2}C$ 
 $(R^{11})_{n}$ 
 $(R^{11$ 

wherein  $R^1$  is a member selected from the group consisting of -OH and -NH<sub>2</sub>;  $X^1$  and  $X^6$  are each independently hydrogen or fluorine,  $R^{12}$  is  $(C_1-C_4)$ alkyl; and  $R^2$  is phenyl substituted with at least one member selected from the group consisting of halogen, -CN, -CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>4</sub>)alkyl, -C(O)-(C<sub>1</sub>-C<sub>4</sub>)alkyl, -C(O)-O(C<sub>1</sub>-C<sub>4</sub>)alkyl, -C(O)-NH(C<sub>1</sub>-C<sub>4</sub>)alkyl and -C(O)N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>.

35. A compound in accordance with claim 34, wherein  $R^1$  is -OH;  $X^1$  and  $X^6$  are each fluorine; and  $R^2$  is phenyl substituted with at least one member selected from the group consisting of -CN, -CF<sub>3</sub> and -O-(C<sub>1</sub>-C<sub>4</sub>)alkyl.

CT/US00/06611

36. A compound in accordance with claim 20, wherein said compound is selected from the group consisting of:

37. A compound in accordance with claim 20, wherein said compound is selected from the group consisting of:

38. A compound in accordance with claim 20, wherein said compound is selected from the group consisting of:

40. A method of modulating LXR function in a cell, tissue or animal, said method comprising contacting said cell, tissue or animal with a pharmaceutical composition comprising an LXR-modulating amount of a compound of the formula:

$$X^{1} \xrightarrow{X^{2}} X^{3}$$

$$R^{1} \xrightarrow{A_{1}} A_{1} \xrightarrow{Y}$$

$$X^{4} \xrightarrow{X^{5}} X^{6}$$

5

WO 00/54759 PCT/US00/06611

or a pharmaceutically acceptable salt thereof, wherein Ar is an aryl group;

 $R^{T}$  is a member selected from the group consisting of -OH, -CO<sub>2</sub>H, -O-(C<sub>1</sub>-C<sub>7</sub>)alkyl, -OC(O)-(C<sub>1</sub>-C<sub>7</sub>)alkyl, -O-(C<sub>1</sub>-C<sub>7</sub>)heteroalkyl, -OC(O)-(C<sub>1</sub>-C<sub>7</sub>)heteroalkyl, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>7</sub>)alkyl, -N((C<sub>1</sub>-C<sub>7</sub>)alkyl)<sub>2</sub> and -NH-S(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>5</sub>)alkyl;

 $R^2$  is a member selected from the group consisting of  $(C_1-C_7)$ alkyl,  $(C_1-C_7)$ heteroalkyl, aryl and aryl $(C_1-C_7)$ alkyl;

 $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$  and  $X^6$  are each independently a member selected from the group consisting of H,  $(C_1-C_5)$ alkyl,  $(C_1-C_5)$ heteroalkyl, F and Cl, with the proviso that no more than three of  $X^1$  through  $X^6$  are H,  $(C_1-C_5)$ alkyl or  $(C_1-C_5)$ heteroalkyl; and

Y is a member selected from the group consisting of -N(R<sup>12</sup>)S(O)<sub>m</sub>-, -N(R<sup>12</sup>)S(O)<sub>m</sub>N(R<sup>13</sup>)-, -N(R<sup>12</sup>)C(O)-, -N(R<sup>12</sup>)C(O)N(R<sup>13</sup>)-, -N(R<sup>12</sup>)C(S)- and -N(R<sup>12</sup>)C(O)O-;

wherein  $R^{12}$  and  $R^{13}$  are each independently selected from the group consisting of H,  $(C_1-C_7)$ alkyl,  $(C_1-C_7)$ heteroalkyl, aryl and  $aryl(C_1-C_7)$ alkyl, and optionally when Y is  $-N(R^{12})S(O)_m$ - or  $-N(R^{12})S(O)_mN(R^{13})$ -,  $R^{12}$  forms a five- or six-membered ring fused to Ar or to  $R^2$  through covalent attachment to Ar or to  $R^2$ , respectively; and the subscript m is an integer of from 1 to 2.

- 41. A method in accordance with claim 40, wherein said LXR function is associated with a disease or condition selected from the group consisting of lipid disorders and other metabolic disorders.
- 42. A method in accordance with claim 41, wherein said disease or condition is selected from the group consisting of atherosclerosis, elevated LDL plasma levels, low HDL plasma levels, hypertriglyceridemia, hypertension and hypercholesterolemia.
- 43. A method in accordance with claim 41, wherein said disease or condition is selected from the group consisting of obesity, diabetes, vitamin deficiency, osteoporosis, and multidrug resistance to chemotherapeutic drugs.
- 30 44. A method in accordance with claim 40, wherein said compound is administered in combination with a second lipid-lowering or cholesterol-lowering agent.

10

15

20

25

- 45. A composition of claim 1, further comprising a second lipid-lowering or cholesterol-lowering agent.
- **46.** A composition in accordance with claim 1, wherein said compound has the formula:

$$R^{1}$$
  $Ar-S(O)_{m}$   $R^{2}$   $R^{12}$   $R^{12}$ 

47. A composition in accordance with claim 1, wherein said compound has the formula:

**48.** A composition in accordance with claim 1, wherein said compound has the formula:

$$F_{3}C O H$$

$$F_{$$

F/G. /.

FIG. 2.

# (19) World Intellectual Property Organization International Bureau



# 

(43) International Publication Date 21 September 2000 (21.09.2000)

PCT

# (10) International Publication Number WO 00/54759 A3

- (51) International Patent Classification<sup>7</sup>: A61K 31/18, 31/27, 31/24, 31/381, 31/27, 31/17, 31/167, C07C 311/21, C07D 333/34
- (21) International Application Number: PCT/US00/06611
- (22) International Filing Date: 15 March 2000 (15.03.2000)
- (25) Filing Language:

English

(26) Publication Language:

English

- (30) Priority Data: 60/124,525
- 15 March 1999 (15.03.1999) US
- (71) Applicant: TULARIK INC. [US/US]; Two Corporate Drive, South San Francisco, CA 94080 (US).
- (72) Inventors: LI, Leping; 2100 Davis Drive, Burlingame, CA 94010 (US). MEDINA, Julio, C.; 1407 Cedar St., San Carlos, CA 94070 (US). HASEGAWA, Hirohiko; 1-98, I Kasugadenaka 3-chome, Konohana-ku, Osaka 554 (JP). CUTLER, Serena, T.; 449 Hawthorne Ave. #3, Palo Alto, CA 94301 (US). LIU, Jiwen; Apt. 211, 1075 Rollins Rd., Burlingame, CA 94010 (US). ZHU, Liusheng; Apt. 211, 2001 Trousdale Drive, Burlingame, CA 94010 (US). SHAN, Bei; 349 Quay Lane, Redwood City, CA 94065 (US). LUSTIG, Kevin; Two Corporate Drive, South San Francisco, CA 94080 (US).

- (74) Agents: KEZER, William, B. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco. CA 94111 (US).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- -- With international search report
- (88) Date of publication of the international search report: 15 February 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

V 6

(54) Title: LXR MODULATORS

(57) Abstract: The invention provides compounds, compositions and methods for modulating the effects of LXR in a cell. The compounds and compositions are useful both as diagnostic indicators of LXR function and as pharmacologically active agents. The compounds and compositions find particular use in the treatment of disease states associated with cholesterol metabolism, particularly atherosclerosis and hypercholesterolemia.

Interna al Application No PCT/L /06611

C. DOCUMENTS CONSIDERED TO BE RELEVANT

A. CLASSIFICATION OF SUBJECT MATTER TO A A CLASSIFICATION OF SUBJECT MATTER TO A CLASSIFICATION OF SUBJECT M A61K31/17

A61K31/277 A61K31/167

A61K31/24 C07C311/21

A61K31/381 C07D333/34 A61K31/27

According to International Patent Classification (IPC) or to both national classification and IPC

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, MEDLINE, BIOSIS, EMBASE, SCISEARCH

Category *	Citation of document, with indication, where appropriate, of the	Relevant to claim No		
E	WO 00 46203 A (MILLENNIUM PHARM 10 August 2000 (2000-08-10)	1 INC)	1-5,7-9, 11,12, 20-24, 26-28, 30,31, 40-45	
	abstract page 9, line 1 -page 11, line 1 page 27 page 47 -page 48; claims	8		
		-/		
X Fur	ther documents are listed in the continuation of box C.	Patent family members are listed	ın annex.	
"A" docum consider filing of "L" docum which citatic "O" docum other "P" docum	ent defining the general state of the lart which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority claim(s) or is cred to establish the publication date of another on or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but than the priority date claimed	"T" later document published after the interest or priority date and not in conflict with cited to understand the principle or the invention."  "X" document of particular relevance, the coannot be considered novel or cannot involve an inventive step when the document of particular relevance, the coannot be considered to involve an indocument is combined with one or moments, such combination being obvious the art.  "&" document member of the same patent	the application but early underlying the claimed invention be considered to comment is taken alone claimed invention ventive step when the pre other such docu-us to a person skilled	
	actual completion of the international search 26 October 2000	Date of mailing of the international second	arch report	
Name and	mailing address of the ISA  European Patent Office, P.B. 5818 Patentiaan 2  NL - 2280 HV Rijswijk  Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer Hoff, P		

Intern: all pation No PCT/US 00/06611

C.(Continua	ition) DOCUMENTS CONSIDERED TO BE RELEVANT		· · · · · · · · · · · · · · · · · · ·
Category 1	Citation of document, with indication,where appropriate, of the relevant passages		Relevant to claim No.
Р,Х	EP 0 919 542 A (NIHON NOHYAKU CO LTD) 2 June 1999 (1999-06-02) abstract		1-9,11, 12, 20-28, 30,31
	page 71 -page 72 page 75 page 80; claims		
(	US 4 230 635 A (NEUSTADT BERNARD R) 28 October 1980 (1980-10-28)		1-13, 20-32, 40-42, 46-48
	the whole document	•	
<b>(</b>	US 4 093 742 A (NEUSTADT BERNARD R) 6 June 1978 (1978-06-06)		1-4,7-9, 11, 20-23, 26-28, 30,40-42
•	the whole document		
,	GB 1 507 340 A (SCHERICO LTD) 12 April 1978 (1978-04-12)		1-4,7-9, 11, 20-23, 26-28,
÷	the whole document		30,40-42
(	US 3 281 466 A (H.C. STECKER) 25 October 1966 (1966-10-25)		1-9,11, 12, 20-28, 30,31
	the whole document		
<b>X</b>	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MIRYAN, N. I. ET AL: "Derivatives of pyridinecarboxylic acids. Synthesis and antiexudative effect of fluorinated derivatives of nicotinamide and		1-5,7-9, 11,12, 20-24, 26-28, 30,31
	isonicotinamide" retrieved from STN		
	Database accession no. 86:139798 CA XP002151153		
	abstract & KHIMFARM. ZH. (1977), 11(1), 70-2, 1977,		
•	-/	•	
			•

Intern: al Application No PCT/US 06611

		PC1/UŞ	706611
	on) DOCUMENTS CONSIDE TO BE RELEVANT		
Category 1	Citation of document, with indication where appropriate, of the relevant passages		Relevant to claim No
(	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;		20-23, 26-28,30
-	POLISHCHUK, V. R. ET AL: "Electron paramagnetic resonance spectra of 2-arylpolyfluoroisopropyl radicals"		
	retrieved from STN Database accession no. 91:4737 CA XP002151154 abstract	·	
	& IZV. AKAD. NAUK SSSR, SER. KHIM. (1979), (3), 659-61 , 1979,		
	DATABASE 'Online! GILBERT, EVERETT E. ET AL: "perhalo ketones - (VI) aromatic amino derivs. of the penhaloacetones"		20-23, 26-28,30
	retrieved from STN Database accession no. 16091f XP002151155 abstract		
	US 4 251 534 A (ALDRICH PAUL E ET AL) 17 February 1981 (1981-02-17) examples 22-33		20-23, 26-28,30
	US 4 240 979 A (ADOLPHI HEINRICH ET AL) 23 December 1980 (1980-12-23) the whole document		1-9,11, 12,20-28
A	EP 0 193 249 A (DUPHAR INT RES) 3 September 1986 (1986-09-03) abstract; table A compound no.4 claims		1-9,11, 12,20-28
		•	
		,	
		*	
		•	
İ		*	

1

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-9,11,12,20-28,30,31,40-48 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds prepared in the examples and closely related homologous compounds, with due regard to the gneral idea underlying the present invention.

Claims searched completely: 10,13-19,29,32-38

Claims searched incompletely: 1-9,11,12,20-28,30,31,40-48

Remark: claim 39 is missing

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Intern:

al Application No

ation on patent family members PCT/ 0/06611 Patent document Publication Patent family Publication cited in search report date member(s) date WO 0046203 Α 10-08-2000 NONE EP 0919542 Α 02-06-1999 ΑU 712421 B 04-11-1999 AU 9329298 A 24-06-1999 BR 9805060 A 21-03-2000 CZ 9803799 A 16-06-1999 HU 9802725 A 30-08-1999 JP 11240857 A 07-09-1999 PL 329898 A 07-06-1999 ZA 9810677 A 26-05-1999 US 4230635 Α 28-10-1980 NONE US 4093742 Α 06-06-1978 ES 442992 A 01-08-1977 ES 457806 A 01-03-1978 ES 457807 A 01-03-1978 US 4081547 A 28-03-1978 US 4058612 A 15-11-1977 US 4159335 A 26-06-1979 AR 219478 A 29-08-1980 ÁR 218436 A 13-06-1980 AT 368146 B 10-09-1982 15-01-1982 AT 520678 A AT 357557 B 25-07-1980 AT 898575 A 15-12-1979 ΑU 31-05-1979 4416979 A AU 501512 B 21-06-1979 AU 8698975 A 02-06-1977 BE 835899 A 25-05-1976 1063112 A CA 25-09-1979 CH 623044 A 15-05-1981 CS 188299 28-02-1979 В CS 188259 28-02-1979 В DD 124730 A 09-03-1977 DE 2552933 A 10-06-1976 DK 535275 A 03-06-1976 FI 03-06-1976 753332 A FR 2346000 A 28-10-1977 GB 1507340 A 12-04-1978 HU 175541 B 28-08-1980 IE 42759 B 08-10-1980 ΙL 48557 A 31-05-1979 IT 1051024 B 21-04-1981 JP 51082239 A 19-07-1976 LU 73888 A 06-09-1976 NL 7513804 A 04-06-1976 NO 753984 A.B. 03-06-1976 PH 14474 A 07-08-1981 SE 7513331 A 03-06-1976 SE 8004364 A 11-06-1980 SU 655311 A 30-03-1979 SU 685146 A 05-09-1979 ZA 7507457 A 24-11-1976 GB 1507340 Α 12-04-1978 AR 219478 A 29-08-1980 AR 218436 A 13-06-1980 AT 368146 B 10-09-1982 15-01-1982 AT 520678 A

Form PCT/ISA/210 (patent lamily annex) (July 1992)

on on patent family members

Intern: (Intern: Ication No. PCT/US 00/06611

Patent document Publication				Patent family Publication		
	cited in search report		date		member(s)	date
	GB 1507340	A		AT	357557 B	25-07-1980
	25 250,0,0	••		ΑT	898575 A	15-12-1979
			•	AU	4416979 A	31-05-1979
				AU	501512 B	21-06-1979
				AU	8698975 A	02-06-1977
			•	BE	835899 A	25-05-1976
				CA	1063112 A	25-09-1979
	•			CH	623044 A	15-05-1981
				CS	188299 B	28-02-1979
			•	CS	188259 B	28-02-1979
				DD	124730 A	09-03-1977
				DE	2552933 A	10-06-1976
			•	DK	535275 A	03-06-1976
			*			
				ES	442992 A	01-08-1977
				ES	457806 A	01-03-1978
	•			ES	457807 A	01-03-1978
				FI	753332 A	03-06-1976
	4			FR	2346000 A	28-10-1977
				HU	175541 B	28-08 <b>-</b> 1980
				ΙE	42759 B	08-10-198 <b>0</b>
				IL	48557 A	31-05-1979
				IT	1051024 B	21-04-1981
	* .			JP.	51082239 A	19-07-1976
				LU	73888 A	06-09-1976
			•	NL		04-06-1976
				NO	753984 A,B,	03-06-1976
	•			PH	14474 A	07-08-1981
				SE	7513331 A	03-06-1976
				SE	8004364 A	11-06-1980
				SU	655311 A	30-03-1979
				SU	685146 A	05-09-1979
				US	4081547 A	28-03-1978
				US	4093742 A	06-06-1978
				US	4058612 A	15-11-1977
	•			US	4159335 A	26-06-1979
				ZA	7507457 A	24-11-1976
	US 3281466		25-10 <b>-</b> 1966			
	00 3201400	^	23 10 1300	DE GB	1543912 A 1096369 A	05-02-1970
	US 4251534	 А	17-02-1981	 BE	872956 A	21-06-1979
		**		CA	1099712 A	21-04-1981
				DE	2854727 A	28-06-1979
				DK	574978 A	23-06-1979
				FR	2412533 A	20-07-1979
				GB	2010821 A,B	04-07-1979
			•	IT	1102419 B	07-10-1985
				JP	54098780 A	03-08-1979
			•	LU	80720 A	22-01-1980
				. NL	7812422 A	26-06-1979
	US 4240979	 А	23-12-1980	DE	2839462 A	27-03-1980
	- · · · · ·			AT	38 T	15-05-1981
				AU .	522721 B	24-06-1982
				AU	5057679 A	20-03-1980
	•	•		DE	2960273 D	07-05-1981
	and the second s			LD	MANUJEO A	
	•			EP Hu	0008768 A 179118 B	19-03-1980 28-08-1982

intern at Application No

						10179	7 00011
	Patent document ed in search report		Publication date		Patent family member(s)		Publication date
U:	S 4240979	Α		JP	1510053	3 C	26-07-1989
				JP	55038390	0 · A	17-03-1980
•	, ,		•	JP	63057418	8 B	11-11-1988
				US	427117	1 A	02-06-1981
	·			ZA	7904787	7 A	24-09-1980
E	P 0193249	Α	03-09-1986	AU	601149	5 B	06-09-1990
				AU	5410886	5 A	04-09-1986
				DK	88186	5 A	02-09-1986
	•			ES	552432	2 D	01-03-1988
				ES	8801896	5 A	16-05-1988
-	•	•	•	GR	860542	2 A	25-06-1986
		•		JP	61218569	9 A	29-09-1986
				PH	23163	3 A	19-05-1989
	•			ZA	8601446	5 A	29-10-1986